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ABSTRACT	
This	 thesis	 focuses	 on	 infection	 and	 immunity	 within	 the	 airways	 in	 cystic	 fibrosis	 (CF),	
particularly	the	role	of	the	antimicrobial	peptides	(part	of	the	 innate	 immune	system)	and	
their	relationship	to	vitamin	D	status.	Vitamin	D	response	elements	have	been	identified	in	
the	 genes	 encoding	 the	 antimicrobial	 peptides	 cathelicidin	 (LL37)	 and	 human	β	 defensins	
(HBD-2)	and	in-vitro	vitamin	D	significantly	induces	expression	of	these	peptides	in	both	CF	
and	non-CF	bronchial	epithelial	cells.	
As	innate	defence	is	pivotal	to	airway	health	and	is	one	of	the	proposed	ways	that	vitamin	D	
deficiency	 contributes	 to	 worsening	 respiratory	 health,	 this	 thesis	 will	 consider	 first	
immunity	 of	 the	 normal	 airway	 and	 the	 interactions	with	 vitamin	D	 and	 then	 discuss	 the	
pathophysiology	of	CF	and	the	role	of	vitamin	D	on	the	innate	immune	system	within	CF.	
The	 role	 of	 vitamin	 D	 on	 infection	 and	 inflammation	 in	 the	 airways	 of	 infants	 with	 CF	 is	
explored	and	the	impact	of	Vitamin	D	levels	seen	immunologically	and	functionally	over	the	
first	year	of	life	is	described.	Finally	the	role	of	vitamin	D	as	an	immunomodulatory	molecule	
is	explored	in	a	greater	range	of	CF	disease	severity	and	age.		
Through	 the	 various	 parameters	 explored,	 in	 different	 CF	 patient	 populations,	 the	
conclusion	 remains	 the	 same;	 vitamin	 D	 deficiency	 is	 not	 associated	 with	 increased	
infection,	greater	inflammation	nor	a	worse	clinical	outcome.		
The	possible	reasons	for	the	lack	of	any	relationship	are	discussed	in	the	final	chapter;	
either	a	missed	signal	because	the	levels	studied	were	on	the	low	or	high	flat	parts	of	a	
2
sigmoid	relationship	thus	effects	seen	only	in	really	severe	deficiency	or	because	supra-high	
levels	are	needed	to	see	any	effect,	the	effect	being	lost	in	the	inflammation	seen	within	the	
CF	airway	or	a	true	lack	of	relationship.	
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	1 CHAPTER	 1:	 INFECTION,	 IMMUNE	 RESPONSE	 AND	 INNATE	
IMMUNITY	
1.1 Airway	immunity		
1.1.1 Innate	immune	system	
The	 airway	 requires	 an	 effective	 immune	 system	 as	 over	 11,000	 litres	 of	 only	 partially	
filtered	air	enter	the	adult	airway	each	day	(2).	Once	the	upper	airway	has	been	bypassed,	
the	 initial	 defences	 are	 expulsive	 coughing	 and	 the	 mucociliary	 escalator.	 The	 latter	
comprises	motile	cilia,	the	airway	surface	liquid	and	mucus,	which	combine	to	expel	inspired	
pathogens	and	debris	from	the	airways	thereby	preventing	infection	and	airway	damage.		
The	epithelium	of	the	upper	and	lower	respiratory	tract	is	largely	comprised	of	ciliated	cells,	
each	 possessing	 100-200	 cilia.	 The	 cilia	 beat	 in	 a	 co-ordinated	 fashion	 in	 order	 to	 expel	
inhaled	particles	and	pathogens.	In	normal	individuals	each	cilium	is	made	up	of	9	doublet	
tubules	 arranged	 around	 a	 central	 tubule	 pair.	 The	outer	 doublet	 tubules	 have	 inner	 and	
outer	dynein	arms	and	radial	spokes	associated	with	them	to	maintain	structural	integrity.	
The	respiratory	epithelium	is	 lined	by	a	 layer	of	airway	surface	 liquid	that	 is	made	up	of	a	
periciliary	layer	and	a	mucous	layer.	The	cilia	beat	within	the	periciliary	layer	and,	in	health,	
the	height	of	the	cilia	is	approximately	the	same	as	the	height	of	this	fluid	layer,	providing	an	
optimal	 environment	 for	 the	 beat	 pattern	 and	 mucous	 clearance.	 Results	 of	 cell	 culture	
experiments	suggest	that	both	the	periciliary	layer	and	the	mucous	layer	travel	at	the	same	
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	rate,	up	to	20	mm/min	and	this	movement	aids	the	expulsion	of	particles	from	the	airway	
(3).		
If	 a	 pathogen	 overcomes	 the	 body’s	 barrier	 defence	 systems,	 the	 immune	 response	 is	
triggered.	 This	 can	 be	 classified	 into	 two	 main	 parts;	 the	 innate	 and	 adaptive	 immune	
systems.	The	 innate	 immune	system	does	not	 rely	on	previous	exposure,	and	has	a	more	
generic	 response	 to	 invading	pathogens,	whilst	 the	adaptive	 immune	system	has	memory	
functions	and	has	organism-specific	responses,	either	as	a	result	of	a	previous	encounter	or	
immunisation.	 Antibodies	 are	 produced,	 and	 if	 subsequent	 exposure	 occurs,	 the	 acquired	
immune	 system	 is	 able	 to	 trigger	 a	 response	 involving	 production	 of	 these	 specific	
antibodies.	 Because	 of	 these	 differences,	 it	 was	 previously	 thought	 that	 the	 acquired	
immune	 system	 was	 a	 sophisticated	 system,	 and	 the	 innate	 immune	 system	 crude	 and	
clumsy.	 However,	 a	 better	 understanding	 of	 the	 innate	 immune	 system	 has	 led	 to	 the	
discovery	that	this	 is	not	the	case,	 that	this	 is	also	an	elaborate	and	sophisticated	system,	
signalling	 in	what	way	and	 for	how	 long	the	adaptive	 immune	system	should	respond	 (4).	
The	 innate	 immune	 system	 can	 activate	 the	 adaptive	 immune	 system	 via	 a	 variety	 of	
pathways,	and	 recognised	pathogens	also	 trigger	 the	adaptive	 immune	system	directly.	 In	
health,	 the	 two	 systems	 work	 together	 in	 order	 to	 provide	 protection	 against	 invading	
pathogens.	
As	 acquired	 immunity	 develops	 throughout	 life	 with	 exposure	 to,	 or	 vaccination	 against,	
disease	older	children	and	adults	have	a	better	system	in	place	able	to	cope	with	a	greater	
diversity	of	organisms.	 The	 innate	 immunity	 therefore	plays	a	 greater	 role	 in	 immunity	 in	
younger	children,	as	this	is	present	from	birth.		
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	1.1.2 The	innate	immune	response	
As	well	as	providing	a	mechanical	defence	the	respiratory	epithelium	has	a	major	role	within	
the	innate	defence	system.		
Organisms	that	are	not	cleared	by	the	airway	barrier	defences	are	detected	and	recognised	
by	 the	 innate	 immune	 system	 via	 specific	 molecular	 patterns	 on	 the	 surface	 of	 the	
pathogen,	its	pathogen-associated-molecular	patterns	(PAMPs).	The	PAMPs	are	detected	by	
pattern	recognising	receptors	(PRRs),	small	proteins	expressed	by	innate	immune	cells.		
Pattern	recognition	receptors	(PRR)	are	a	diverse	group	of	receptors	that	can	be	divided	into	
at	least	five	different	families:	the	toll-like	receptors	(TLR),	c-type	leptin	receptors,	NOD-like	
receptors,	 RIG-like	 helicase	 receptors	 and	 scavenger	 receptors.	 Others	 are	 likely	 to	 be	
identified	 as	 this	 is	 an	 area	 of	 active	 research.	 PRRs	 reside	 in	 the	 plasma	membrane	 and	
endosomal	compartments,	the	exact	location	varying	with	the	type.	TLRs,	which	are	located	
in	the	cytoplasmic	membrane,	are	the	most	frequently	encountered	PRR	in	the	respiratory	
tract.	Once	the	PRR	has	become	engaged	by	encountering	its	PAMP,	the	receptor	switches	
from	 its	 quiescent	 state	 to	 an	 activated	 one.	 Binding	 to	 TLRs	 leads	 to	 the	 expression	 of	
various	cytokines,	antimicrobial	peptides	and	proteins	through	activation	of	nuclear	 factor	
kB	 (NFkB)	or	 interferon	regulated	factors	 (IRF).	The	exact	pathway	triggered	will	vary	with	
the	TLR	to	which	PAMPs	are	bound	(5,	6).	
The	 functions	of	 the	 innate	 immune	system	can	be	broadly	 classified	 into	 two	categories;	
phagocytosis	 by	 cellular	 components,	 and	 pathogen	 destruction	 by	 soluble	 components.	
Macrophages	are	present	 in	most	tissues	 in	a	quiescent	state	and	engagement	of	PRR	
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	on	the	plasma	membrane	by	the	PAMP	of	an	invading	organism	switches	on	genes	enabling	
the	macrophage	to	perform	new	functions.		The	activated	macrophage	is	now	optimised	for	
engulfing	 and	 killing	micro-organisms.	 As	well	 as	 phagocytosis,	macrophages	 also	 secrete	
cytokines,	chemokines,	complement,	and	lysosome	and	act	as	an	antigen	presenting	cell	to	
the	 adaptive	 immune	 system.	 The	 secreted	 chemokines	 and	 cytokines	 allow	 neutrophils,	
normally	 restricted	 to	 the	 blood,	 to	 invade	 tissues	 by	 increasing	 vascular	 permeability.	
Neutrophils	 aid	 pathogen	 killing	 by	 direct	 phagocytosis	 and	 they	 also	 produce	 numerous	
soluble	 immune	 factors	 including	 cytokines,	 proteases	 and	 defensins.	 The	 expressed	
cytokines	 are	 crucial	 for	 B-cell	 functioning	 therefore	 neutrophils	 have	 a	 role	 in	 both	 the	
innate	 and	 the	 adaptive	 immune	 systems.	 Recent	 evidence	 suggests	 that	 neutrophils	 are	
involved	 in	 the	 active	 induction	 of	 resolution	 of	 inflammation	 by	 the	 conversion	 of	
leukotriene	B4	to	lipoxin	A4,	which	inhibits	neutrophilic	recruitment	and	their	contribution	
to	the	synthesis	of	resolvins,	lipid	mediators	of	inflammation	resolution	(7).		
Sustained	 neutrophilic	 inflammation	 causes	 uncontrolled	 release	 of	 the	 toxic	 granule	
contents	 of	 the	 neutrophil,	 oxidants,	 serine	 and	metalloproteases	 (7).Therefore,	 it	 is	 not	
only	 important	 that	 an	 inflammatory	 response	 is	 mounted,	 but	 that	 it	 is	 regulated	 to	
prevent	 it	becoming	exaggerated	.	Failure	to	 initiate	this	 inflammatory	reaction,	to	sustain	
it,	or	to	halt	it	appropriately,	can	result	in	lung	disease.	
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	1.1.3 Antimicrobial	peptides		
The	antimicrobial	peptides	are	soluble	innate	immune	factors	present	in	the	airway	surface	
liquid	that	have	direct	and	indirect	actions	on	a	variety	of	bacteria,	viruses	and	fungi.		
Antimicrobial	 peptides	 are	 comprised	 of	 between	 50	 -150	 amino	 acids,	 are	 positively	
charged	 and	 contain	 both	 hydrophilic	 and	 hydrophobic	 components	 enabling	 them	 to	 be	
soluble	 both	 in	 lipid	membranes	 and	water.	 Numerous	 antimicrobial	 peptides	 have	 been	
identified	in	humans	including	larger	proteins	such	as	lysozyme,	lactoferrin	and	cathepsin	G	
and	 smaller	 peptides	 such	 as	 secretory	 leukocyte	 protease	 inhibitors	 (SLPI),	 RNase	 7,	
defensins	and	cathelicidins.	
	
1.1.4 Antimicrobial	peptides	in	relation	to	vitamin	D	
Previous	work	has	found	that	the	promoter	regions	of	the	genes	for	two	of	these	peptides,	
human-β-defensin	-2	(HBD-2)	and	cathelicidin	(LL-37)	contain	vitamin	D	response	elements	
(VDRE)	suggesting	a	role	for	vitamin	D	in	their	regulation	and	for	this	reason	these	are	the	
two	peptides	focussed	on	in	the	work	of	this	thesis.	
	
1.1.5 Defensins	
First	 identified	 in	1985	(8)	defensins	have	now	been	divided	 into	3	categories,	alpha,	beta	
and	 theta;	 however	 the	 latter	 have	 not	 been	 found	 in	 humans	 (9)	 and	 so	 will	 not	 be	
discussed	 here.	 All	 peptides	 within	 the	 family	 have	 a	 similar	 role	 but	 there	 are	
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	specificities	 of	 structure,	 function	 and	 biological	 properties	 within	 each	 group	 making	 it	
unique.	
Defensins	 are	 antimicrobial	 peptides	 active	 against	 a	 wide	 range	 of	 pathogens	 including	
gram	positive	and	gram	negative	bacteria,	fungi	and	enveloped	and	non-enveloped	viruses	
(5).	The	mechanism	of	action	is	not	fully	understood	but	it	appears	that	defensins	alter	the	
permeability	 of	 the	 invading	 pathogen	 cell	 membrane	 and	 have	 both	 bactericidal	 and	
bacteriostatic	effects	(2).	For	viral	killing,	there	is	either	a	direct	effect	against	the	virus	itself	
by	disruption	of	the	envelope	or	interaction	with	the	glycoproteins	at	the	virus	cell	surface	
inhibiting	replication;	or	modulatory	effects	on	the	target	of	 the	virus	 increasing	epithelial	
cell	expression	of	defensin	mRNA	and	acting	as	a	chemotactic	agent	(10).	The	antimicrobial	
properties	are	greatly	affected	by	the	environment	and	the	activity	of	all	the	host	defence	
peptides	is	greatest	in	environments	of	low	ionic	strength.	The	activity	of	human	β-defensin	
-1(HBD-1)	and	to	lesser	extent	HBD-2	is	reduced	in	the	presence	of	sodium	ions	meaning	a	
far	higher	concentration	of	the	peptide	is	required	for	killing	ability;	magnesium	and	calcium	
ions	 have	 a	 detrimental	 effect	 on	 the	 antimicrobial	 activity	 of	 α-defensins.	 Such	
environments	 are	 commonly	 seen	 in-vivo	 in	 healthy	 subjects	 raising	 questions	 about	 the	
physiological	 relevance	 of	 these	 peptides,	 which	 reside	 in	 environments	 sub-optimal	 for	
their	antimicrobial	activity.	The	activity	of	these	peptides	is	also	affected	by	a	reduced	pH,	
and	a	reduction	in	airway	surface	liquid	(ASL)	pH	from	8	to	6.8	rendered	HBD-3	ineffective	to	
Staphylococcus	 aureus	 (S.	 aureus)	 and	 the	 synergistic	 effects	 of	 various	 antimicrobial	
peptides	are	also	reduced	by	a	decrease	 in	the	environmental	pH	(11).	 It	has	been	shown	
that	 in	 addition	 to	 their	 direct	 antimicrobial	 action,	 they	have	 immunomodulatory	effects	
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(12)	
The	number	of	α	and	β	defensins	varies	between	species;	 there	are	currently	6	α	and	4	β	
defensins	identified	in	humans	(12).	The	human	α-defensins	(HNP1-4)	are	expressed	mainly	
in	neutrophils,	where	 they	are	 stored	 in	 the	azurophil	 granules	 (4,	 13),	 although	 they	are	
also	produced	to	a	lesser	extent	by	eosinophils.	Macrophages	are	able	to	store	α-defensin,	
and	 in	 addition	 to	 storage,	 they	 acquire	 more	 by	 ingestion	 of	 apoptotic	 neutrophils.	 If	
Mycobacterium	tuberculosis	(TB)	and	α-defensins	are	both	ingested	by	a	macrophage,	they	
are	initially	transported	to	the	early	endosome	where	the	defensin	contributes	to	inhibition	
of	mycobacterial	growth	(14).	Alpha	defensins	are	chemotactic,	stimulate	IL-8	production	by	
human	bronchial	epithelial	cells	and	cause	aggregation	of	bacteria	and	viruses	to	facilitate	
phagocytosis	 by	 macrophages	 and	 neutrophils.	 Alpha	 defensins	 5	 and	 6	 (HD5-6)	 are	
expressed	only	in	the	small	intestine	by	Paneth	cells	(2,	10,	12).	
The	β-defensins	are	widely	expressed	in	epithelial	cells,	including	those	lining	the	respiratory	
tract	 (8).	 HBDs	 are	 secreted	 onto	 the	 cell	 surface	 in	 their	 mature	 form	 and	 are	 thereby	
active	at	the	time	of	secretion	(14).	HBD-1	is	constitutively	expressed	whilst	HBD-2,	3	and	4	
are	 up-regulated	 in	 response	 to	 infection	 or	 inflammatory	 stimuli.	 HBD-2	 is	 most	 highly	
expressed	in	lungs,	HBD-3	in	skin	and	tonsils	and	HBD-4	in	the	testes	and	stomach.	Although	
it	 is	known	that	HBD-2	 is	expressed	by	the	respiratory	epithelium	in	the	proximal	airways,	
the	epithelial	expression	and	level	of	defensins	at	different	airway	generations	has	not	been	
evaluated	 (14).	 HBD-2	 is	 chemotactic	 and	 causes	 migration	 of	 other	 inflammatory	 cells	
including	 neutrophils	 (thereby	 increasing	 the	 levels	 of	 neutrophil-derived	 α-defensins	 and	
cathelicidin),	and	causing	mast	cells	to	migrate	and	to	become	activated	(9,	14,	15).		
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1.1.6 Cathelicidin	
Cathelicidin	 is	secreted	by	neutrophils,	macrophages	and	epithelial	cells	 including	those	of	
the	respiratory	tract	(14)	and	has	a	similar	role	to	defensins	 in	 lung	 immunity	 (8).	There	 is	
considerable	 variation	 in	 structure	 amongst	 cathelicidins	 but	 they	 are	 grouped	 together	
because	they	are	all	stored	as	inactive	prepropeptides,	with	a	signal	residue,	an	N-terminus	
peptide	 and	 then	 a	 smaller,	 highly	 variable	 C-terminus	 peptide	 (16-18).	 The	 structural	
heterogeneity	 between	 cathelicidins	 also	 translates	 into	 variable	 activity	 of	 the	 peptides,	
which	 have	 differing	 functions	 and	 mechanisms	 of	 action.	 Cathelicidins	 have	 now	 been	
identified	 in	 chicken	and	 fish,	 as	well	 as	 in	 all	mammals	 in	which	 they	have	been	 sought.	
Their	presence	 in	hag	 fish	suggests	 that	 they	have	been	conserved	 through	evolution	 (17,	
19).	 Although	 many	 different	 cathelicidins	 exist	 in	 nature,	 only	 one	 is	 found	 in	 humans,	
human	 cationic	 antimicrobial	 protein	 18	 (hCAP18).	 This	 cathelicidin	 has	 an	 alpha-helical	
structure	(18,	19),	which	is	the	most	common	structure	seen	in	this	family,	and	which	is	also	
seen	in	cows,	monkeys,	mice,	rabbits,	guinea	pigs,	sheep,	pigs	and	horses	(16,	20).	As	with	
all	 cathelicidins,	 the	 human	 cathelicidin,	 hCAP18,	 is	 stored	 intracellularly	 as	 the	 inactive	
prepeptide.	Once	secreted	from	the	cell,	the	C-terminus	is	cleaved	by	the	enzyme	protease	
3. The	 cleaved	 product	 consists	 of	 37	 amino	 acids,	 the	 first	 2	 of	 which	 are	 leucine	 (21),
hence	 its	 name	 LL-37.	 The	 terms	hCAP18	and	 LL-37	 are	 sometimes	used	 interchangeably,	
but	in	this	thesis,	hCAP-18	refers,	more	accurately,	to	the	inactive	prepeptide	and	LL-37	the	
smaller,	 active	 peptide.	 Alpha-helical	 cathelicidins	 are	 active	 against	 a	 wide	 range	 of	
pathogens	 including	 gram	 positive	 and	 negative	 bacteria,	 fungi,	 parasites	 and	 enveloped	
viruses	(16,	18,	20).	The	concentration	required	for	killing	varies	between	pathogens	
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(Table	1)	with	salmonella	being	killed	at	relatively	low	concentrations,	whereas	
Streptococcus	group	B,	E.	coli	and	Pseudomonas	aeruginosa	require	a	much	higher	
concentration	(17).	
Table	1:	Concentrations	required	for	LL-37	killing	
LL-37	 activity	 against	 two	 viruses	 has	 been	 investigated:	 it	 has	 minimal	 activity	 against
herpes	 simplex	but	 does	 reduce	 replication	of	 vaccinia	 virus	 (17).	Activity	 of	 LL-37	 is	 very	
much	affected	by	its	environment	(22)	with	its	antimicrobial	activities	being	reduced	by	the	
presence	 of	 plasma,	 and	 by	 sodium,	 magnesium	 and	 calcium	 ions	 (19).	 However	
investigators	disagree	as	to	the	extent	of	the	reduction.	Some	studies	found	that	activity	in	
high	 salt	 environments	 is	 reduced,	 but	 less	 so	 than	 the	 reduction	 in	 activity	 of	 other	
antimicrobial	 peptides	 (17)	 whilst	 other	 studies	 found	 no	 demonstrable	 antimicrobial	
activity	 at	 all	 in	 normal	 physiological	 conditions	 (23).	 Its	 activity	 has	 been	 found	 to	 be	
reduced	by	apolipoprotiens	and	by	low	environmental	pH	(12).	
LL-37	expression	 is	up-regulated	by	certain	bacteria,	but	conversely,	 the	peptide	 is	broken
down	 by	 proteases	 produced	 by	 some	 bacteria,	 including	 Pseudomonas	 aeruginosa	 (P.	
aeruginosa)	 (16,	18).	LL-37	has	been	shown	to	alter	membrane	permeability	and	different	
mechanisms	are	proposed,	but	 the	exact	mechanism	 is	unclear.	The	amphipathicity	of	
Organism	 Concentration	required	for	killing (μM)	
Salmonella	 2.8	–	6	
P. aeruginosa 16	
E. Coli >32
Streptococcus	group	B	 >32
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LL-37	 is	 important	 in	 its	 action	 of	 membrane	 disruption	 and	 the	 three	 main	 proposed
mechanisms	are	barrel-stave,	carpet	and	toroidal	pore	models	(18,	19).	
Figure	1:	Proposed	mechanisms	of	LL-37	induced	antimicrobial	activity	(18).	
LL-37	may	form	cylindrical	pores	(B)	;	it	may	coat	the	surface	of	the	cell	until	the	cell	membrance	dissolves	(C);
or	it	may	coat	the	cell	surface,	until	curvature	of	the	cell	membrane	occurs	and	pores	form.
One	 postulated	 mechanism	 is	 that	 LL-37	 attaches	 perpendicular	 to	 the	 membrane	 and	
forms	large	cylindrical	pores	therein	(Figure	1B).	Alternatively,	and	more	likely,	it	coats	the	
surface	until	a	critical	concentration	is	reached	when	it	acts	to	either	dissolve	the	membrane	
(Figure	1C)	or	causes	curvatures	that	form	toridal	pores	(Figure	1D).		
In	addition	to	antimicrobial	activity,	as	with	defensins,	LL-37	exhibits	immmunomodulatory	
properties	 (8,	12,	14,	19)	and	these	properties	appear	 less	 influenced	by	the	environment	
(23).	 These	 properties	 include	 chemoattraction,	 stimulation	 of	 gene	 expression	 of	
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various	 cytokines	 and	 chemokines	 and	 altering	 bacterial	 signalling	 by	 binding	 to	 LPS	
disabling	its	usual	inflammatory	trigger	(19).	
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2 CHAPTER	2:	CYSTIC	FIBROSIS	
2.1 CF	–	clinical	disease	
2.1.1 Clinical	features	of	CF	
CF	is	a	multi-system	disease	and	whilst	lung	disease	accounts	for	the	majority	of	morbidity	
in	CF,	and	respiratory	failure	is	the	cause	of	death	in	over	90%	of	CF	patients,	there	is	also	
significant	 pancreatic,	 liver	 and	 gastrointestinal	 (GI)	 involvement	 and	 infertility	 in	 the	
majority	of	males.	Lung	involvement	occurs	from	an	early	age	with	intermittent	then	chronic	
bacterial	 infection,	 inflammation	 and	 eventual	 bronchiectasis,	 fibrosis	 and	 death	 from	
respiratory	 failure.	 Infection	 is	 frequently	 seen	 in	 the	airways	of	people	with	CF	 (24)	with	
particular	 susceptibility	 to	 certain	 bacteria	 including	 S.	 aureus,	 P.	 aeruginosa	 and	
Burkholderia	 cepacia	 (B.cepacia);	 the	 use	 of	molecular	 detection	 techniques	 has	 revealed	
much	 more	 diverse	 bacterial	 populations	 present	 in	 the	 lower	 airway	 than	 hitherto	
suspected	(more	details	in	section	2.3).	The	organisms	most	commonly	isolated	change	with	
age;	 in	 infancy	 and	 in	 the	 pre-school	 years,	 S.	 aureus	 and	 Haemophilus	 influenzae	 (H.	
influenzae)	are	most	commonly	cultured	with	a	tendency	for	these	organisms	to	be	replaced	
by	 P.	 aeruginosa	 by	 the	 teenage	 years	 (25),	 up	 to	 80%	 of	 adults	 having	 isolated	 this	
pathogen.	Chronic	P.	aeruginosa	is	associated	with	a	worse	outcome,	as	are	B.	cenocepacia,	
Achromobacter	 xylosoxidans	 (24),	 and	 certain	 non-tuberculous	 mycobacteria	 (NTMs),	
particularly	 Mycobacterium	 abscessus.	 	 There	 remains	 debate	 as	 to	 whether	 MRSA	 is	
associated	with	worse	clinical	outcomes	(26)	but	recent	data	shows	that	MRSA	colonisation	
in	CF	adolescents	correlated	with	worse	pulmonary	 function	 (27).	 It	was	recognised	 in	
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	the	 1990s	 that	 cross-infection	 occurred	 within	 CF	 centres	 (28-31)	 and	 subsequently	
segregation	 and	 isolation	was	 introduced	and	 is	 now	a	 standard	of	 care	 in	UK	CF	 centres	
(32).	
In	the	pancreas,	cystic	fibrosis	transmembrane	regulator	(CFTR)	is	predominantly	located	at	
the	apical	membrane	of	the	cells	that	line	the	small	pancreatic	ducts.	Defective	CFTR	leads	
to	mucus	plug	formation	leading	to	pancreatic	injury,	the	consequence	of	which	is	failure	of	
secretion	of	pancreatic	enzymes	and	bicarbonate	to	the	GI	tract	and	therefore	an	inability	to	
absorb	fat	manifested	by	steatorrhoea	and	failure	to	gain	weight.	Most	individuals	with	CF	
(85%)	 are	 pancreatic	 insufficient	 from	 birth	 whilst	 pancreatic	 endocrine	 dysfunction	
commonly	 occurs	 later	 in	 life	 at	 a	 median	 of	 20	 years.	 	 Affected	 individuals	 develop	 CF	
related	diabetes	and	this	occurs	in	approximately	one	third	of	CF	patients.		
	
2.1.2 Diagnosis	of	CF	
CF	 can	 be	 detected	 on	 screening	 in	 the	 newborn	 period	 by	 the	 detection	 of	 elevated	
immune	 reactive	 trypsin	 (iRT)	 in	 a	 routinely	 collected	 blood	 spot,	 usually	 combined	with	
genetic	 testing	 (33).	 IRT	 is	 elevated	 at	 birth	 in	 individuals	 with	 CF	 and	 remains	 so	 for	
approximately	8	weeks.	The	elevation	of	this	protein	in	the	blood	was	first	described	in	1979	
(34)	 and	 screening	was	 introduced	 shortly	 after	 this	 in	 some	parts	 of	 the	world	 including	
Australia,	France	and	in	the	UK	in	East	Anglia	but	it	was	not	until	30	years	later,	in	2007,	that	
screening	 became	 routine	 in	 the	 whole	 of	 the	 UK	 (35-37). Following	 this	 screening	 test,	
infants	deemed	to	have	a	likely	diagnosis	of	CF	are	referred	for	sweat	testing	and	clinical	
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	review	at	 a	 CF	 centre.	 The	 iRT	 assay	 is	 a	 screening,	 rather	 than	diagnostic,	 test	 and	 false	
negatives	and	false	positives	will	occur;	there	is	thought	to	be	an	approximately	3-6%	false	
negative	rate	(38-41).	 In	order	to	minimise	such	errors,	most	centres	employ	a	3	or	4	step	
process	testing	a	combination	of	iRT	and	DNA	mutation	analysis	(33).	The	experience	of	East	
Anglia	after	30	years	of	 screening	was	 that	 incorporating	DNA	mutation	analysis	 in	 to	 the	
screening	process	improved	the	positive	predictive	value	from	67	to	86%	(38).	The	children	
missed	 on	 new	 born	 screening	 (NBS),	 and	 children	 born	 prior	 to	 2007,	 are	 diagnosed	
following	clinical	suspicion	from	symptoms	including	cough,	respiratory	tract	infections	and	
failure	to	thrive.	 
Once	referred	for	testing,	either	through	NBS	detection	or	on	clinical	suspicion,	a	sweat	test	
is	performed.	This	allows	measurement	of	the	sweat	chloride	concentration	and	a	diagnosis	
of	CF	is	made	with	a	sweat	chloride	of	≥	60	mmol/L	in	a	properly	performed	sweat	test	(42).		
Sweat	chloride	 levels	<30	are	considered	normal	and	≥30	-	<60	are	borderline	and	further	
testing	in	the	way	of	genotyping	(42,	43),	gene	sequencing	(44)	or	nasal	potential	difference	
measurements	(45)	are	recommended	(43).	
	
2.1.3 Introduction	of	new	born	screening	in	UK	
Screening	started	in	East	Anglia	and	Trent	in	1980s	(38,	46)	and	in	Wales	in	1996	whilst	the	
rest	of	the	UK	began	screening	much	later	with	routine	nationwide	screening	occurring	from	
October	 2007.	 The	 reason	 for	 this	 delay	 was	 the	 lack	 of	 evidence	 to	 support	 a	 better	
outcome	with	screening.	The	diagnosis	of	CF	 is	made	at	a	younger	age	with	screening	
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	than	diagnosis	on	clinical	presentation;	median	age	1	month	versus	6	months	in	the	UK	and	
2	weeks	versus	14	months	in	the	US	(47).	Whilst	it	is	clear	that	screening	does	lead	to	earlier	
diagnosis,	whether	this	translated	to	a	clinical	benefit	was	undetermined.	With	this	lack	of	
certainty	it	was	argued	that	screening	might	offer	no	advantage	over	clinical	diagnosis	and	
one	 study	 found	 worse	 clinical	 respiratory	 outcomes	 in	 screened	 babies	 compared	 with	
those	diagnosed	later	(48).		
Shortly	after	the	turn	of	the	century,	more	evidence	was	emerging	suggesting	there	was	a	
clinical	 benefit	 (49-53)	 and	 following	 this	 screening	 became	 routine	 although	 there	 is	 no	
universally	agreed	system	and	the	screening	testing	protocols	vary	between	countries	(54).	
	
2.1.4 Benefits	of	newborn	screening		
As	 discussed	 above,	 whether	 earlier	 diagnosis	 was	 beneficial	 was	 initially	 unclear.	 The	
evidence	 is	 growing	 that	 there	 are	 improved	 respiratory	 outcomes	 in	 the	 paediatric	
population	but	the	strongest	evidence	relates	to	nutritional	data,	which	has	highlighted	the	
importance	of	improved	nutritional	state	after	NBS.		
One	of	the	benefits	of	screening	is	thought	be	the	early	identification	of	infants	with	disease	
in	 order	 to	 start	 treatments	 before	 the	 onset	 of	 symptoms	 and	 airway	 inflammation	 and	
subsequent	 airway	 destructive	 changes.	 However,	 in	 one	 cohort	 of	 170	 screened	 infants,	
48%	were	already	displaying	some	symptoms	by	the	time	of	diagnosis	at	a	median	age	of	3	
weeks	(39)	and	2	other	large	cohorts	found	presence	of	airflow	obstruction	at	3	months		of	
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	age	(55,	56).	
The	Wisconsin	 randomised	controlled	 trial	of	 screening	 found	more	P.	aeruginosa	 in	 their	
screened	infants	compared	with	those	diagnosed	clinically	(48).	This	increased	infection	rate	
was	thought	 to	be	due	to	cross	 infection	with	children	with	established	CF	 in	one	of	 their	
centres	and	would	therefore	expect	to	be	abolished	by	segregation.		This	study	did	not	find	
any	pulmonary	advantage	of	screening	by	the	age	of	6	years,	and	this	was	thought	to	be	due	
to	the	increased	P.	aeruginosa	rate	in	this	group.	Not	all	centres	found	more	P.	aeruginosa	
in	the	screened	infants;	a	study	in	UK	found	less	P.	aeruginosa	in	the	screened	infants	(57)	
and	an	Australian	study	found	less	bacteria	in	the	airways	of	those	diagnosed	on	newborn	
screening	(58).	The	earlier	acquisition	of	P.	aeruginosa	in	the	non-screened	infants	in	these	
studies	was	found	to	correlate	with	a	poorer	clinical	outcome	with	lower	lung	function,	less	
good	 nutritional	 status	 and	 poorer	 survival	 (59).	 Other	 centres	 found	 no	 difference	 in	 P.	
aeruginosa	rates	between	their	screened	and	non-screened	cohorts	(60,	61).	
Evaluation	of	the	CF	patients	in	Australia,	who	have	been	screening	for	CF	for	over	20	years,	
found	 that	 adolescents	 who	 had	 been	 diagnosed	 on	 screening	 had	 a	 better	 forced	
expiratory	 volume	 in	 1	 second	 (FEV1)	 and	 forced	 vital	 capacity	 (FVC)	 at	 transition	 to	 the	
adult	clinic	than	their	clinically	diagnosed	counterparts	(59).	
In	 terms	 of	 structural	 lung	 damage,	 an	 Australian	 study	 found	 better	 chest	 x-ray	 (CXR)	
scores	 in	 the	 screened	 cohort	 (59).	 Worse	 CXR	 scores	 were	 seen	 in	 follow-up	 chest	
radiographs	in	the	Wisconsin	cohort	in	the	screened	cohort	(48),	but	scores	correlated	with	
P.	aeruginosa	 infection	 rate,	which	as	discussed,	was	higher	 in	 the	 screened	 infants	most	
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	likely	due	to	cross-infection	within	clinics.		
The	most	convincing	benefit	for	screening	comes	from	nutritional	data.	Studies	have	shown	
that	 screening	 leads	 to	better	 early	 nutrition,	 as	 treatments,	 including	pancreatic	 enzyme	
replacement	 treatment,	 are	 started	 earlier.	 Unsurprisingly,	 screened	 infants	 had	 a	 higher	
height	 and	weight	 percentage	 compared	with	 these	 diagnosed	 clinically,	 as	 less	 time	had	
passed	prior	to	introduction	of	treatments	during	which	they	risk	becoming	malnourished.	
What	was	more	surprising	was	that	this	difference	persisted	and	was	present	on	analysis	of	
nutritional	status	at	the	age	of	10	years	(51)	and	at	time	of	transition	to	adult	care	(59).		
The	 most	 recent	 data	 from	 the	 Wisconsin	 study	 examined	 clinical	 outcomes	 of	 the	
individuals,	now	aged	20	years	old	and	found	that	the	infants	with	better	nutrition	in	early	
life	had	better	 clinical	 status	at	20	years	of	age	 (62).	 The	 importance	of	nutritional	 status	
was	 also	 highlighted	 in	 a	 recent	 prospective	 observational	 study	 of	 the	 US	 CF	 registry	
patients	born	1989-1992	(63).	This	identified	that	nutritional	status	at	age	4	has	an	impact	
on	health	at	age	18	years	with	weight-for-age	percentile	predicting	lung	function	in	later	life.	
Those	with	the	highest	FEV1	at	18	years	of	age	had	a	weight-for-age	percentile	>50th	centile	
at	4	years	of	age,	and	mortality	in	this	group	was	also	lower.	Despite	this	survival	and	lung	
function	 advantage	 there	 was	 no	 difference	 in	 P.	 aeruginosa	 acquisition	 between	 the	
weight-for-age	percentile	groups.	
The	screened	infants,	with	better	nutritional	status,	were	also	found	to	have	better	health	
related	 quality	 of	 life	 in	 their	 teenage	 years	 (64).	 Better	 nutrition	 would	 be	 expected	 to	
result	in	a	better	quality	of	life,	which	would	hopefully	impact	on	general	well	being.	
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	Screening	 of	 infants	 with	 CF	 leads	 to	 earlier	 diagnosis	 and	 the	 ability	 to	 introduce	
treatments	 from	 early	 on	 before	 significant	 symptoms	 have	 occurred,	 and	 there	 is	 also	
evidence	 of	 better	 survival.	 A	 significant	 improvement	 in	 survival	 was	 seen	 in	 the	
Netherlands	 with	 screening;	 survival	 at	 age	 11	 years	 increased	 from	 65%	 the	 previous	
cohort	of	non-screened	children	to	94%	in	the	screened	cohort.	Clearly	treatments	overall	
have	improved	since	publication	of	this	paper	in	1995,	and	we	would	not	expect	a	survival	of	
just	 65%	 in	 non-screened	 children	 now,	 but	 nonetheless	 it	 showed	 that,	 at	 that	 time,		
screening	offered	a	clinical	advantage.		More	recent	survival	outcome	data	come	from	the	
Australian	 cohort.	 There	 was	 no	 survival	 advantage	 of	 screening	 at	 transition	 from	
paediatric	to	adult	care,	but	by	the	age	of	25	years,	there	was	a	difference	in	survival	of	20%	
between	screened	and	non-screened	individuals	(59).	
One	big	problem	with	such	studies	is	the	methodology	used.	There	is	only	one	randomised	
control	 trial	 (RCT)	of	screening	(51)	and	all	 the	others	have	 inferior	methodology	and	pre-	
and	post-	screening	results	are	complicated	by	better	treatments	available	with	time.	This	
important	 factor	 should	 be	 remembered	 when	 considering	 the	 results	 of	 pre	 and	 post	
screening	comparative	studies.		
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2.2 Cystic	fibrosis	-	pathophysiology	
2.2.1 CF	genetic	mutations	
	CF	 occurs	 in	 the	 presence	 of	 two	 CF	 disease	 causing	 mutations	 and	 is	 inherited	 as	 an	
autosomal	recessive	disease	with	a	prevalence	of	approximately	1:2,500	and	a	carrier	rate	
of	around	1:25	in	the	UK	Caucasian	population.	It	is	estimated	that	there	are	approximately	
60,000-70,000	 people	 with	 CF	worldwide	 (65).	 It	 is	 caused	 by	 a	 defect	 in	 the	 CFTR	 gene	
located	on	the	 long	arm	of	chromosome	7.	 In	1985	the	gene	that	caused	this	disease	was	
localised	to	the	long	arm	of	chromosome	7,	position	7q21-24	(66),	with	the	sequence	being	
fully	identified	in	1989	(67).	This	gene	encodes	the	CFTR	protein,	which	in	its	normal,	wild-
type	form	is	made	up	of	1480	amino	acids(68).	
Over	 2000	 mutations	 within	 the	 CFTR	 gene	 have	 been	 described	 but	 less	 than	 200	 are	
known	to	be	disease-causing	(69);	some	mutations	still	produce	a	functional	protein	and	are	
probably	 merely	 benign	 polymorphisms.	 Disease	 causing	 mutations	 can	 be	 divided	 into	
6	classes	according	to	the	way	in	which	the	resulting	protein	is	defective,	described	in		Table 
2. 
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	Table	2:	Summary	of	mutation	classes	
Mutation	
class	 Basic	defect	 CFTR	protein	abnormality	
Examples	 Potential	treatments		
Old	name	 New	name	 	
I	 Non-sense	mutations	
Premature	termination	codon	(PTC)	leads	to	a	truncated	
protein	with	no	function.	
G542X	 Gly542X	 Drugs	aiming	to	read-through	the	PTC	are	in	
development	and	clinical	trials	but	to	date	results	
have	been	disappointing	(70-72).		
	
W1282X	 Trp1282X	
II	
	
Trafficking	
defect	
Misfolding	causes	the	protein	to	fail	to	traffic	to	the	
apical	surface	of	the	cell	
	
ΔF508	 Phe508del	 CFTR	correctors	have	been	developed	and	one,.	
Lumacaftor	stabilises	the	CFTR	protein	to	allow	
transport	to	the	cell	membrane.		Orkambi®;	a	
combination	of	Lumacaftor	and	the	CF	
potentiator	`Ivacaftor	(see	below)	has	now	been	
licensed	in	the	USA.	(73,	74)		
N1303K	 Asn1303Lys	
III	 Gating	defect	
Normal	quantities	of	CFTR	protein	reach	the	cell	
membrane	but	remain	closed	preventing	normal	
function.	
G551D	 Gly551asp	
Ivacaftor;	CFTR	potentiator	allowing	opening	the	
gate	to	improve	function.	Now	licensed	in	USA	
and	Europe	those	with	all	class	3	mutations	and	
≥2years	of	age	s	
(75,	76)		
	
IV	 Decreased	conductivity	
Protein	reaches	the	apical	surface	but	conductance	
across	the	channel	is	poor	due	to	the	abnormal	
conformation	
R117H	 Arg117His	
Ivacaftor;	some	evidence	that	function	is	
improved	by	Ivacaftor	in	this	class	with	
improvement	in	sweat	chloride	and	improved	
lung	function	in	some	adult	patients,	but	not	
children(77).	Approval	has	been	granted	in	USA	
and	being	sought	in	Europe.			
	
V	 Splicing	defect	
Decreased	amounts	of	CFTR	reach	the	apical	membrane.	
The	CFTR	that	does,	probably	functions	normally;	hence,	
many	patients	with	these	mutations	have	a		
milder	phenotype	
38949+10kbC>T	 	
	
VI	 Decreased	Half-life	
CFTR	is	functional	but	half-life	is	decreased	leading	to	
overall	decreased	amount	of	CFTR	present	at	the	cell	
surface	and	may	impair	regulation	of	other	channels	
Q1412X	 Gln1412X	
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2.2.2 CFTR	mutation	classes	
Class	 I	 mutations	 lead	 to	 a	 premature	 ‘stop’	 in	 mRNA	 transcription	 and	 a	 short,	 non-
functioning	protein,	which	is	immediately	destroyed.	Those	of	class	II	encode	a	structurally	
abnormal,	 misfolded,	 protein	 that	 is	 degraded	 by	 the	 endoplasmic	 reticulum	 before	
reaching	the	cell	surface.	Protein	of	classes	III	to	VI	reach	the	cell	surface	but	fail	to	function	
appropriately:	 Class	 III	 mutations	 have	 decreased	 activation	 of	 the	 channel	 and	 remain	
closed	 and	 class	 IV	 mutations	 cause	 decreased	 conductance	 of	 ions	 across	 the	 channel.	
Class	V	mutations	are	usually	splice	site	mutations	which	lead	to	a	reduced	amount	of	CFTR	
at	the	cell	surface,	so	some	function	occurs	but	at	a	reduced	level.	Class	VI	mutations	lead	to	
a	 shortened	 half-life	 due	 to	 protein	 instability	 and	 may	 also	 impair	 the	 regulation	 of	
neighbouring	 channels	 by	 CFTR.	Whilst	 these	 6	 classes	 have	been	well	 described	 it	 is	 not	
always	 clear-cut	 as	 to	 which	 class	 a	 mutation	 belongs	 to	 and	 classes	 are	 not	 mutually	
exclusive;	for	example	F508del	is	described	a	class	II	mutation	but	also	has	class	III	and	class	
VI	properties.		
2.2.3 CF	pathophysiology	
In	 normal	 health,	 the	 CFTR	protein	 crosses	 the	 cytoplasm	 to	 the	 cell	membrane	where	 it	
functions,	the	best-described	function	being	as	a	chloride	channel,	with	inhibitory	effects	on	
its	 neighbouring	 epithelial	 sodium	 channel,	 ENaC.	 It	 is	 therefore	 critical	 in	 chloride	 and	
sodium	transport	across	the	cell	membrane	and	as	a	consequence,	regulates	the	hydration	
of	 the	 epithelial	 surface	 (water	 following	 sodium	down	 its	 osmotic	 gradient).	 Bicarbonate	
secretion	 is	 also	 impaired	 and	 the	 abnormal	 pH	 of	 the	 cell	 surfaces	 is	 thought	 to	 cause	
40
dysregulation	 of	 innate	 defence	molecules	within	 this	 environment.	 Thus,	 defective	 CFTR	
protein	 leads	 to	 absent	 or	 decreased	 chloride	 secretion,	 increased	 sodium	 and	 water	
absorption	and	airway	surface	liquid	depletion.	This	results	in	the	classical	manifestations	of	
CF:	infection,	inflammation	and	eventual	bronchiectasis	(Figure	2).	
Figure	2:	Flow	chart	to	illustrate	the	downstream	consequences	of	CFTR	mutations.	
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The	 eventual	 outcome	 is	 on-going	 airway	 infection	 and	 inflammation	 leading	 to	 airway	
obstruction	and	ultimately	respiratory	failure	(78)	but	the	exact	reason	as	to	why	increased	
infections	 and	 inflammation	 occur	 is	 not	 completely	 understood	 and	 studies	 provide	
conflicting	 results.	 Excessive	 inflammation	 and	 altered	 immune	 signalling	 occur,	 but	
whether	this	due	to	an	innate	immune	defect,	altered	ion	transport,	the	consequence	of	a	
dehydrated	 airway,	 defective	 mucociliary	 clearance	 or	 a	 combination	 of	 these	 remains	
debated.		
2.2.4 High-salt	model	
One	theory	as	to	how	the	abnormal	CFTR	protein	leads	to	abnormal	airway	function	is	the	
high	 salt	 hypothesis	 (79),	 although	 this	 is	 not	 currently	 a	 commonly	 held	 view	 .	 It	 was	
suggested	 that	 normal	 epithelial	 cells	 with	 normal	 CFTR	 produce	 a	 low	 salt	 solution	
environment	 optimising	 the	 efficacy	 of	 the	 activity	 of	 the	 antimicrobial	 peptides	 (80,	 81).	
Some,	although	not	all,	antimicrobial	peptides	are	salt	sensitive	and	function	less	effectively,	
or	not	at	all,	in	a	high	salt	environment.	Because	the	CF	respiratory	epithelium	cells	exhibit	
increased	sodium	chloride	transport	due	to	the	defective	CFTR,	there	is	an	assumption	that	
the	 airway	 surface	 liquid	will	 be	 hypertonic	 thereby	 rendering	 these	 peptides	 less	 active.	
This	assumed	hypertonicity	of	 the	airway	 surface	 liquid	has	been	difficult	 to	prove	and	 in	
fact,	most	studies	have	found	it	to	be	isotonic	(82).		
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2.2.5 Bicarbonate	and	pH	
Defence	molecules	within	the	airway	are	affected	by	the	acidity	of	the	environment	and	so	
alterations	in	the	composition	of	the	airway	surface	liquid	that	alter	pH	may	play	a	role	the	
functioning	of	the	immune	system.	Cell	studies	found	that	altering	the	pH	of	ASL	from	8	to	
6.8	decreased	the	ability	of	LL-37	to	kill	both	S.	aureus	and	P.	aeruginosa	and	decreased	the	
synergism	between	the	antimicrobial	peptides	(11).		The	pH	of	nasal	ASL	has	been	shown	to	
be	more	acidic	 in	CF	infants	than	in	non-CF	infants	suggesting	this	may	play	a	role	in	early	
immunity;	this	difference	was	not	seen	in	older	children	and	adults	(83)	making	it	unclear	if	
it	has	relevance	to	human	disease.		
The	CF	pig	develops	 lung	disease	very	 similar	 to	 that	 seen	 in	humans,	with	 inflammation,	
airway	 obstruction	 and	 mucous	 plugging.	 Whilst	 these	 features	 are	 not	 present	 at	 birth	
there	 is	 evidence	of	 airway	disease	very	early	on	 (84)	 and	evidence	of	 an	 innate	 immune	
defect	with	reduced	bacterial	killing	of	H.	Influenza,	P.	aeruginosa	and	S.	aureus	by	airway	
surface	liquid	as	compared	to	that	from	non-CF	pigs	(84).	A	series	of	experiments	isolating	
different	components	immune	function	found	that	the	reduced	bacterial	killing	was	due	to	
altered	 functioning	 of	 the	 antimicrobial	 peptides,	 despite	 these	 being	 present	 at	 normal	
concentrations.	The	authors	found	that	the	ASL	was	more	acidic	in	the	CF	pigs	than	the	non-
CF	pigs.	By	decreasing	the	acidity	of	the	ASL	of	the	CF	pigs,	antimicrobial	activity	and	thus	
bacterial	 killing	was	 improved;	 and	 similarly,	 antimicrobial	 bacterial	 killing	was	 reduced	 in	
the	non-CF	pigs	by	decreasing	the	environmental	pH	(85).	This	finding	implies	that	there	is	
normal	production	of	the	innate	defence	peptides,	but	their	function	is	reduced	within	the	
environment	of	the	CF	airway,	at	least	in	the	pig.		
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2.2.6 Defective	mucociliary	clearance	
2.2.6.1 Overall	view	
Mucociliary	 clearance	 (MCC)	 appears	 to	 be	 the	 primary	 form	 of	 innate	 defence	 of	 the	
respiratory	 tract	against	bacteria,	and	effective	MCC	 relies	upon	 the	cilia	being	 intact	and	
having	 normal	 structure	 and	 function,	 the	 depth	 and	 composition	 of	 the	 periciliary	 fluid	
layer	to	be	optimal	and	mucous	rheology	to	be	within	the	normal	range.	Defective	MCC	can	
occur	 as	 a	 consequence	of	 a	 decreased	periciliary	 layer	 in	which	 the	 cilia	 reside	or	 due	 a	
primary	defect	 in	 the	action	of	MCC	 itself	 rather	 than	a	consequence	of	ASL	dehydration.		
Although	it	is	generally	accepted	that	MCC	is	impaired,	there	is	some	disagreement	amongst	
studies	 evaluating	MCC	 in	 CF	 individuals	with	 reports	 of	 increased,	 decreased	 and	 similar	
clearance	 to	 healthy	 individuals	 (82,	 86).	 It	 has	 been	 suggested	 that	 differences	 in	
methodology	may	account	for	the	differences	described.		
2.2.6.2 Low	fluid	leading	to	impaired	MCC		
A	 commonly	 held	 view	 is	 that	 effective	MCC	 is	 impaired	 as	 a	 consequence	 of	 abnormal	
sodium,	chloride	and	water	transport	arising	from	the	defective	function	of	the	CFTR	protein	
in	the	apical	cell	membrane	(87).	 It	has	been	shown	that	the	height	of	the	periciliary	layer	
on	 the	 respiratory	 epithelial	 cells	 is	 dramatically	 reduced	 in	 CF	 and	 the	 effect	 of	 this	 is	 a	
predisposition	 to	 accumulation	 of	 debris	 from	 decreased	 pathogen	 clearance	 and	 the	
increased	 mucous	 layer	 provides	 excellent	 nutrition	 for	 invading	 organisms	 to	 thrive	
promoting	bacterial	growth	(82,	88).		
There	 is	 considerable	 evidence	 to	 support	 this	 theory	 including	 cell-culture	 studies,	 and	
animal	 and	 human	 studies.	 Cell	 culture	 experiments	 identified	 that	 7μm	 is	 the	 optimal	
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height	for	cilia	functioning	and	that	in	CF,	the	height	of	this	layer	is	just	3	μm,	with	this	fluid	
appearing	to	be	present	but	trapped	by	collapsed	cilia.	In	addition,	such	studies	have	found	
that	mucus	 in	CF	 is	much	denser	with	a	much	higher	 concentration	of	 solids	 than	 the	2%	
seen	in	the	mucus	secreted	by	normal	epithelial	cells	(87,	89).	A	study	of	MCC	in	CF	airway	
cell	cultures	found	that	MCC	decreased	secondary	to	loss	of	periciliary	volume	and	could	be	
restored	by	 replacement	of	water	 (86)	suggesting	depleted	ASL	 the	cause	of	 the	 impaired	
MCC.		
Whilst	 CF	 mice	 display	 little	 in	 the	 way	 of	 lung	 disease,	 likely	 due	 to	 the	 absence	 of	
significant	 CFTR	 in	 the	 airway	 of	 wild	 type	 mice	 with	 sodium	 and	 chloride	 secretion	
dependent	upon	other	mechanisms,	ENaC	overexpressing	mice	do	display	lung	disease	akin	
to	that	seen	in	CF;	decreased	airway	surface	liquid,	increased	mucus	concentration,	mucus	
obstruction,	goblet	–cell	hyperplasia	and	neutrophilic	infiltration.	This	suggests	that	the	low	
ASL	volume	is	responsible	for	producing	the	much	of	the	CF	lung	disease	and	illustrates	the	
importance	of	ASL	depletion	in	CF	pathophysiology	(87).		
Findings	of	studies	evaluating	the	effects	on	7%	hypertonic	saline	in	CF	patients	support	the	
airway	hydration	hypothesis	in	that	the	addition	of	the	salt	solution	lead	to	improved	MCC,	
a	 clinical	 improvement	 and	 reduced	 bacterial	 load,	 whereas	 one	 would	 expect	 a	
deterioration	with	 the	high-salt	 theory	upon	 increasing	 the	salt	 concentration	 further	 (90,	
91).		
MCC	with	decreased	ASL	 appears	 to	be	 slowed	 in-vivo,	 but	 static	 in-vitro,	 suggesting	 that	
other	factors	play	a	part	in	the	human	airway	that	do	not	translate	to	cell-culture	studies.	It	
has	 been	 demonstrated	 that	 sheer	 forces	 double	 the	ATP	 release,	which	 in	 turn	 increase	
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MCC	and	sheer	forces	are	increased	by	exercise,	ventilation	and	motion	(87).	Many	of	these	
cell	 culture	 experiments	were	 done	 in	 static	 cultures	 and	 further	work	 (discussed	 below)	
suggests	that	a	2nd	hit	is	needed	for	these	effects	to	be	seen	in-vivo.	
2.2.6.3 MCC	independent	of	airway	surface	liquid	
An	alternative	view	 is	 that	MCC	 is	 independent	of	ASL	volume	and	 this	hypothesis	will	be	
discussed	here	in	brief.	It	is	uncertain	whether	the	MCC	is	abnormal	from	birth,	contributing	
to	lung	disease,	or	if	it	becomes	abnormal	due	to	the	disease	course,	which	then	accelerates	
disease	progression.	CF	mouse	studies	found	tracheal	MCC	rates	at	birth	to	be	half	of	that	in	
wild	type	mice	 implying	MCC	is	decreased	prior	to	 infection	(92).	 In-vivo	assessment	of	CF	
piglets	was	performed	using	radioactive	particles	to	assess	MCC	at	birth.	The	authors	of	this	
study	concluded	that	MCC	was	normal	at	birth	but	became	less	effective	with	metacholine	
challenge,	 contrary	 to	 the	 expected	 response	 and	 as	 is	 seen	 in	 the	 non-CF	 piglets.	 In	
addition,	 the	 study	 found	 that	 MCC	 was	 impaired	 even	 when	 methods	 were	 used	 to	
preserve	the	periciliary	 layer,	therefore	concluding	that	reduced	effectiveness	of	MCC	was	
due	 to	 abnormalities	 of	 sub-mucous	 gland	 function	 and	 not	 to	 surface	 epithelial	
function(93).		
2.2.6.4 Mucus	rheology	
Altered	mucus	 rheology	may	 also	have	 an	 impact	on	MCC.	 In	 the	CF	piglet	model,	 it	was	
found	 that	 mucus	 rheology	 was	 abnormal	 even	 before	 it	 reached	 the	 airway,	 therefore	
precluding	airway	dehydration	causing	loss	of	mucus	water	as	a	cause	of	the	dense	mucus	
seen	in	CF	(93).	These	results	suggest	that	MCC	is	normal	at	birth	but	function	is	reduced	in	
response	to	stimuli.		The	findings	of	this	study	were	supported	by	another	study	evaluating	
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normal	and	CF-pig	tracheas	which	found	abnormally	viscous	mucous	as	an	inherent	defect	
and	reduced	MCC	not	related	to	periciliary	layer	(PCL)	depth	(94).	
2.2.6.5 Second	viral	hit	
It	is	hypothesised	that	MCC	may	initially	be	normal	but	a	second	hit	from	exposure	to	a	virus	
can	 cause	 impaired	 cilia	 function.	 The	 presence	 of	 viruses	 within	 the	 airway	 in	 a	 clinical	
environment	also	appears	to	have	a	role	to	play	in	the	differences	seen	between	the	in-vivo	
and	 in-vitro	 environments.	 Cell-culture	 experiments	 have	 shown	 that	 RSV	 infection	
decreases	the	PCL	as	a	direct	consequence	(87,	95).	This	suggests	that	a	viral	hit	to	the	CF	
airways	leads	to	a	depletion	in	the	ASL	predisposing	to	bacterial	infection.	It	may	therefore	
be	that	ASL	is	sufficient	for	MCC	under	normal	circumstances	but	exposure	to	viruses	alters	
this	and	leads	to	bacterial	infections	and	the	intermittent	exacerbations	seen	in	the	clinical	
course	of	the	disease.		
2.2.7 Innate	pro-inflammation	and	innate	immune	defect	theory	
2.2.7.1 Overall	view	
There	are	four	proposed	models	as	to	how	inflammation	occurs	within	the	CF	airway,	which	
are	not	mutually	exclusive;		
1. Abnormal	signalling	initiates	inflammation	in	the	absence	of	infection
2. Inflammation	occurs	only	secondary	to	infection	encountered	in	the	airway
3. Inflammation	occurs	secondary	to	infection	but	in	an	excessive	fashion
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4. There	is	a	failure	to	resolve	inflammation	that	has	occurred	in	response	to	infection
Inflammation	 occurs	 as	 a	 protective	 mechanism	 as	 part	 of	 host	 defence	 and	 so	 can	 be	
argued	 that	 it	 a	 positive,	 not	 a	 negative	 factor	 within	 the	 airways.	 Certainly	 a	 degree	 of	
inflammation	 may	 be	 beneficial	 but	 once	 it	 becomes	 excessive	 or	 not	 switched	 off	
appropriately,	this	balance	is	tipped	and	it	becomes	detrimental	with	destructive	effects	of	
the	integrity	of	the	airway	wall	(96).		
CFTR	is	located	within	the	apical	membrane	of	the	surface	epithelium,	and	as	this	is	an	area	
housing	many	innate	defence	molecules,	the	link	between	CF	and	innate	immunity	has	been	
the	subject	of	much	research	(97).		
Altered	 signalling	 pathways	 with	 abnormal	 initiation	 of	 inflammation	 along	 with	 an	
exaggerated	and	prolonged	inflammatory	response	(98,	99)	have	been	described	suggesting	
a	predisposition	towards	an	inflammatory	state	within	the	CF	airway.	No	unifying	pathway	
connecting	 these	 defective	 inflammatory	 response	 pathways	 to	 defective	 CFTR	 has	 been	
identified	but	the	combination	of	these	abnormalities	may	help	to	explain	the	inflammatory	
phenotype	seen	in	CF.		
TLR2	is	the	receptor	most	predominantly	expressed	on	the	cell	surface	in	the	airway;	it	is	up-
regulated	by	bacterial	stimulation	and	this	response	is	reduced	in	people	with	CF	(97,	100)	
compared	to	those	without	CF	suggesting	a	defect	in	the	innate	immune	system	and	leading	
to	reduced	effectiveness	of	pathogen	clearance.		
It	was	 thought	 that	CFTR	may	have	a	 role	 in	clearance	of	P.	aeruginosa	and	 the	defective	
channel	 altered	 this	 ability	 but	 more	 recent	 studies	 have	 shown	 that	 this	 organism	 is	
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predominantly	found	in	the	mucous	layer	and	not	directly	at	the	cell	surface	making	a	direct	
role	of	CFTR	in	P.	aeruginosa	clearance	less	likely	(82).	
It	is	debated	if	neutrophil	dysfunction	in	CF	is	due	to	chronic	inflammation	or	to	expression	
of	CFTR	in	immune	cells	leading	to	impaired	function	(Table	3).	
Recent	 studies	 of	 the	 CF	 ferret	 have	 found	 reduced	 antimicrobial	 activity	 against	 P.	
aeruginosa,	 reduced	MCC	 by	 7	 days	 of	 age	 and	 also	 altered	 inflammatory	 cytokines	 and	
signalling	 pathways	 in	 sterile	 newborn	 lungs	 suggesting	 that	 more	 than	 one	 defect	 is	
responsible	 for	 the	 lung	 disease	 seen	 and	 that	 CF	 ferrets	 have	 defects	 in	 both	 innate	
immunity	and	in	their	inflammatory	signalling	(101).		
It	 is	 likely	that	there	 is	not	one	explanation	for	the	CF	 lung	disease	seen	 in	humans,	but	a	
combination	of	defects	culminating	in	the	phenotypic	picture	seen.		
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Table	3:	Immune	cells	in	CF	lung	disease	(from	(97)	
Immune	cell		 Functional	role	 Impairment	in	CF	lung	disease	
Neutrophils		 Anti-bacterial	 and	 -fungal	 host	
defense	
• Impaired	 chlorination/intracellular	
killing	of	phagocytosed	bacteria
Cytokine/chemokine	release	 • Delayed	apoptosis
• Proteolytic	 and	 oxidative	 tissue	
damage
• Cleavage	 of	 leukocyte	 surface	
receptors
• DNA	release	(necrosis/NETosis)
• Increased	elastase	release
• Enhanced	chemotaxis
Macrophages/	
monocytes		
Anti-bacterial	 and	 -fungal	 host	
defense	
• Removal	 of	 apoptotic	 cells	
(efferocytosis)
• Antigen-presentation
• Cytokine/chemokine	release
• Immune	regulation
• Increased	 secretion	 of	 pro-
inflammatory	cytokines
• Disturbed	ceramide	metabolism
• Dysregulated	TLR4	trafficking
• Downregulated	autophagy
• Macrophages:	hyper-
responsiveness	towards	LPS
• Monocytes:	 downregulation	 of	
TREM/hyporesponsiveness	to	LPS
• Reduced	 expression	 of	 scavenger	
receptors
• Cleavage	 of	 phosphatidylserine	
receptors/impaired	efferocytosis
T	cells	 Anti-bacterial,	 -Fungal	 and	
-viral	host	defense
• CFTR-mediated	Th2	shift
Antibody	production	 • P.	aeruginosa-mediated	Th2	shift
Neutrophil	recruitment	(Th17)	 • Th17	activation
Allergic	responses	(ABPA,	Th2)	 • P.aeruginosa-mediated	impairment	
of	T	cell	proliferation
Immune	regulation	(Tregs)	
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2.2.7.2 Abnormal	initiation	of	inflammation	
It	has	been	argued	that	this	theory	 is	supported	by	the	presence	of	 inflammation	that	has	
been	 reported	 in	 infants	with	 CF,	 prior	 to	 detected	 infection	 or	 symptoms	 (56,	 102-105).	
This	finding	is	not	universal,	however,	and	other	studies	report	that	inflammation	is	absent	
if	infection	is	not	detected	(106).	Some	soluble	inflammatory	markers,	the	cytokines	IL-8	and	
TNF-α,	 have	 also	 been	 reported	 to	 be	 higher	 in	 bronchoalveolar	 lavage	 fluid	 (BALF)	 of	
infants	 with	 CF	 even	 in	 the	 absence	 of	 detected	 pathogens,	 and	 in	 the	 presence	 of	
pathogens	the	response	was	 found	to	be	exaggerated	 (103,	104,	107).	However,	although	
infection	was	not	detected	 in	 the	BALF	samples,	 this	was	taken	at	a	single	 time	point	and	
therefore	 earlier	 infection	 with	 persisting	 and	 prolonged	 inflammation	 could	 account	 for	
this.	Alternatively,	 infection	could	be	present	but	not	detected	as	studies	have	 found	that	
whilst	inflammation	may	be	seen	throughout	airways,	bacterial	organisms	may	not	be	found	
in	all	lobes	and	if	lavage	taken	from	just	one	or	two	lobes	as	is	standard	practice	(108),	the	
presence	of	 infection	may	be	missed	 (109,	110).	 In	addition,	 samples	are	 taken	whilst	 the	
person	 is	on	antibiotics	 in	some	cases	 in	which	case	the	bacteria	may	not	grow	of	the	cell	
culture	plate	even	if	present.		
NFκB	has	a	central	role	as	a	regulator	of	downstream	inflammation	including	regulation	of	
IL-8,	GM-CSF,	Il-1β	and	IL-6.	Animal	experiments	and	cell	culture	studies	have	shown	that	CF	
cells	 have	 an	 increase	 in	 reactive	 oxygen	 species,	 which	 have	 a	 role	 in	 NFkB	 activation,	
leading	 to	 an	 increase	 in	 the	 pro-inflammatory	 cytokines	 suggesting	 a	 non-infective	
inflammatory	 response	 (111,	 112).	 Whilst	 NFκB	 appears	 to	 be	 normal	 in	 CF	 cells,	 this	
transcription	factor	is	released	from	its	precursor	IκB	during	degradation.	Degradation	of	IκB	
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occurs	under	the	 influence	of	 IκBKinase	(IKK),	which	has	been	found	to	be	 increased	 in	CF	
cells.	
2.2.7.3 Exaggerated	inflammatory	response	
Recent	 work	 has	 suggested	 that	 the	 adaptive	 immune	 system	 may	 play	 a	 role	 in	
inflammation,	with	increased	Th17	signalling	and	consequent	increased	expression	of	IL-17	
being	seen	in	patients	with	CF	(113-116).	IL-17	is	thought	to	be	important	in	the	recruitment	
of	neutrophils	to	the	airways	in	response	to	infections,	thereby	increasing	the	neutrophilic	
inflammation	within	the	CF	airway.	The	inflammatory	response	that	 is	seen	may	therefore	
be	appropriately	initiated	but	due	in	part	to	this	increase	in	IL-17,	the	response	heightened.		
In-vitro	 studies	 using	 respiratory	 epithelial	 cells	 have	 show	 heightened	 inflammatory	
responses	 in	 the	 absence	 of	 CFTR	 and	 that	 the	 CFTR	 function	 correlates	 with	 basal	 and	
inducible	 inflammatory	 responses	 (117,	 118).	 These	 cell	 studies	 also	 show	 that	 the	
inflammatory	response	is	heightened	in	cells	treated	with	chemical	 inhibitors	of	CFTR,	and	
conversely	a	decreased	inflammatory	response	is	seen	following	treatment	of	the	cells	with	
CFTR	potentiators	–	small	molecules	that	have	been	developed	to	bind	to	CFTR	at	the	cell	
surface	and	increase	its	gating	potential.		
2.2.7.4 Prolonged	response/failure	of	resolution	
Once	 the	 inflammatory	 signalling	 event	 is	 no	 longer	 present,	 resolution	 of	 inflammation	
must	occur	to	prevent	unnecessary	on-going	recruitment	of	inflammatory	cells	and	without	
appropriate	 active	 mechanisms	 to	 do	 the	 inflammation	 persists	 leading	 to	 tissue	
destruction.	Resolution	of	infection	is	now	thought	of	as	an	active	process,	not	merely	the	
result	 of	 an	 absence	 of	 a	 pro-inflammatory	 drive.	 	 Neutrophils	 and	macrophages	 express	
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CFTR	giving	rise	to	the	suggestion	that	CF	neutrophils	have	abnormal	function	and	this	has	
also	been	demonstrated	in	genetic	studies	evaluating	the	possibility	of	polymorphisms	of	CF	
modifier	genes	 (119).	They	release	 less	of	 the	antimicrobial	peptides	LL-37	and	 lactoferrin	
and	 the	 proteinase	 MMP-9,	 which	 has	 role	 within	 the	 regulation	 of	 neutrophil	 activity.	
Correcting	 the	 CFTR	 protein	 defect	 corrects	 the	 expression	 of	 these	 components	 by	
neutrophils	suggesting	an	innate	immune	defect	that	can	be	corrected	(120).		
IL-10	is	generally	considered	to	be	an	anti-inflammatory	cytokine	with	a	role	in	resolution	of	
inflammation	 and	 which	 acts	 in	 part	 by	 decreased	 activation	 of	 NFκB	 through	 IκB	
preservation	 and	 has	 been	 found	 to	 be	 decreased	 in	 the	 CF	 airway	 (98,	 99,	 111).	 This	
reduction	 in	 IL-10	 may	 be	 an	 important	 factor	 in	 the	 heightened	 and	 prolonged	
inflammatory	response	that	has	frequently	been	described.	Lipoxin	A4,	which	also	has	a	role	
in	 resolution	 of	 inflammation	 decreasing	 IL-8	 expression	 and	 arresting	 neutrophilic	
inflammation,	is	decreased	in	people	with	CF	(121).		
In-vitro	 cell	 culture	 studies	 have	 not	 conclusively	 shown	 an	 exaggerated	 inflammatory	
response	 and	 whether	 there	 is	 a	 constitutional	 CFTR	 related	 innate	 immune	 defect	 in	
remains	unclear	(122).	
2.2.8 Antimicrobial	peptides	in	the	CF	airway	
Studies	have	reported	that	levels	of	BALF	HBD-2	and	LL37	are	increased	in	CF	as	compared	
to	healthy	controls;	levels	increase	in	the	presence	of	infection	and	HBD-2	is	undetectable	in	
health	 (123,	 124).	 A	 weak	 association	 has	 been	 reported	 between	 these	 antimicrobial	
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peptides	 and	 MEF25	 (maximal	 expiratory	 flow	 at	 25%	 VC)	 but	 no	 other	 spirometric	
parameters.		A	lower	MEF25	was	related	to	increased	levels	of	LL-37	but	lower	levels	of	HBD-
2	(124).	Cell	studies	however	have	found	that	HBD-2	mRNA	expression	is	similar	between	CF	
and	 non-CF	 cells	 which	 may	 suggest	 that	 any	 increase	 in	 protein	 levels	 is	 due	 to	 the	
presence	of	infection	rather	than	an	innate	alteration	in	signalling	(125),	or	it	may	merely	be	
that	the	protein	has	a	shorter	half-life	in	non-CF	individuals	or	reduced	mRNA	translation.		
LL-37	 is	 found	 in	 high	 concentration	with	 the	 CF	 airway,	 but	 it	 has	 been	 shown	 that	 this
peptide	binds	 to	glycosaminoglycans	 (GAGs)	 (126),	and	 is	 inactive	 in	 this	bound	 form.	Cell	
studies	 found	 that	 GAG-lysases	 cleave	 this	 bond,	 thereby	 releasing	 LL-37	 and	 allowing	
microbial	killing.	A	study	evaluating	the	effect	of	hypertonic	saline	found	that	this	was	also	
capable	 of	 releasing	 LL-37	 from	 GAGs	 (127).	 It	 has	 also	 been	 shown	 that	 LL-37	 has	
significantly	attenuated	action	against	both	S.	aureus	and	P.	aeruginosa	with	a	lowered	pH	
(11),	as	has	been	suggested	may	be	the	case	in	the	CF	airway,	particularly	 in	the	CF	infant	
(11).	CF	human	infants	and	CF	piglets	have	acidic	ASL	when	examined	in	cultured	cells,	 in-
vitro	experiments	and	 in-vivo	measurements,	but	the	picture	is	considerably	more	variable	
in	older	children	and	adults	(83,	85,	128-130)	making	this	component	more	relevant	to	pre-
school	children	with	CF.	
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2.3 CF	airway	infection	
Although	infection	is	frequently	seen	in	infants	and	younger	children	with	CF,	the	incidence	
of	 infection	 rises	 with	 age	 (13).	 It	 was	 traditionally	 thought	 that	 the	 bacterial	 organisms	
commonly	encountered	within	the	CF	airway	were	S.	aureus,	H.	influenza,	P.aeruginosa,	B.	
cepacia	complex,	Stenotrophomonas	maltophilia	and	Achromobactera	xyloxidans.	
Although	 still	 only	 used	 in	 the	 research	 setting,	 pathogens	 can	 now	 be	 detected	 using	
molecular	techniques,	rather	than	conventional	microscopy	and	culture	(131)	and	molecular	
techniques	 have	 allowed	 recognition	 that	 the	 range	of	 bacteria	 is	 a	 great	 deal	 larger	 and	
more	complex	than	previously	thought,	both	in	healthy	and	CF	individuals	(132,	133)	.	The	
entire	 airway	microbiome	 can	 now	 be	 explored	 and	 a	 diverse	 array	 of	microbes	 is	 being	
detected	using	molecular	assays	(132,	133).	A	study	of	patients	with	CF	exacerbations	found	
that	17%	of	patients	were	negative	for	all	bacterial	organisms	on	conventional	testing,	but	
molecular	 testing	 revealed	 a	 diverse	 range	 of	 pathogens	 (132).	 The	 significance	 of	 the	
presence	 of	 many	 of	 these	 organisms	 is	 not	 known	 and	 research	 is	 currently	 being	
undertaken	 to	 understand	 this	 (Reviewed	 in	 (134)).	 In	 young	 children	with	 CF,	 there	 is	 a	
complex	microbiome	with	increasing	diversity	in	the	first	two	years	of	life	(135),	but	as	age	
increases	diversity	decreases	and	specific	pathogen	communities	become	apparent	(136).	
	NTM	 are	 also	 now	 being	 identified	more	 frequently	 within	 the	 CF	 airway	 (111)	 and	 can	
cause	 significant	 morbidity	 for	 some	 individuals.	 The	 two	 most	 commonly	 encountered	
disease	 causing	 NTMs	 are	 Mycobacterium	 abscessus	 and	 Mycobacterium	 avium	
intracellulare;	 these	 organisms	 do	 not	 always	 lead	 to	 lung	 disease	 but	 individual	
susceptibility	 appears	 important	 and	 severe	 disease	 is	 seen	 in	 some	 (particularly	 M.	
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abscessus)	with	the	need	for	intensive	and	prolonged	treatments.	Patient	to	patient	cross-
infection	of	NTMs,	without	direct	contact	but	from	sharing	an	environment	but	at	different	
times,	has	been	seen	and	knowledge	about	susceptibility,	 infection,	disease	spectrum	and	
response	to	treatments	is	increasing.			
2.4 Airway	inflammation	in	cystic	fibrosis	
2.4.1 Inflammation	in	the	airway	of	infants	with	CF	
The	 lungs	 are	 thought	 to	be	normal	 at	 birth	 (84)	but	 inflammation	 is	 seen	 in	 the	 airways	
from	early	on	in	infants	with	CF	(105,	137)	although	as	already	discussed,	the	origin	of	the	
inflammation	 is	 debated.	 Until	 a	 curative	 therapy	 is	 found,	 reducing	 the	 degree	 of	
inflammation	 from	 birth	 is	 thought	 by	most	 to	 be	 likely	 to	 improve	 the	 outlook.	 For	 this	
reason,	 it	 is	 an	 area	 of	 importance	 and	 several	 clinical	 observational	 studies	 have	 been	
conducted	 into	 this	 area.	Armstrong	et	al	 found	 that	 almost	40%	of	 infants	diagnosed	on	
NBS	 had	 infection	 in	 their	 airways	 by	 the	 age	 of	 3	months	 (137)	 and	 one	 third	 of	 these	
infants	had	no	symptoms	despite	having	infection	identified	in	their	airways.	Supporting	the	
theory	 that	 inflammation	 is	 secondary	 to	 infection	 and	 not	 an	 innate	 defect,	 BALF	 of	 10	
infants	with	CF,	none	of	whom	had	had	antibiotics	or	had	any	respiratory	symptoms	at	all	
was	 examined	 and	 no	 inflammation	 or	 increased	 pro-inflammatory	 cytokines	 were	 seen	
(106).	However,	other	studies	provide	conflicting	results	and	have	reported	inflammation	in	
the	airways	of	such	infants,	increased	neutrophil	count,	IL-8,	and	neutrophil	elastase	even	in	
the	absence	of	 infection	(103-105),	although	 it	may	be	that	 infection	was	present	but	had	
been	cleared	ahead	of	the	sampling	whilst	resulting	inflammatory	changes	remained.	It	has	
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also	been	shown	that	although	airways	are	structurally	normal	at	birth,	structural	changes	
start	at	a	relatively	young	age	and	occur	 in	early	childhood	(138,	139).	 	Structural	changes	
have	 been	 seen	 both	 radiologically	 (140-144)	 and	 histologically	 (145)	 in	 children	with	 CF.	
Increase	 in	 reticular	 membrane	 thickening	 (146)	 and	 smooth	 muscle	 hyperplasia	 and	
hypertrophy	(147)	have	been	reported	and	occur	in	early	stage	lung	disease.		
Further	details	of	the	airway	in	the	newborn	period	can	be	seen	in	chapters	6	and	7.		
2.4.2 Inflammation	in	the	CF	airway	in	established	disease	
Inflammatory	cells,	the	proportion	of	neutrophils	in	BALF,	IL-8	and	neutrophil	elastase	have	
all	 been	 shown	 to	 be	 elevated	 in	 the	CF	 airway	 compared	 to	 the	 healthy	 population	 (99,	
106,	137,	148,	149).	Several	studies	have	reported	an	exaggerated	inflammatory	response	in	
the	 presence	 of	 infection,	 and	 a	 deficiency	 in	 anti-inflammatory	 cytokines	 and	 altered	
lipoxin	A4:leukotriene	B4	ratio	meaning	inflammation	is	abnormally	sustained	(98,	121,	150).	
Most	 studies	 report	an	association	between	airway	 inflammation	and	pulmonary	 function	
(56,	151)	although	one	study	reports	that	pulmonary	function	was	associated	with	infection	
but	not	inflammation	(152).		
2.4.3 Clinical	sequelae	of	inflammation	
CF	 is	a	multi-organ	disease	but	premature	death	usually	occurs	as	a	 result	of	 lung	disease	
(153).		
57
The	 inflammation	 seen	 in	 the	 CF	 airway	 is	 predominantly	 neutrophilic	 (145,	 154,	 155)	 as	
with	 on-going	 or	 frequent	 bacterial	 stimulation,	 neutrophils	 are	 continuously	 recruited.	
Neutrophils	 release	proteases	 including	elastase,	overwhelming	 the	anti-proteases,	 and	 in	
excess,	 these	 proteases	 directly	 damage	 the	 airway	 wall	 by	 catabolism	 of	 elastin	 and	
structural	 proteins	 within	 the	 airway	 wall	 structure,	 leading	 to	 bronchiectasis	 (154).	 The	
degree	of	inflammation	has	been	shown	to	correlate	well	with	clinical	lung	disease	severity	
with	 inflammatory	 markers,	 especially	 neutrophil	 elastase,	 increasing	 as	 FEV1	 decreases	
(156,	157).	Whilst	it	seems	logical	that	minimising	airway	inflammation	would	minimise	lung	
damage,	this	was	not	supported	by	a	recent	trial	evaluating	the	effect	of	a	drug	designed	to	
suppress	inflammation,	BIL284	–	an	LTB4	receptor	antagonist	(96).	This	randomised	double	
blind	placebo	controlled	trial	was	stopped	early	due	to	the	 increased	incidence	of	adverse	
events	 in	 the	 treatment	 arm,	 36%	 vs.	 21%	 in	 adults	 and	 30%	 vs.,	 23%	 in	 children	 and	
suggests	caution	in	the	use	of	anti-inflammatory	agents	as	these	may	suppress	a	beneficial	
inflammatory	response	resulting	in	adverse	outcomes.		
2.4.4 Current	CF	management	
Until	 very	 recently,	 all	 respiratory	 treatments	 were	 aimed	 at	 tackling	 the	 downstream	
consequences	 that	 occurred	 as	 a	 result	 of	malfunctioning	 CFTR.	 Such	 treatments	 include:	
prevention/	 suppression	 of	 infection	 by	 use	 of	 long-term	 oral	 or	 nebulised	 antibiotics;	
prompt	 and	 aggressive	 treatment	 of	 exacerbations	 with	 oral	 or	 intravenous	 antibiotics;	
exercise,	physiotherapy	and	inhaled	mucolytics	to	aid	airway	secretion	clearance.		
58
Despite	airway	inflammation	being	a	major	issue	in	the	CF	airway,	anti-inflammatory	agents	
are	not	often	used	in	Europe.	Systemic	corticosteroids	are	beneficial	in	slowing	lung	function	
decline	(158,	159)	but	the	adverse	events	(160,	161)	seen	have	prevented	widespread	use	
and	a	recent	Cochrane	review	(159)	advised	that	benefit	should	be	weighed	against	the	risk.	
Inhaled	corticosteroids	were	evaluated	with	the	hope	of	providing	unequivocal	benefits	to	
pulmonary	health	whilst	avoiding	the	significant	adverse	effects	seen	with	systemic	steroids.	
Tracheal	 xenografts	 implanted	 in	 mice	 showed	 decreased	 IL-6	 and	 IL-8	 secretion	 with	
inhaled	 fluticasone	 (162)	 and	 cell	 culture	 studies	 showed	 a	 reduction	 in	 these	 pro-
inflammatory	cytokines	via	the	IκB	pathway	with	fluticasone	(163).	Disappointingly	though,	
this	effect	has	not	been	seen	 in-vivo	and	no	convincing	clinical	benefit	on	lung	function	or	
inflammatory	markers	has	been	observed	(111).			
The	 improvement	 in	 lung	 function	 with	 oral	 corticosteroids	 and	 no	 increase	 in	 infection	
burden	 supports	 that	 there	 is	 excessive	 inflammation	 relative	 to	 the	 infection	 and	would	
suggest	 that	anti-inflammatory	medication	would	be	of	benefit	 to	many	patients	with	CF.	
Given	the	side	–effects,	only	in	patients	with	more	severe	disease	would	the	benefit	seem	to	
out-weigh	the	risks.		
Azithromycin	is	used	in	CF	with	undoubted	benefit.	The	mechanism	of	action	is	not	known.	
It	is	known	to	have	anti-inflammatory	properties,	as	well	as	antibacterial	actions.	One	study	
has	 suggested	 that	 it	 inhibits	 neutrophilic	 recruitment	 and	 prevents	 an	 increase	 in	 pro-
inflammatory	cytokine	levels	(164).	A	recent	study	using	CF	bronchial	epithelial	cells	found	
that	 azithromycin	 had	 a	 positive	 impact	 on	 cell	 chloride	 efflux	 and	 also	 had	 a	 weakly	
beneficial	 effect	 to	 the	 innate	 immune	 system	 by	 up-regulating	 the	 NOD-like	 receptors	
NLRC1	and	NLRC2	(165).	It	also	appears	to	have	anti-pseudomonal	antibacterial	activity	with	
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a	 greater	 effectiveness	 in	 the	 pseudomonal	 stationary	 phase	 and	 an	 impact	 on	 biofilm	
formation	 and	 quorum	 sensing	 (111);	 clinical	 studies	 found	 reduction	 in	 pulmonary	
exacerbations	 in	 both	 pseudomonas	 infected	 and	 pseudomonas	 naïve	 children	 (166).	
Azithromycin	may	therefore	decrease	 inflammation	by	a	combination	of	antimicrobial	and	
immunomodulatory	properties.		
It	 has	 also	 been	 suggested	 that	 the	 mucolytic,	 nebulised	 rhDNAse,	 may	 have	 anti-
inflammatory	properties	with	a	decrease	 in	neutrophil	elastase,	neutrophils	and	IL-8	being	
seen	in	patients	with	DNAse	use	(167-169),	although	a	causative	association	was	not	proven	
and	may	be	a	consequence	of	 indirect	actions.	As	described	above,	NFκB	 is	 integral	 in	the	
pathway	of	pro-inflammatory	cytokines	and	studies	have	suggested	an	increased	activation	
of	 NFκB	 by	 CF	 airway	 secretions	 and	mucous.	 This	may	 explain	 the	 benefit	 of	 decreased	
inflammation	as	has	been	reported	with	improved	airway	clearance	by	the	indirect	means	of	
a	reduction	in	NFκB	activation	leading	to	a	reduction	in	IL-8,	IL-6,	IL-1B	and	GMCSF	(111).		It	
may	 also	 have	 a	 role	 in	 releasing	 the	 antimicrobial	 peptide	 LL-37	 bound	 in	 DNA/actin	
bundles	in	CF	sputum	(170)	also	contributing	to	the	potentially	beneficial	anti-inflammatory	
actions	seen.		
In	 the	 USA	 ibuprofen	 is	 commonly	 used	 and	 the	 Cystic	 Fibrosis	 Foundation	 (CFF)	
recommend	consideration	of	ibuprofen	in	patients	with	mild	lung	disease	(171).	A	Cochrane	
review	 (172)	 concluded	 that	high	dose	 ibuprofen	 can	 slow	disease	progression	of	CF	 lung	
disease,	 especially	 in	 children	 and	 randomised	 controlled	 trials	 reported	 no	 significant	
increase	in	adverse	events	but	concerns	regarding	the	side	effects	have	precluded	its	wide	
scale	 use	 in	 Europe.	 The	 exact	 action	 is	 not	 known	 but	 is	 thought	 to	 act	 via	 two	 pro-
inflammatory	transcription	factors,	NFκB	and	AP-1	(111)	although	a	further	study	found	no	
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impact	of	 ibuprofen	on	 IL-8	 (173).	 In	order	 to	achieve	the	anti-inflammatory	response	the	
plasma	levels	have	to	be	monitored	closely	and	kept	within	a	narrow	range	of	50-100	μg/ml	
with	lower	levels	potentially	having	a	pro-inflammatory	effect	by	an	increasing	recruitment	
of	neutrophils	to	the	airway.		Interestingly	a	recent	paper	has	identified	ibuprofen	as	a	CFTR	
corrector	 improving	 CFTR	 trafficking,	which	may	 account	 for	 some	of	 the	 clinical	 benefits	
seen	(174).		
Following	 the	 findings	 of	 preliminary	 studies	 evaluating	 sildenafil	 in	 CF	 which	 found	
decreased	BALF	inflammation	(175),		decreased	IL-8	levels	in	75%	of	people	taking	sildenafil	
and	 a	 reduction	 in	 neutrophil	 elastase	 in	 67%	 (176)	 larger	 studies	 are	 planned.	 Following	
laboratory	 based	 studies	 (177,	 178)	 a	 phase	 2	 study	 of	 alpha-1-antitrypsin	 evaluating	 the	
safety	and	efficacy	as	an	anti-inflammatory	agent	in	CF	is	also	planned.		
Standard	 treatments	 are	 aimed	 at	 managing	 down-stream	 effects	 of	 the	 disease	 whilst	
newer	 treatments	are	aimed	at	 correcting	 the	protein	defect,	and	 thus	allowing	sufficient	
chloride	transport	(179-181).		
Advances	 in	 the	 technology	 of	 high-through-	 put	 screening	 have	 allowed	 up	 to	 100,000	
small	 molecules	 to	 be	 tested	 simultaneously,	 in	 an	 attempt	 to	 identify	 those	 with	 the	
potential	to	improve	the	function	of	the	defective	CFTR	protein	(182,	183).	CFTR	correctors	
are	designed	to	correct	trafficking	of	misfolded	CFTR	protein	to	the	cell	membrane,	where	it	
can	 function,	 albeit	 not	 at	 wild-type	 levels	 whilst	 CFTR	 potentiators	 target	 CFTR	 that	 is	
already	at	the	cell	surface	(either	naturally,	as	in	the	class	III–VI	mutations,	or	as	the	result	of	
successful	 correction),	 improving	 its	 function.	 Ivacaftor	 is	 a	 small	 molecule	 therapy	 now	
approved	for	use	in	patients	over	the	age	of	2	with	a	gating	mutation	following	randomised,	
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double-blind,	 placebo-controlled,	 multinational	 phase	 3	 studies	 that	 demonstrated	
significant	 improvements	 in	 lung	 function	 of	 around	 17%	 of	 baseline,	 which	 were	
maintained	out	to	48	weeks	along	with	significant	decrease	(c50%)	in	sweat	chloride	levels	
(75,	 76,	 184-188).	 It	 has	 also	 received	 approval	 for	 those	 over	 18	 years	 of	 age	 with	 the	
R117H	mutation.	A	study	of	 ivacaftor	 in	pre-school	children	identified	some	concerns	with	
elevated	liver	function	tests	(189)	and	further	work	is	being	done	into	this	age	group.		
Phase	 3	 studies	 of	 the	 corrector	 VX-809	 (Lumacaftor)	 alone	 and	 in	 combination	 with	
Ivacaftor	have	been	completed	and	show	only	modest	improvements	in	FEV1	but	significant	
reduction	 in	 exacerbations	 (73,	 190,	 191)	 and	 approval	 has	 now	 been	 granted	 in	 US	 and	
Europe.	The	huge	clinical	success	of	Ivacaftor	has	catalysed	research	in	this	area,	with	many	
different	pharmaceutical	companies	now	researching	and	developing	corrector	compounds	
but	an	ideal	compound	is	yet	to	be	found.		
Gene	 therapy	 is	 also	 being	 explored	 as	 a	 therapeutic	 option	 for	 individuals	 with	 CF	 and	
would	 be	 applicable	 to	 all	 affected	 rather	 than	 genotype	 specific	 like	 the	 small	molecule	
treatments.	A	recent	12-month	study	of	nebulised	gene	therapy	showed	an	overall	modest	
improvement	in	FEV1	of	3%,	but	bigger	changes	were	seen	in	some	individuals	and	it	proved	
the	principal	of	gene	therapy	and	further	work	is	being	done	in	this	field	(192).		
CF	 continues	 to	 carry	 a	 significant	 morbidity	 and	 treatment	 burden,	 despite	 which,	 life	
expectancy	still	falls	far	short	from	that	of	normal.	Median	age	at	death	is	currently	27	(193)	
but	most	children	born	today	with	CF	are	expected	to	survive	to	their	fifth	decade.	Further	
understanding	of	the	onset	and	progression	of	airway	inflammation	and	factors	influencing	
this	may	lead	to	improved	treatments	and	subsequent	decreased	morbidity	and	mortality.		
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2.5 Summary	of	infection	and	inflammation	in	the	CF	airway	
Infection	 and	 inflammation	 occur	 in	 early	 infancy	 with	 progression	 to	 structural	 and	
functional	changes	occurring	well	within	the	paediatric	age	group	and	by	the	teenage	years,	
CF	lung	disease	is	well	established,	although	spirometry	may	be	preserved	initially.	A	better	
understanding	of	the	origin	and	cause	of	these	early	life	events	will	clearly	be	advantageous	
in	 developing	 new	 treatment	 strategies	 with	 the	 aim	 of	 delaying	 the	 onset	 of	 chronic	
suppurative	and	destructive	 lung	disease.	 It	 remains	unclear	as	 to	whether	all	defects	are	
secondary	 to	 early	 airway	 infection	 or	 whether	 an	 innate	 immune	 deficiency	 exists	 but	
regardless	 of	 cause,	 an	 exaggerated	 sustained	 and	 prolonged	 inflammatory	 response	 is	
seen.	Recent	evidence	 suggests	 that	 innate	 immunity	may	be	modulated	by	other	 factors	
including	 vitamin	 D.	 Medications	 are	 now	 available	 that	 “correct”	 the	 abnormal	 CFTR	
protein.	Once	 these	 drugs	 are	 available	 for	 newborn	 infants,	 correcting	 this	 protein	 from	
birth	 or	 soon	 after,	 this	 conundrum	 may	 be	 definitively	 answered.	 For	 the	 time	 being,	
further	 research	 into	 the	mechanisms	of	 inflammation	and	 infection	will	 lead	 to	a	greater	
understanding	of	the	inflammatory	processes	allowing	more	appropriate	and	possibly	new	
treatments	to	be	developed	in	the	aim	of	minimising	and	delaying	lung	damage.		
2.6 Non-CF	chronic	suppurative	lung	diseases	
Critical	to	any	 investigation	 is	the	choice	of	a	control	group.	 In	order	to	ascertain	whether	
any	effects	seen	were	specific	to	the	effects	of	CFTR	dysfunction,	or	a	merely	a	non-specific	
consequence	 of	 airway	 inflammation,	 a	 control	 group	 of	 children	 with	 other	 respiratory	
illnesses	that	also	cause	neutrophilic	airway	inflammation	was	also	studied.		
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2.6.1 Primary	ciliary	dyskinesia	
Primary	ciliary	dyskinesia	(PCD)	is	also	a	genetic	disease	inherited	as	an	autosomal	recessive	
with	 the	 classic	 triad	 of	 symptoms	 consisting	 of	 situs	 inversus,	 chronic	 sinusitis	 and	
bronchiectasis.	 The	 true	 incidence	 is	 unknown	 but	 has	 been	 estimated	 to	 be	 between	
1:4,100	 and	 1:40,000	 births	 (194,	 195).	 	 There	 are	 currently	 thought	 to	 be	 around	 3000	
people	in	the	UK	with	PCD	but	the	number	who	have	been	given	a	diagnosis	is	significantly	
lower	 than	 this	 (196).	PCD	 is	 caused	by	an	alteration	 to	 the	 function	and	usually	 also	 the	
ultrastructure	of	the	cilia	within	the	respiratory	epithelium.	The	most	common	abnormality	
seen	 is	 absent	 dynein	 arms;	 other	 abnormalities	 include	 absent	 radial	 spokes	 and	
microtubular	 transposition.	 The	 cilia	 are	 static	 or	 dyskinetic,	with	 an	 un-coordinated	beat	
motion.	 The	 consequence	 is	 that	 inhaled	matter	 is	 not	 removed	 from	 the	 airway.	 As	 the	
entire	 respiratory	 tract	 is	 involved,	 there	 are	 both	 lower	 and	 upper	 respiratory	 tract	
symptoms.	 Nasal	 congestion	 and	 rhinorrhoea	 are	 common	 features,	 frequently	 with	
offensive	 mucopurulent	 nasal	 discharge.	 	 Nasal	 douching	 can	 be	 effective	 at	 reducing	
symptoms.	 Chronic	 otitis	 media	 is	 present	 in	 nearly	 all	 individuals	 to	 some	 degree	 and	
hearing	aids	may	be	required,	although,	as	with	all	causes	of	chronic	secretory	otitis	media,	
improvement	in	the	teenage	years	is	to	be	anticipated.	Frequent	audiology	reviews	should	
be	performed	in	order	to	detect	hearing	loss.	Unlike	other	causes	of	persistent	chronic	otitis	
media,	 tympanostomy	 is	 not	 recommended	 as	 this	 commonly	 results	 in	 copious	
mucopurulent	discharge	 that	can	be	quite	distressing	 for	 the	 individual.	 Lower	 respiratory	
tract	 involvement	occurs,	with	recurrent	 infection,	a	productive	cough	and	bronchiectasis.	
Treatment	is	with	antibiotics,	inhaled	mucolytics	and	chest	physiotherapy.	The	arrangement	
of	organs	in	utero	is	related	to	nodal	ciliary	function,	and	if	nodal	cilia	are	immotile	(which	is	
not	 the	 case	 in	 all	 ultrastructural	 causes	 of	 PCD,	 for	 example	 transposition	 defect,	 since	
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there	are	no	central	pairs	in	nodal	cilia),	situs	is	determined	by	chance	(197).	Situs	inversus	
or	heterotaxia	 is	seen	 in	approximately	40-	60%	of	 individuals	with	PCD	(195).	Nasal	nitric	
oxide	 is	 decreased	 in	 PCD	 (198,	 199)	 and	 this	 technique	 can	 be	 used	 as	 a	 screening	
investigation	 in	 a	 diagnostic	 work	 up	 for	 PCD	 (200).	 	 Definitive	 diagnosis	 is	 made	 by	
examining	the	structure	and	function	of	cilia	from	biopsy	samples	taken	from	brushings	of	
nasal	 epithelium	 and	 the	 cilia	 examined	 under	 light	 microscopy.	 In	 PCD,	 ciliary	 beat	
frequency	is	usually	reduced	(196,	201)	and	an	abnormal	beat	pattern	is	seen.	The	cilia	can	
then	 be	 examined	 using	 electron	microscopy	 where	 the	 ultrastructure	 is	 assessed	 (202).	
Genetic	 mutations	 have	 been	 identified	 with	 2	 mutations	 (DNAI1	 and	 DNAH5)	 being	
identified	in	about	20-30%	of	individuals	with	PCD.	To	date,	over	30	genetic	mutations	have	
been	identified	(195)	and	account	for	approximately	65	%	of	people	with	PCD.	Prognosis	is	
variable,	and	many	individuals	have	normal	life	span	(196)	although	morbidity	can	be	high,	
especially	 in	patients	with	a	 late	diagnosis.	 It	 is	unclear	why	 this	group	of	patients	have	a	
significantly	better	outcome	than	their	CF	counterparts	despite	the	fact	 that	children	with	
PCD	have	increased	level	of	the	pro-inflammatory	cytokine	IL-8.		
a" b" c"
Figure	3:	Electron	microscope	images	of	cilia	showing	a)	normal	cilia,	b)	outer	dynein	arm	defect	and	c)	inner	
dynein	arm	and	microtubular	disorganisation.	(Pictures	courtesy	of	Amelia	Shoemark).		
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2.6.2 Non-CF	bronchiectasis	
Bronchiectasis	 can	 occur	 as	 a	 result	 of	 numerous	 insults	 to	 the	 airways.	 Causes	 include	
severe	 viral	 infections,	 inhaled	 foreign	 body,	 aspiration	 from	 gastro-oesophageal	 reflux	
disease	 (GORD),	 tracheo-oesophageal	 fistula	 or	 laryngeal	 cleft,	 immunodeficiency	 and	 in	
about	 up	 to	 30%	 of	 paediatric	 cases	 the	 cause	 remains	 unknown	 (203).	 Diagnosis	 of	
bronchiectasis	 is	 made	 on	 high-resolution	 computerised	 tomography	 (HRCT)	 with	 the	
characteristic	 finding	 of	 a	 “signet	 ring”	 sign	 where	 the	 bronchus	 is	 dilated	 and	 larger	 in	
diameter	than	its	adjacent	blood	vessel	(204-206).	Bronchiectasis	can	either	be	localised	to	
one	specific	area,	or	more	generalised	disease	can	be	seen.	Investigation	to	try	to	identify	a	
cause	 is	 necessary	 and	 CF	 and	 PCD	 should	 be	 excluded.	 Specific	 diagnoses	 including	
immunodeficiency,	aspiration	and	GORD	should	be	looked	for	in	order	to	allow	appropriate	
management	of	these	conditions	if	found.	 In	practice,	treatment	is	similar	to	that	of	other	
chronic	 respiratory	 diseases,	 in	 the	 absence	 of	 any	 randomised	 controlled	 trials,	 and	
individuals	may	require	antibiotics,	mucolytics	and	chest	physiotherapy,	although	much	of	
this	 is	extrapolated	from	CF	as	there	is	a	 lack	of	evidence	in	bronchiectasis.	 It	 is	 important	
not	to	extrapolate	too	much	however,	as	pathophysiology	is	different	and	treatments	may	
have	 different	 effects.	 A	 double-blind	 randomised	 placebo	 controlled	 trial	 of	 DNAse	 in	
patients	 with	 non-CF	 bronchiectasis	 found	 that	 the	 DNAse	 group	 had	 more	 hospital	
admission,	more	exacerbations,	increased	antibiotic	and	steroid	use	and	a	greater	decrease	
in	 their	 FVC	 over	 the	 24	 weeks	 of	 the	 trial	 (207)	 and	 another	 of	 non-CF	 bronchiectasis	
patients	 including	4	with	PCD	found	no	benefit	 (208)	of	DNAse.	This	 is	the	opposite	of	the	
results	seen	in	DNAse	in	CF	patients	and	highlights	the	importance	of	studies	within	disease	
populations	rather	than	extrapolating	data.	Longitudinal	 follow	up	of	children	with	non-CF	
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bronchiectasis	found	that	whilst	lung	function	stabilised	it	did	not	improve	to	normal	levels	
highlighting	the	importance	of	prompt	diagnosis	and	early	treatment	(209).	
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3 CHAPTER	3:	VITAMIN	D	
3.1 Vitamin	D	synthesis	
Vitamin	D	is	a	fat-soluble	secosteroid,	which	is	a	steroid	in	which	one	bond	of	the	chain	is	
broken.	There	are	five	forms	of	vitamin	D	but	the	2	major	forms	are	ergocalciferol	(vitamin	
D2)	 and	 cholecalciferol	 (vitamin	D3);	 the	 2	 together	 can	 be	 referred	 to	 as	 calciferol.	 From	
here	on,	reference	to	“vitamin	D”	means	vitamin	D2	and	vitamin	D3	together.	The	structural	
difference	 between	 these	 2	 forms	 is	 in	 the	 side	 chain	 with	 ergocalciferol	 having	 an	
additional	double	bond	and	a	methyl	group.	Vitamin	D	can	be	obtained	either	from	the	diet	
or	 by	 the	 conversion	 of	 the	 steroid	 7-dehydrocholesterol,	 present	 in	 the	 skin,	 to	
cholecalciferol	 by	 the	 exposure	 to	 ultra-violet	 B-light	 (UV-B).	 Vitamin	D	 obtained	 through	
either	route	requires	hydroxylation	to	its	active	form	and	this	is	done	in	2	stages;	firstly	by	
hepatic	 enzymes,	 to	 calcidiol	 (25(OH)D)	 and	 secondly	 by	 renal	 hydroxylation	 to	 calcitriol	
(1,25(OH)2D)	 (Figure	 4	 and	 Figure	 5)(210,	 211).	Whilst	 it	 is	 1,25(OH)2D	 that	 is	 biologically	
active	within	the	body,	this	molecule	is	biologically	unstable	with	a	very	short	half-life	which	
makes	measurement	of	this	secosteriod	challenging	and	therefore	clinical	measurement	of	
vitamin	 D	 is	 a	measurement	 of	 25(OH)D.	 1,25(OH)2D	 binds	 to	 vitamin	 D	 receptors	 (VDR)	
which	 are	 located	 on	 both	 cell	 membrane	 and	 nucleus.	 Binding	 of	 1,25(OH)2D	 to	 VDR	
located	on	 cellular	membranes	 leads	 to	 intracellular	 signalling	pathways	whilst	 binding	 to	
nuclear	 receptor	 VDR	 has	 an	 impact	 on	 more	 than	 900	 genes	 and	 micro-RNA	 via	 a	
transcription	complex.		It	therefore	has	the	possibility	of	having	numerous	roles	within	the	
body.		
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Ergocalciferol	 								Cholecalciferol	 						Calcidiol	 Calcitriol	
VITAMIN	D2	 								VITAMIN	D3	 													25(OH)D	 1,25(OH)2D	
Figure	4:	Chemical	structure	of	vitamin	D	and	its	active	metabolites	
Figure	5:	Activation	of	vitamin	D				(Taken	from	(212))	
3.2 Classical	actions	of	vitamin	D	
Vitamin	D	 has	 a	 significant	 role	 in	 calcium	homeostasis	 and	metabolism	 by	 promotion	 of	
intestinal	 absorption	 of	 calcium	 and	 promotion	 of	 bone	 resorption	 allowing	 the	 body	 to	
maintain	 adequate	 levels	 of	 calcium	 and	 phosphate	 for	 bone	 formation.	 Vitamin	 D	
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deficiency	can	 lead	 low	calcium	deposition	and	decreased	mineralisation	of	bones	causing	
rickets	in	children	and	osteomalcia	in	adults.		
3.3 Non-classical	actions	of	vitamin	D	
Whilst	 it	has	 long	been	established	that	vitamin	D	is	required	for	good	bone	health	recent	
evidence	 has	 pointed	 to	 a	 role	 of	 vitamin	 D	 beyond	 this,	with	 vitamin	 D	 receptors	 being	
identified	 on	 many	 immune	 cells	 (5,	 213,	 214).	 It	 is	 now	 known	 that	 the	 final	 stage	 of	
activation,	 from	 25(OH)D	 to	 1,25(OH)2D,	 by	 the	 enzyme	 1-α-hydroxylase	 (CYP27b1),	 can	
occur	in	a	number	of	cells	and	not	just	the	kidney	as	was	previously	thought	(212,	215).	This	
enzyme	 has	 been	 found	 in	 keratinocytes,	 gastrointestinal	 cells,	 breast	 and	 prostate,	 and	
immune	cells	including	macrophages,	monocytes	and	dendritic	cells	(215).	
1,25(OH)2D	crosses	the	cell	membrane	to	enter	the	cytoplasm	where	it	binds	to	VDR,	which	
have	been	identified	on	many	immune	cells	(5,	213,	214).	The	1,25VitD/VDR	complex	then	
enters	the	cell	nucleus	and	binds	to	the	retinoid	X	receptor	(RXR).	The	activated	vitamin	D	
subsequently	 binds	 to	 vitamin	 D	 response	 elements	 (VDRE)	 located	 on	 DNA,	 which	 have	
been	identified	on	genes	coding	for	the	antimicrobial	peptides	LL-37	and	HBD-2	(213,	216,	
217).		
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	3.4 The	role	of	vitamin	D	in	airway	defence	
That	 vitamin	 D	 is	 activated	 in	 immune	 cells,	 and	 that	 it	 promotes	 antimicrobial	 peptides	
gave	rise	to	the	hypothesis	that	vitamin	D	is	important	in	host	defence.	
Vitamin	 D	 exhibits	 numerous	 actions	 within	 the	 immune	 system	 including	 both	 indirect	
antimicrobial	and	immunomodulatory	actions.	Several	immune	pathways	are	influenced	by	
vitamin	 D	 via	 VDR	 modulation	 of	 gene	 expression	 with	 an	 overall	 effect	 of	 increasing	
mucosal	defences	and	reducing	excessive	inflammation.		
Vitamin	 D	 regulates	 the	 adaptive	 immune	 system	 to	 prevent	 an	 excessive	 response	with	
potentially	 damaging	 inflammatory	 changes	 by	 influencing	 T-cell	 receptor	 signalling,	
inhibiting	 lymphocyte	 proliferation	 and	 Th1	 and	 Th17	 cytokines	 (218).	 Whilst	 the	 exact	
pathways	 are	 not	 fully	 understood,	 vitamin	 D	 appears	 to	 have	 an	 impact	 on	 numerous	
cytokines	 (Table	4)	 and	 these	may	be	 consequences	of	effects	of	 vitamin	D	on	up-stream	
protein	 expression	 rather	 than	 direct	 action	 (214,	 219-221).	 	 Overall	 there	 is	 an	 anti-
inflammatory	effect	by	the	decrease	in	pro-inflammatory	cytokines	and	an	increase	in	anti-
inflammatory	 molecules.	 Animal	 studies	 have	 demonstrated	 a	 40	 %	 reduction	 in	 LPS	
induced	neutrophil	recruitment	with	vitamin	D	administration	(222).		
More	relevant	to	this	thesis,	vitamin	D	also	affects	the	innate	immune	system	by	increasing	
epithelial	 cell	 production	 of	 antimicrobial	 peptides	 including	 HBD-2	 and	 LL-37	 and	
stimulating	the	expression	of	these	peptides	from	macrophages	and	neutrophils.	As	well	as	
an	increase	in	gene	expression	with	vitamin	D,	inhibiting	CYP27b1	led	to	a	decrease	in	gene	
expression	(215).	Whilst	it	has	been	well	demonstrated	in-vitro	that	expression	of	LL-37	and	
HBD-2	is	significantly	up-regulated	by	vitamin	D(213,	223),	in-vivo	data	is	lacking.	One		
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	Table	4:	Immunomodulatory	effects	of	1,25(OH)D2	
The	effect	of	vitamin	D		 Immunological	molecule	
Antibacterial	effects	
Increased	 Cathelicidin	and	HBD-2(223-225)	
Increased	 Nitric	oxide(226)	
Anti-inflammatory	effects	
Decrease	 in	 pro-inflammatory	
response	
Il-8(224)	
IL-1B(227,	228)	
IL6(224,	228-230)	
TNF-α(227-231)	
IL-12(228,	230)	
IFN-γ(232,	233)	
IL-2(234,	235)	
IL17(230,	236)	
IL21(236)	
T	cell	proliferation(234,	235)	
B	cells(237)	
TLr-2	and	TLR-4(238)	
Increase	 in	 anti-inflammatory	
response	
T	regulatory	cells(5,	239)	
IL-10	(232,	239-241)	
IL-4(232,	233,	240)	
IL-5(232)	
CD200	ligand(220)	
Other	
Decreased	 Matrix	metalloproteinases(242)	
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	prospective	study	looked	at	serum	LL-37	levels	 in	response	to	high	doses	of	vitamin	D	and	
found	no	response	but	did	see	an	increase	in	hCAP-18	mRNA	expression	in	peripheral	blood	
monocytes	(225).	This	study	evaluated	the	relationship	of	25(OH)D,	1,25(OH)D	and	LL-37	in	
serum	 and	 found	 no	 relationship.	 The	 authors	 commented	 that	 it	 was	 this	 lack	 of	
relationship	 that	 supported	 their	hypothesis	 that	 vitamin	D	only	exerted	 its	effects	at	 the	
cellular	level.	They	studied	the	effect	of	vitamin	D	at	a	cellular	level,	by	examining	peripheral	
blood	cells	taken	from	vitamin	D	deficient	individuals,	supplementing	these	individuals	and	
again	extracting	blood.	They	found	that	monocyte	activation	of	CYP27b1	was	dependent	on	
vitamin	D	and	that	expression	of	LL37	by	monocytes	was	significantly	higher	after	vitamin	D	
supplementation.			
LL-37	and	to	a	lesser	extent	HBD-2	are	induced	by	vitamin	D	in	cultured	bronchial	epithelial	
cells	 (213).	 Vitamin	 D	 exerts	 its	 effects	 via	 vitamin	 D	 receptor	 and	 vitamin	 D	 response	
elements,	 which	 have	 been	 found	 to	 be	 located	 within	 the	 genes	 encoding	 these	
antimicrobial	peptides(213).	Wang	et	al	evaluated	the	response	of	vitamin	D	on	synthesis	of	
these	peptides	in	cultured	normal	epithelial	cells	and	showed	that	vitamin	D	increased	gene	
expression.	Def-B	expression	was	enhanced	by	vitamin	D	and	in	the	presence	of	IL-1,	known	
to	 be	 an	 inducer	 of	 def-B,	 vitamin	 D	 further	 increased	 expression.	 As	 well	 as	 gene	
expression,	immunohistochemistry	and	western	blotting	confirmed	that	protein	levels	were	
also	 increased.	 	The	activity	of	the	antimicrobial	peptides	against	E.	coli	and	P.	aeruginosa	
was	 tested	 and	 an	 increased	 activity	 against	 these	 bacteria	 was	 seen	 in	 the	 presence	 of	
vitamin	D.		
A	 second	study	 (1)	 studied	 the	 impact	of	 vitamin	D	on	wild-type	and	CF	human	epithelial	
cells	using	western	blot	and	PCR	to	detect	LL37	and	HBD-2	mRNA	and	protein.	The	activity	
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	of	 the	antimicrobial	peptides	 found	within	 the	airway	surface	 fluid	of	 these	cells	was	also	
assessed	 by	 observing	 their	 efficacy	 against	 laboratory	 strain	 bacteria.	 LL37	 mRNA	 was	
increased	10	fold	by	the	addition	of	vitamin	D	in	both	normal	(Figure	6a)	and	CF	bronchial	
epithelial	cells,	and	the	activity	of	LL37	against	bacterial	organisms	including	P.	aeruginosa	
was	increased	in	the	presence	of	vitamin	D	(Figure	6b).	Unlike	the	first	study,	by	Wand	et	al,	
there	 was	 no	 impact	 on	 HBD-2.	 IL-8	 secretion	 by	 human	 macrophages	 and	 respiratory	
epithelial	cells	(224)	is	decreased	by	vitamin	D	,	another	possible	downstream	consequence	
of	 the	 vitamin.	 Vitamin	D	 deficiency	may	 therefore	 have	 numerous	 consequences	 on	 the	
immune	system.	
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Figure	6:	a)	Increase	in	LL37	MRNA	following	treatment	with	1,25(OH)2D3.	b)a	decrese	
in	bacterial	colonies	was	seen	following	exposure	to	1,25(OH)2D3.	Figures	from			(1) 
b	
a	
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	3.5 Factors	affecting	Vitamin	D	levels	
Whilst	 it	 is	 the	 inactive	 form	 of	 vitamin	 D	 generally	 measured,	 it	 is	 the	 active	 form	
(1,25)OHD2	that	has	the	effects.	The	reason	the	 inactive	 form	 is	measured	 is	 that	 it	has	a	
longer	half-life	and	 is	 therefore	easier	 to	assay	 reliably.	However,	differences	may	exist	 in	
individuals	 ability	 to	 convert	 this	 to	 its	 active	 state	 meaning	 a	 high	 25(OH)D2	 may	 not	
equate	 to	 a	 high	 1,25(OH)D2.	 The	 enzyme	 1-alpha-hydroxylase,	which	 is	 a	 P450	 enzyme,	
carries	out	this	conversion	and	results	from	experiments	in	mice	show	that	gene	expression	
of	 this	enzyme	 is	 inhibited	by	VDR	 (243).	Numerous	polymorphisms	 in	gene	expression	of	
VDR	have	been	described	and	these	in	turn	may	have	an	impact	of	the	gene	expression	of	1-
alpha-hydroxylase	 and	 consequently	 the	 levels	 of	 25	 and	 1-25(OH)D2.	 Other	 factors	 also	
play	a	part	 in	the	activation	of	 this	gene	and	dietary	restriction	of	phosphate	 increases	 its	
activity	 but	 not	 associated	with	 serum	 levels	 of	 phosphate	or	 calcium	 suggesting	 another	
factor,	 possibly	 hormone	 related.	 This	 observation	 demonstrated	 the	 lack	 of	 full	
understanding	of	 the	 inhibition	and	activation	of	 the	genetic	expression	of	 this	converting	
enzyme.	Mutations	in	this	gene;	at	locus	12q13.1-913.3;	have	led	to	vitamin	D	independent	
rickets	 (244).	Some	drugs	such	as	protease	 inhibitors	have	an	 inhibitory	effect	on	1-alpha-
hydroxylase	 therefore	 potentially	 having	 the	 effect	 of	 increasing	 level	 of	 25(OHD2	 but	
decreasing	 the	 level	 of	 the	 active	 form	 1,25(OH)D2.	 The	 presence	 of	 inflammation	 may	
promote	 activation	 of	 the	 enzyme	 via	 CYP27B1	 increasing	 1,25(OH)D2	 temporarily	 (245),	
but	as	the	half-life	is	short,	just	4-6	hours,	the	effect	of	this	is	depletion	of	25(OH)D2	levels	
and	a	decrease	subsequently	of	1,25(OH)D2	levels	from	lack	of	availability.		
Another	factor	which	may	be	of	relevance	is	the	level	of	vitamin	D	binding	protein	(VDBP)	
which	is	essential	for	transportation	of	25(OH)D;	approximately	99.5%	of	the	body’s	vitamin	
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	D	level	is	bound	to	VDBP	(246).	It	is	hypothesised	that	it	is	the	free	vitamin	D	that	is	available	
for	action.	Although	the	exact	relationship	between	VDBP	and	vitamin	D	level	is	not	known	
it	is	thought	that	circulating	vitamin	D	binds	to	VDBP,	lowering	the	vitamin	D	bioavailability	
(247).	VDBP	gene	is	highly	polymorphic	and	different	polymorphisms	have	differing	affinities	
for	vitamin	D.	Therefore	genetic	 variations	may	also	have	a	 role	 to	play	 in	 the	amount	of	
vitamin	D	bound	to	VBDP,	which	alter	the	available	vitamin	D	for	action	(248)	and	thus	will	
also	 have	 an	 impact	 on	 the	 actions	 of	 this	molecule	 clinically.	 The	 level	 and	 genotype	 of	
VDBP	will	therefore	have	an	effect	on	the	amount	of	free	vitamin	D	available	and	a	patient	
who	 is	vitamin	D	deficient	may	have	adequate	vitamin	D	activity	 if	VDBP	 levels	are	 low	or	
there	is	a	genetic	variation	giving	low	affinity.		
	
	
3.6 Vitamin	D	reference	ranges	
Whilst	 it	 is	apparent	that	vitamin	D	deficiency	 is	 linked	with	adverse	events,	 it	 is	not	clear	
what	constitutes	deficiency.	Unlike	many	normal	ranges	which	are	derived	from	the	values	
observed	in	the	normal	population,	i.e.	height,	weight	(249)	and	lung	function	(250),	vitamin	
D	 normal	 ranges	 are	 derived	 from	 clinical	 and	 biochemical	 parameters.	 Parathyroid	
hormone	 increases	 rapidly	when	25(OH)D	 is	 lower	 than	50	nmol/L,	and	reaches	a	plateau	
when	25(OH)D	is	over	50	nmol/L	(251,	252).	The	effect	that	25(OH)D	has	on	this	hormone	is	
taken	 into	account	when	considering	 the	 ‘normal	 range’.	The	 level	 that	 is	 required	 to	 see	
clinical	 benefit	 in	 the	way	 of	 decreased	 fractures	 is	 also	 considered.	 As	 these	 factors	 are	
both	open	 to	different	 interpretations,	 the	“normal”	 range	 is	debatable	and	different	cut-
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	offs	 for	 vitamin	D	deficiency	have	been	 suggested	 (253-257).	 The	 Institute	of	Medicine	 in	
the	USA	suggests	 that	a	 level	of	≥	50	nmol/L	 is	adequate	 for	good	bone	health	 in	healthy	
individuals	and	no	additional	benefit	 is	gained	by	achieving	levels	higher	than	this	 (258).	A	
meta-analysis	 evaluating	 vitamin	D	and	 skeletal	 fractures	 concluded	 that	 a	higher	 level	of	
vitamin	D	would	be	better	and	25(OH)D	should	be	maintained	≥	60	nmol/L.	The	Institute	of	
Endocrinology	concluded	that	vitamin	D	should	only	be	measured	in	at	risk	 individuals	but	
should	be	≥	75nmol/L,	with	deficiency	being	<	50	nmol/L	and	levels	between	50-75	nmol/L	
considered	‘insufficient’	(259).	The	US	CF	Foundation	(260)	and	the	Canadian	Osteoporosis	
scientific	advisory	committee	agree	(261)	with	these	definitions.	As	there	 is	no	agreement	
on	what	constitutes	vitamin	D	deficiency,	 reported	prevalence	varies,	but	 is	quoted	 in	the	
literature	as	being	between	20	and	100%	 in	non-disease	populations	 (259,	262,	263).	The	
Royal	Brompton	Hospital	 paediatric	 CF	department	 considers	 levels	 over	 75	nmol/L	 to	be	
optimal	and	levels	over	50	nmol/L	to	be	adequate.	Levels	below	50	nmol/L	are	inadequate	
and	 patients	 are	 considered	 to	 be	 vitamin	 D	 deficient	 and	 prescribed	 additional	
supplementation.	
These	 “normal”	 values	 are	 based	 on	 optimal	 levels	 for	 bone	 health	 and	 it	 cannot	 be	
assumed	that	for	other	functions	of	vitamin	D	including	immunomodulatory	levels	would	be	
the	same.		
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3.7 Vitamin	D	deficiency	
Whatever	 definition	 is	 used,	 vitamin	 D	 deficiency	 is	 highly	 prevalent	 for	 a	 number	 of	
reasons.	As	the	major	source	of	vitamin	D	is	derived	from	sunlight,	a	lack	of	this	is	a	major	
contributing	factor.	 In	the	northern	hemisphere,	 the	position	of	the	sun	during	the	winter	
months	means	that	there	is	insufficient	UVB	light	to	derive	vitamin	D	(264)	and	vitamin	D	is	
lower	in	the	winter	months	than	the	summer.	Moreover,	during	the	months	when	sunlight	
is	 sufficient	 for	 conversion	 of	 7-cholesterol	 to	 25(OH)D	 to	 occur,	 the	 widespread	 use	 of	
sunscreen	reduces	UVB	penetration	and	impairs	vitamin	D	synthesis	(265).	For	this	reason,	
vitamin	D	deficiency	is	commonly	seen	in	the	normal	population	year	round.	These	factors	
are	compounded	in	certain	ethnic	groups	by	the	practice	of	wearing	skin	covering	clothing.		
3.8 Vitamin	D	deficiency	in	CF	
Vitamin	D	deficiency	is	particularly	prevalent	in	the	CF	population	being	seen	in	up	to	90%	of	
individuals	 (266-269).	 There	 are	 a	 number	 of	 reasons	 why	 people	 with	 CF	 are	 at	 risk	
including	generalised	malabsorption	of	fat	soluble	vitamins,	avoidance	on	sunlight	exposure	
and	impaired	hepatic	hydroxylation	(267).	In	addition,	vitamin	D	derived	from	sunlight	may	
be	stored	in	subcutaneous	fat	for	the	winter	months	but	in	CF	patients	tend	to	have	less	fat	
and	subsequent	less	storage.	
CF	patients	have	also	been	shown	to	have	reduced	VDBP	levels	(270,	271).	The	reason	for	
this	 is	unclear	but	 it	has	been	suggested	 that	 it	 could	be	 to	 impaired	glycosylation	of	 this	
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protein	 (270).	 Most	 vitamin	 D	 is	 carried	 by	 VDBP	 which	 may	 impact	 the	 availability	 of	
vitamin	D	for	action	but	the	effects	of	VDBP	on	vitamin	D	levels	are	not	entirely	clear.		
Vitamin	D	supplementation	is	recommended	for	all	patients	with	cystic	fibrosis	and	studies	
have	shown	that	adequate	levels	can	be	achieved	but	in	some	cases	very	high	doses	of	up	to	
50,000	 IU	weekly	was	 used	 to	 achieve	 this	 (267).	 The	 CF	 trust	 advises	 vitamin	D	 dose	 of	
1000-2000	IU	daily	for	infants	and	1000-5000	in	others	(272).		
3.9 Vitamin	D	in	respiratory	health	(non-CF)	
Vitamin	D	has	been	 implicated	as	having	a	 role	 in	a	 variety	of	 respiratory	diseases.	 It	has	
been	used	empirically	as	a	treatment	for	respiratory	disease	for	many	years	although	it	was	
not	known	why	at	the	time.	As	far	back	as	the	1800s,	sunlight	was	used	as	a	treatment	for	
TB	(273)		but	with	the	introduction	of	antibiotics,	this	approach	fell	out	of	favour.	As	part	of	
the	 body’s	 defence	 mechanisms,	 mycobacteria	 are	 ingested	 by	 macrophages	 and	 LL-37	
induced	 killing	 can	 then	 destroy	 these	 macrophage-mycobacterium	 complexes.	 In-vitro	
studies	 have	 shown	 that	 killing	 does	 not	 occur	 in	 the	 absence	 of	 vitamin	 D	 but	 can	 be	
restored	by	the	addition	of	vitamin	D	 (223).	Moreover,	clinical	 studies	have	 found	greater	
levels	of	severity	and	mortality	in	tuberculosis	(TB)	patients	with	vitamin	D	deficiency	(253,	
274).	 Other	 studies	 have	 reported	 associations	 between	 low	 vitamin	 D	 and	 respiratory	
infections,	including	influenza	and	lower	respiratory	tract	infections	(254-257),	especially	in	
the	 asthmatic	 and	 COPD	 populations	 (275).	 It	 has	 also	 been	 shown	 that	 in	 the	 healthy	
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	population,	better	pulmonary	function	is	seen	in	people	with	higher	levels	of	vitamin	D	(276)	
–	 although	 the	 clinical	 significance	 of	 these	 small	 differences	 has	 not	 been	 established.	
However,	not	all	studies	report	an	association	between	vitamin	D	and	respiratory	infection.	
Two	studies	of	young	Canadian	children	found	no	relationship	between	vitamin	D	and	the	
incidence	of	bronchiolitis	(277,	278)	although	in	one,	low	vitamin	D	was	associated	with	an	
increased	risk	of	admission	to	 intensive	care	 (278).	 	 Inflammatory	markers	have	also	been	
shown	 to	be	 related	 to	 vitamin	D,	with	 vitamin	D-deficient	bronchiectasis	patients	having	
higher	 levels	of	pro-inflammatory	cytokines	 than	 those	vitamin	D	sufficient	 (227).	A	 lower	
vitamin	D	was	also	observed	 in	patients	chronically	 infected	with	bacteria	 in	 this	group	of	
patients.		
Given	 the	mounting	 evidence	 suggesting	 a	 role	 for	 vitamin	 D	 in	 lung	 health,	 randomised	
double	 blind,	 placebo	 controlled	 studies	 have	 been	 conducted	 to	 assess	 if	 vitamin	 D	
supplementation	prevents	 lower	respiratory	 infection.	The	largest	randomised	control	trial	
(RCT)	to	date	included	just	over	3000	children	randomised	to	receive	either	3	monthly	high	
dose	vitamin	D	or	placebo;	the	investigators	found	no	difference	in	incidence	of	pneumonia	
between	 the	 2	 groups,	 although	 a	 higher	 vitamin	 D	 level	 was	 achieved	 in	 the	 vitamin	 D	
group	 (p<0.01)	 (279).	 However,	 a	 meta-analysis	 of	 5	 studies	 found	 vitamin	 D	 to	 be	
associated	 with	 fewer	 infections	 in	 children	 but	 not	 adults	 (280),	 whilst	 a	 meta-analysis	
involving	 11	 studies	 (including	 all	 5	 studies	 in	 the	 previous	 meta-analysis)	 reported	 that	
vitamin	D	had	a	protective	effect	 (OR	0.64,	95%	CI	0.49-0.84)	against	 respiratory	 infection	
(281).	 This	 meta-analysis	 found	 that	 daily	 dosing	 was	 more	 effective	 than	 less	 frequent	
bolus	dosing.	Even	 in	TB,	where	observational	 studies	have	convincingly	 shown	benefit	of	
adequate	vitamin	D	levels,	studies	evaluating	vitamin	D	against	placebo	as	a	treatment	have	
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	reported	mixed	results;	some	have	demonstrated	no	clinical	improvement	(282,	283)	whilst	
a	more	recent	study	 (284)	 reported	both	radiological	and	clinical	 improvement.	Results	of	
studies	looking	for	a	relationship	between	vitamin	D	and	respiratory	infection	are	mixed	and	
the	 question	 of	 whether	 vitamin	 D	 deficiency	 plays	 a	 role	 in	 respiratory	 disease	 remains	
controversial	 but	 there	 is	 mounting	 evidence	 that	 adequate	 levels	 of	 vitamin	 D	 may	 be	
important	in	TB	(253,	274),	influenza	and	other	lower	respiratory	tract	infections	(254-257),	
as	well	as	asthma	(231,	285).	
	
	
3.10 		The	role	of	Vitamin	D	in	CF	lung	disease		
Evidence	 from	 studies	 evaluating	 the	 role	 of	 vitamin	 D	 in	 respiratory	 infections	 and	
respiratory	health	in	CF	is	limited	and	results	are	mixed.	The	largest	study	to	date,	involving	
800	individuals	with	CF,	found	that	vitamin	D	had	a	positive	but	very	weak	correlation	with	
FEV1	 and	 a	 negative	 correlation	with	 IgG	 (286)	 (used	 a	marker	 of	 lung	 inflammation	 and	
previously	reported	to	correlate	negatively	with	FEV1	(287)	(Figure	7).	However	the	results	
of	 several	 smaller	 studies	 are	 conflicting	 (268,	 288-291)	 	 and	 this	 effect	 has	 not	 been	
observed	 in	 children	 with	 CF	 (266).	 	 One	 small	 pilot	 study	 found	 increased	 survival,	
increased	hospital	free	days	and	decrease	in	serum	TNF-α	and	IL-6	following	a	single	bolus	
dose	of	vitamin	D	(292).	A	systematic	review	(293)	concluded	that	there	is	a	weak	positive	
correlation	 between	 vitamin	 D	 and	 spirometry.	 Given	 the	 research	 interest	 in	 vitamin	 D	
within	 the	medical	world	 at	 present,	 the	 lack	 of	 data	within	 CF,	 and	 especially	within	 CF	
airway	inflammation	is	surprising.	
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Figure	7:	Scandanavian	CF	nutritional	study	outcomes	
Figure	a	shows	the	vitamin	D	level	against	the	IgG,	which	is	used	as	a	proxy	for	inflammation	and	shows	a	weak	
relationship	with	 r2	=	0.376,	p	<	0.001.	 Figure	b	 shows	 the	 relationship	between	vitamin	D	and	FEV1	 in	 this	
cohort	(R2=0.308;	P=0.025).	Figures	from	(286).	
	
b	
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	4 CHAPTER	4:	Hypothesis,	aims	and	objectives	
4.1 Hypotheses	
1. The	 earlier	 institution	 of	 improved	 and	 more	 aggressive	 treatments	 strategies	
possible	 in	 infants	 diagnosed	with	CF	by	NBS	 leads	 to	 a	 healthy	 airway	during	 the	
first	year	of	life	
2. Vitamin	 D	 has	 immunomodulatory	 effects	 via	 antimicrobial	 peptide	 pathways;	
consequently	vitamin	D	deficiency	will	lead	to	greater	risk	of	bacterial	infection	and	
subsequent	inflammation	and	worse	clinical	outcomes	in	CF	throughout	childhood		
	
	
4.2 Aims	
a. To	describe	the	spectrum	of	airways	disease	in	a	large	cohort	of	young	infants	with	
CF	 diagnosed	 on	 NBS	 by	 evaluating	 the	 relationships	 between	 infection	 and	
inflammation	 and	 structural	 and	 functional	 changes	 cross-sectionally	 and	
longitudinally	over	the	first	year	of	life	
b. To	describe	vitamin	D	 levels	 in	children	with	CF	of	all	ages	comparing	them	to	two	
control	 groups:	 chronic	 airway	 disease	 and	 healthy	 children	 and	 relate	 them	 to	
airway	structure,	function	and	infection	and	inflammation	status	
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	4.3 Objectives	
i. Gather	 samples	of	BALF	 from	children	undergoing	 routine	 fibreoptic	bronchoscopy	
(FOB)	 at	 3	 months	 of	 age	 and	 process	 samples	 according	 to	 set	 protocol,	 or	 use	
previously	 stored	 samples	 and	measure	 cellular	 and	 soluble	 inflammatory	markers	
and	utilise	microbiological	culture	results	from	clinically	run	tests		
ii. Measure	 serum	 levels	 of	 25(OH)D	 by	 collecting	 serum	 samples	 from	 children	
undergoing	 general	 anaesthesia	 (GA)	 for	 FOB	 procedure,	 using	 previously	 stored	
samples	 or	 by	 obtaining	 results	 from	 the	 electronic	 patient	 records	 for	 levels	
measured	 for	 clinical	 evaluation	 and	 compare	 levels	 in	 3	 discrete	 populations;	 CF,	
non-CF	CSLD	and	healthy	controls		
iii. Using	collected	BALF	samples,	measure	the	levels	of	the	antimicrobial	peptides	LL-37	
and	HBD-2,	 relate	them	to	Vitamin	D	status,	and	establish	 if	 there	 is	a	relationship	
between	 these	 peptides	 and	 the	 presence	 of	 infection	 and	 levels	 of	 soluble	 and	
cellular	inflammation	
iv. Use	longitudinal	outcome	data	available	explore	the	relationship	between	vitamin	D	
at	3	months	and	airway	health	at	12	months	
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	5 CHAPTER	5:	Patients	and	Methods	
This	 chapter	 describes	 methods	 common	 to	 all	 parts	 of	 this	 research.	 Details	 regarding	
methods	specific	to	particular	investigations	can	be	found	in	the	relevant	chapters.		
	
5.1 Patients	
5.1.1 Patient	selection	
Children	aged	<17	years	at	the	Royal	Brompton	hospital,	who	fulfilled	criteria	for	one	of	the	
following	groups	were	included.	If	patients	fulfilled	the	criteria	on	more	than	one	occasion,	
the	first	occasion	was	selected	and	each	individual	patient	included	only	once.		
	
5.1.2 	 Group	1:	Cystic	fibrosis	
Subjects	had	a	diagnosis	of	CF	(42,	294),	and	had	undergone	examination	of	their	airways	by	
fibreoptic	bronchoscopy.			
	 	 Group	1a)		 Infants	 diagnosed	 on	 newborn	 screening	 and	 undergoing	
routine	FOB	at	approximately	3	months	of	age.	
	 	 Group	1b)		 Children	who	had	undergone	FOB	previously	for	exacerbations	
or	if	having	GA	for	another	reason	and	had	stored	serum	AND	
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	BALF	 available,	 OR	 children	 recruited	 prospectively	 whose	
parents	agreed	to	these	samples	being	used	for	research.		
	
5.1.3 	 Group	2:	Non-CF	chronic	suppurative	lung	disease	(CSLD)		
Children	 recruited	 to	 this	 group	 had	 either	 primary	 ciliary	 dyskinesia	 (PCD)	 diagnosed	 on	
conventional	 criteria	 (295)	 or	 non-CF	 bronchiectasis	 (diagnosed	 on	 HRCT	 by	 consultant	
radiologists	independent	of	this	study).	
	 	 Group	2a)	 Children	who	 had	 undergone	 FOB	 previously	 and	 had	 stored	
serum	AND	BALF	available,	OR	children	recruited	prior	 to	the	
FOB	and	these	samples	collected.	
	 	 Group	2b)	 Non-bronchoscopic	 cohort	 comprising	 children	 with	 a	
measurement	 of	 serum	 vitamin	 D	 and	 spirometry	 (within	 4	
days	 of	 the	 vitamin	 D	 sample)	 results	 available	 from	 clinical	
testing.		
	
5.1.4 Group	3:	Healthy	Controls	
Other	 children	 undergoing	 FOB	were	 included	 as	 ‘healthy’	 controls	 (HC)	 only	 if	 they	 had	
macroscopically	 normal	 airways,	 no	 bacteria,	 fungi	 or	 viruses	 identified	 and	 a	 BALF	
neutrophil	and	eosinophil	differential	of	≤4%	and	<0.5%	respectively.		
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	5.2 Fibreoptic	bronchoscopy	
5.2.1 Royal	Brompton	Hospital	bronchoscopy	programme		
In	 the	 Royal	 Brompton	 Hospital	 (RBH)	 paediatric	 respiratory	 department,	 it	 is	 routine	
practice	 to	 perform	 a	 surveillance	 FOB	 under	 general	 anaesthetic	 at	 around	 3	months	 of	
age.	 This	 practice	 was	 started	 in	 2003	 after	 evidence	 began	 emerging	 from	 the	 London	
Cystic	 Fibrosis	 collaboration	 (LCFC)	 of	 airflow	 limitation	 at	 an	 early	 age	 that	 had	 not	
normalised	by	1	year	of	age	((138,	296,	297),	even	in	those	with	apparently	no	respiratory	
disease.	 In	 the	 first	 2	 years	 of	 doing	 this,	 infection	 was	 detected	 in	 approximately	 one	
quarter	 of	 infants	 (298,	 299),	 underscoring	 the	 importance	 of	 this	 practice.	 This	 rate	 of	
infection	was	 also	 seen	 in	 the	 first	 2	 years	 of	NBS	 infant	 data	 (299).	 Such	 practice	 is	 not	
routine	amongst	CF	centres	and	this	practice	has	been	extensively	analysed	and	it	has	been	
found	to	be	a	safe	procedure,	which	does	not	cause	unacceptable	clinical	side	effects.	
	
5.2.2 	Indications	for	bronchoscopy		
All	 FOBs	were	 carried	out	 for	 clinical	 indications.	 The	 infants	 having	 3-month	 surveillance	
FOB	 made	 up	 part	 of	 the	 CF	 cohort;	 the	 remainder	 of	 the	 CF	 group	 and	 the	 PCD	 and	
bronchiectasis	patients	were	undergoing	 the	procedure	because	of	unexplained	decline	 in	
respiratory	 status	 or	 clinical	 symptoms	 and,	 in	 the	 majority,	 an	 inability	 to	 expectorate	
sputum	for	culture.	Healthy	controls	were	bronchoscoped	for	other	reasons	such	as	upper	
airway	 examination	 or	 a	 history	 of	 haemoptysis.	 No	 child	 underwent	 FOB	 purely	 for	
research	purposes;	all	sampling	was	opportunistic.	
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	5.2.3 Consent	
Written	 informed	 consent	 was	 obtained	 from	 parents/guardians	 of	 children	 undergoing	
clinically	indicated	FOB.	Specific	consent	(and	assent	where	age-appropriate)	was	obtained	
to	retain	samples	surplus	to	clinical	needs,	and	obtain	additional	samples	for	research.	
	
5.2.4 Safety	considerations	
When	 undertaking	 sample	 collection	 from	 bronchoscopy	 for	 research	 purposes	 there	 are	
important	safety	aspects	to	consider.	Previous	researchers	within	this	group	have	explored	
the	safety	aspects	in	detail	(298,	300-302).	
The	 children	within	 the	 study	 underwent	 FOB	 as	 part	 of	 clinical	management	 and	 so	 the	
safety	of	the	actual	bronchoscopy	is	not	a	specific	research	concern,	except	insofar	as	a	little	
extra	time	 is	required	to	obtain	research	samples,	 (303)	but	a	consideration	of	the	clinical	
management	decisions.		The	procedure	is	safe	with	the	majority	of	side	effects	being	minor	
(transient	fever,	short	term	increased	cough,	sore	throat).	Additional	samples	e.g.	addition	
blood	 sampling	 or	 performing	 endobronchial	 biopsies	 may	 be	 taken	 purely	 for	 research	
purposes	 and	 therefore	 it	 is	 important	 to	 consider	 the	 safety	 of	 these	 separately;	 (a)	 the	
clinical	 effects	 of	 study	 sampling;	 (b)	 the	 additional	 time	 required	 for	 sampling;	 and	 (c)	
ensuring	 the	samples	obtained	are	of	 sufficient	quality	 to	address	 the	 research	questions.	
We	 have	 published	 data	 on	 the	 on	 the	 safety	 and	 quality	 of	 research	 samples	 from	
bronchoscopy	 in	 the	 under	 5	 year	 olds	 (300);	 33	 patients	 underwent	 FOB	 with	
endobronchial	biopsy	matched	with	33	controls	in	whom	no	biopsy	was	taken.	The	groups	
were	matched	 for	 age,	weight	 and	 bronchoscopist	 and	were	 performed	within	 the	 same	
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	time	 period.	 Most	 procedures	 were	 done	 for	 investigation	 of	 cough,	 recurrent	 lower	
respiratory	 tract	 infection	or	wheeze.	 Two	patients	who	were	 not	 biopsied	 had	CF;	 there	
were	no	patients	with	CF	in	the	biopsy	group.		
There	 was	 no	 significant	 difference	 between	 groups	 in	 the	 number,	 type,	 or	 severity	 of	
complications	occurring	during	or	after	the	procedure.	Biopsies	from	30	of	the	33	subjects	
could	 be	 assessed;	 reticular	 basement	 membrane	 was	 identified	 in	 all	 30;	 inflammation	
could	be	 assessed	 in	 26	 and	areas	of	 smooth	muscle	were	present	 in	 23.	A	 further	 study	
evaluated	 the	 safety	 of	 research	 bronchoscopies,	 specifically	 endobronchial	 biopsies,	 in	
children	with	CF	compared	with	non-CF	children	(301).	42	children	underwent	45	FOB	and	
endobronchial	biopsies	and	a	comparison	was	made	to	a	control	group	of	39	children	with	
other	 respiratory	 conditions	 also	 undergoing	 FOB	 and	 endobronchial	 biopsies.	 13%	 of	 CF	
children	had	minor	complications	during	the	procedure	compared	with	18%	in	the	control	
group.	 There	was	 one	 significant	 event	within	 the	 control	 group	when	 a	 patient	 suffered	
transient	loss	of	pulse	following	a	cardiac	catheter	done	at	the	same	time,	but	this	was	not	
thought	to	be	related	to	the	bronchoscopy.		
There	 was	 no	 significant	 difference	 in	 the	 post-operative	 complication	 rate	 with	 post	
procedural	fever	being	seen	in	2	patients	in	the	CF	group	(4.4%)	and	3	patients	(7.6%)	in	the	
control	 group,	1	CF	patient	 (2.2%)	 requiring	overnight	oxygen	and	1	patient	 (2.6%)	 in	 the	
control	group	describing	pleuritic	chest	pain.		
The	timing	of	procedures	has	also	been	evaluated	to	assess	if	the	additional	time	taken	for	
research	 sampling	 was	 acceptable.	 This	 study	 was	 done	 covertly	 without	 the	
bronchoscopists	being	aware	of	the	timing.	The	median	(range)	duration	(min)	was	2.5	(1.0-
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	8.2)	for	airway	inspection,	2.8	(1.7-9.4)	for	performing	bronchoalveolar	lavage,	5.3	(2.5-16.6)	
for	 biopsy	 sampling,	 2.4	 (1.5-6.6)	 for	 teaching	 and	 4.1	 (0.8-18.5)	 for	 other	 interventions.	
Three	adequate	biopsies	were	obtained	in	33	(83%)	children	it	took	a	median	of	just	over	5	
min	to	obtain	three	endobronchial	biopsies,	which	was	considered	an	acceptable	increase	in	
the	 duration	 of	 fibreoptic	 bronchoscopy	 for	 the	 purpose	 of	 research	 (303).	 These	 three	
studies	concluded	that	FOB	and	endobronchial	biopsy	was	safe,	requires	minimal	additional	
time	 and	 produces	 samples	 that	 are	 of	 acceptable	 quality	 for	 research.	 In	 addition,	 an	
independent	consultant	anaesthetist	is	present	and	acts	as	a	guarantor	of	the	child’s	safety,	
with	authority	to	stop	research	sampling	at	any	time.		
	
5.2.5 Bronchoscopy	Protocol	
The	 procedure	 was	 carried	 out	 under	 general	 anaesthetic	 as	 is	 usual	 practice	 within	 the	
centre	 and	 the	 specific	 anaesthetic	 technique	 was	 determined	 by	 the	 consultant	
anaesthetist.	 Most	 children	 have	 anaesthetic	 induction	 by	 inhaled	 sevofluorane	 via	 face	
mask,	 with	 the	 remaining	 children	 receiving	 intravenous	 propofol.	 	 Anaesthetic	
maintenance	is	with	sevofluorene	and	intravenous	propofol	if	needed.	The	airway	was	most	
commonly	maintained	by	facemask	and	manual	chin	lift.	Laryngeal	mask	airway	(LMA)	and	
endotracheal	tube	were	used	if	deemed	appropriate	by	the	anaesthetic	consultant.	
2.8	 internal	 diameter	Olympus	 BF-XP40,	 3.6	mm	BF-3C20	 or	 3C40,	 4.0	mm	BF-MP60	 and	
4.6mm	 BF-P2OD	 bronchoscopes	 were	 used,	 the	 choice	 being	 dictated	 by	 the	 size	 of	 the	
child.	 An	 initial	 inspection	 of	 upper	 and	 lower	 airways	 was	made	 prior	 to	 samples	 being	
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	obtained.	Where	 possible,	 no	 suctioning	 was	 carried	 out	 in	 the	 upper	 airway	 to	 prevent	
contamination	of	samples	with	upper	airway	flora	as	far	as	possible.		
	
	
5.3 Samples	collected	at	bronchoscopy	
5.3.1 BALF	collection	and	processing	
BALF	samples	were	obtained	by	instilling	3	aliquots	of	1ml/kg,	up	to	a	maximum	volume	of	
40ml,	 0.9%	 saline	 at	 room	 temperature	 to	 the	 right	middle	 lobe	 and	 lingula,	 or	 the	most	
affected	lobe(s).	The	aliquots	were	pooled.	1ml	aliquots	were	sent	to	clinical	laboratories	for	
microbiology	 analysis	 (304),	 virology	 (immunofluorescence	 and	 PCR)	 and	 cytology	 for	
differential	 cell	 count.	 Cellular	 differential	 was	 performed	 following	 cytospinning	 for	 3	
minutes	 at	 200	 g,	 air	 drying	 then	 fixation	 with	 methanol	 and	 May-Grünwald-Geimsa	
staining.	The	research	aliquot	was	put	immediately	on	to	ice.		A	50	μl	aliquot	of	whole	BALF	
was	mixed	1:1	with	trypan	blue	(Sigma-Aldrich,	USA)	and	a	total	cell	count	performed	using	
a	dual	chamber	Neubauer	haemocytometer	(Assisten,	Sondheim,	Germany).	The	remaining	
BALF	was	centrifuged	at	4˚C,	2000	g	for	10	minutes	and	the	supernatant	stored	in	aliquots	
at	 -80˚C.	 As	 per	 current	 research	 governance	 stipulations,	 samples	 were	 coded	 and	
individual	aliquots	item	tracked.		
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	5.3.2 Sample	suitability	
Not	 all	 samples	 were	 suitable	 for	 cellular	 differential	 counts	 due	 to	 small	 volumes,	 cell	
breakdown	or	 excess	 blood	within	 the	 sample;	 hence	 these	 data	 are	 not	 available	 for	 all	
patients.	 In	addition,	 there	are	some	missing	data	 from	archived	material.	Wherever	both	
neutrophil	cell	differential	and	total	cell	count	were	available,	a	BALF	neutrophil	cell	count	
was	calculated.		
	
5.3.3 Blood	samples	
Blood	 samples	were	 obtained	 through	 venepuncture	whilst	 under	 general	 anaesthetic.	 In	
nearly	all	 cases	venepuncture	was	 clinically	 indicated	and	most	had	 sampling	 through	 the	
line	which	was	placed	 for	anaesthetic	 reasons;	 an	addition	aliquot	of	up	 to	3	ml	of	blood	
taken	in	lithium	heparin	vials	for	research	purposes.	These	samples	were	centrifuged	at	4˚C,	
2200	g	 for	10	minutes	and	the	serum	carefully	pipetted	and	stored	in	aliquots	of	between	
125	and	500	μl	at	-80˚C.		
	
	
5.4 Clinical	patient	data	
Clinical	 data	 were	 obtained	 at	 the	 time	 of	 bronchoscopy	 and	 recorded	 in	 a	 research	
database	(Access	2000)	alongside	data	from	electronic	patient	records	and	the	clinical	lung	
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function	database.	 For	 CF	 patients,	 data	 from	annual	 assessment	was	 also	obtained	 from	
the	national	CF	registry,	“Port	CF”.	Data	recorded	were;	
• Weight	and	height
• Pancreatic	status
• Spirometric	values
• Presence	/absence	CF	related	diabtes
• Use	of	intravenous	antibiotics	(IVAB)
• CRP
• Microbiology
5.5 Lung	function	
Spirometry	was	performed	according	to	ATS/ERS	standards	using	Vitalograph	(Buckingham,	
England)	 alpha	 touch	 spirometer	 and	expressed	 as	percent	predicted	using	 the	Rosenthal	
reference	 equations	 (305),	 in	 all	 children	 old	 enough	 to	 complete	 the	manoeuvre.	 Three	
manoeuvres	 were	 performed	 and	 the	 best	 FEV1	 and	 FVC	 taken	 (306);	 these	 do	 not	
necessarily	have	to	be	from	the	same	manoeuvre.		
5.6 Vitamin	D	measurement	
5.6.1 	Vitamin	D	assay	
Prior	 to	 June	2010,	 vitamin	D	assays	performed	by	 the	Biochemistry	department	at	Royal	
Brompton	 and	 Harefield	 NHS	 trust	 were	 done	 using	 immunoasssay.	 Thereafter,	 samples	
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have	been	analysed	using	mass	spectrometry	with	high	performance	liquid	chromatography	
(HPLC).	 When	 the	 analytical	 method	 was	 changed,	 the	 biochemistry	 department	 ran	
approximately	100	samples	concurrently	with	both	techniques	and	found	a	good	correlation	
with	 minimal	 inter-assay	 variability.	 However,	 to	 maximise	 accuracy,	 vitamin	 D	 levels	
performed	before	June	2010	were	not	included	in	this	study.	 If	such	patients	had	a	stored	
serum	sample	available,	a	repeat	assay	was	performed	using	the	newer	technique,	but	if	no	
serum	was	available	the	patient	was	excluded	from	this	study.	All	samples	were	analysed	in	
the	same	laboratory	and	by	excluding	samples	prior	to	June	2010,	all	samples	were	tested	
using	the	same	technique	and	on	the	same	apparatus.	Included	samples	were	processed	in	
one	of	2	ways:	
Method	1:	assay	performed	at	time	of	FOB	on”	fresh”	samples	(“clinical”)	
Method	2:	assay	performed	on	frozen	/	thawed	samples.	Some	were	performed	as	part	of	
the	 medical	 student	 pilot	 project	 (“pilot”)	 and	 some	 as	 part	 of	 this	 research	 study	
(“research”).		
(Further	explained	in	flow	diagram	in	Figure	11.	
5.6.2 Comparing	vitamin	D	results	when	performed	using	different	methods	
14	samples	were	analysed	using	both	of	these	ways	(clinical	and	research)	and	these	were	
compared	to	assess	agreement.	(The	pilot	study	samples	predated	the	change	to	HPLC	so	no	
clinical	results	are	available	but	the	stored	samples	had	vitamin	D	analysis	using	HPLC	and	so	
are	included	in	the	overall	research	but	not	this	section	of	comparing	clinical	and	research	
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results.)	 There	 was	 no	 statistical	 difference	 seen	 between	 the	 paired	 values	 of	 “clinical”	
result	and	“research”	 result	 (median	 (95%	CI)	62	 (37	–	88)	 vs.	50	 (35	–	73)	nmol/L,	p=0.2	
paired	 t-test).	 However,	 as	 results	 did	 vary,	 this	 was	 explored	 further.	 I	 considered	 the	
following	possibilities:	a)	differences	in	equipment	used	for	the	assay,	b)	different	personnel	
performing	 the	 assay,	 c)	 the	 stability	 of	Vitamin	D	during	 storage.	Of	 note,	 as	mentioned	
previously,	 the	 research	batches	were	 analysed	on	 the	 same	machine	 as	 clinical	 samples,	
and	also	by	the	same	personnel.	The	assays	were	performed	by	the	Biochemistry	staff,	and	
not	by	the	researchers.		
5.6.3 Assessing	stability	of	vitamin	D	over	time	
Firstly,	 I	determined	whether	vitamin	D	had	denatured	over	 time,	as	although	 the	clinical	
samples	 are	 assayed	 within	 7	 days	 of	 sample	 collection,	 the	 rest	 were	 performed	 in	 2	
batches	and	some	samples	analysed	as	many	as	10	years	after	collection.	I	therefore	looked	
to	see	if	the	oldest	samples	had	lower	levels	of	vitamin	D	than	more	recent	samples.	Figure	
8	shows	vitamin	D	by	sample	number	for	all	groups,	with	sample	1	being	the	oldest	sample	
(from	2002)	and	sample	680	being	the	newest	(2011).	The	“pilot”	assays	were	performed	in	
2010,	 and	 “research”	 assays	 in	 2012	 on	 samples	 obtained	 between	 2002	 and	 2012.	 If	
degradation	had	occurred,	 the	 later	groups	would	be	expected	 to	have	 lower	values	 than	
those	analysed	at	the	time.	There	is	no	decrease	over	time	and	the	group	mean	and	spread	
was	unchanged	(Figure	8).		
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The	 5	 samples	 assayed	 in	 both	 the	 pilot	 study	 and	 the	 research	 study	 show	 very	 good	
agreement	on	inspection,	despite	being	done	almost	2	years	apart	(Figure	9)	the	numbers	are	
too	low	for	a	statistical	test.	This	again	suggests	that	vitamin	D	is	not	subject	to	degradation	
over	time	in	frozen	samples.		
Figure	8:	25(OH)D2	levels	over	time.		
There	is	no	decrease	in	vitamin	D	levels	when	assayed	at	a	later	date	(blue	and	red	symbols)	compared	
with	results	obtained	from	serum	assayed	at	the	time	of	collection	(green	symbols).	
Figure	9:	25(OH)D	results	performed	on	separate	occasions.	The	pilot	and	research	study	results	are	very	similar	despite	
being	performed	2	years	apart.	
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Figure	10	shows	agreement	between	paired	clinical	and	research	samples.	Clinical	samples	
are	 processed	 on	 recently	 taken	 “fresh”	 samples,	whilst	 research	 samples	 are	 processed,	
frozen,	stored	and	thawed	at	a	 later	date	for	the	assay.	Positive	values	represent	a	higher	
value	seen	in	clinical	result	than	research	samples.	Overall,	values	are	higher	in	the	samples	
analysed	at	the	time	than	samples	analysed	at	a	later	date	on	stored	aliquots.	However,	as	
shown	above	 this	 does	not	 appear	 to	be	 explained	by	 an	 effect	 of	 time.	An	effect	 of	 the	
freeze/thaw	cycle	was	considered	but	such	an	effect,	if	present,	is	not	uniform	as	2	of	the	14	
samples	are	lower	in	the	clinical	sample	than	that	tested	at	a	later	date	on	frozen/thawed	
sample.		
The	result	of	one	paired	sample	is	grossly	different	and	by	looking	at	other	blood	tests	for	
vitamin	 D	 performed	 clinically	 on	 this	 patient	 it	 appears	 that	 the	 “clinical”	 result	 is	 the	
Figure	10:	Bland	Altman	plot	of	agreement	of	25(OH)D2	levels	
Bland-Altman	agreement	of	the	25(OH)D	level	as	measured	by	clinical	method	and	research	method.	There	is	
a	systematic	difference	seen	with	a	mean	difference	of	16.6	in	the	direction	of	the	clinical	assay	being	higher	
than	research	assay.		
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correct	result	and	is	the	one	used	here	(Table	5).	The	study	sample	aliquot	was	small,	and	
upon	checking,	there	was	no	sample	at	all	left	in	the	vial,	so	the	inaccuracy	could	perhaps	be	
due	to	a	small	sample,	possibly	with	fibrinous	material	included	within	it.		
The	apparent	systematic	difference	was	not	 taken	 into	account	 in	 further	analyses	due	to	
the	 small	 sample	 size	 giving	 rise	 to	a	 very	 large	95%	CI	which	 crossed	 zero	and	 therefore	
accuracy	of	such	an	adjustment	could	not	be	certain	and	may	mislead	results.	
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Table	5:	difference	between	clinical	and	research	results.	
A	large	discrepancy	between	clinical	and	study	result	was	seen	for	patient	640	despite	the	sample	being	taken	
on	the	same	day.	Comparing	the	results	with	other	clinical	blood	tests,	it	is	clear	that	the	clinical	result	is	the	
correct	result.	The	error	in	the	research	result	is	thought	to	be	due	to	too	small	sample.	Of	note,	the	patient	
stopped	his	vitamin	D	supplements	in	November	2011	
5.6.4 Conclusions	of	establishing	methodology	for	vitamin	D	assay	
Overall,	 there	 is	 very	 good	 correlation	 between	 the	 values	 obtained	 from	 clinical	 and	
research	samples	but	not	as	good	agreement	as	expected	given	 the	 fact	 that	 the	samples	
were	taken	at	the	same	time,	from	the	same	patient	and	analysed	in	the	same	way,	in	the	
same	 laboratory.	 Accuracy	 of	 the	 test	 is	 said	 to	 be	 within	 1%.	 A	 decision	 was	 made	 to	
include	clinical,	 research	and	pilot	 study	 samples.	 If	more	 than	1	 result	was	available,	 the	
clinical	 result	 was	 prioritised	 for	 inclusion	 as	 these	 results	 were	 obtained	 from	 samples	
processed	 immediately	 reducing	 potential	 factors,	 followed	 as	 needed	 by	 the	 research	
result	 as	 this	my	own	 study	 and	 samples	 retrieved	 and	observed	by	me,	 then	pilot	 study	
result	(Figure	11).	
In	summary,	the	results	include	71	research	samples,	34	pilot	and	37	clinical	values.		
Date	 sample	
taken	
Days	 between	
collection	and	assay	
Clinical	or	 research	
aliquot	
25(OH)D
(nmol/L)	
16/05/2011	 2	 clinical	 176	
30/09/2011	 5	 clinical	 191	
30/09/2011	 174	 research	 93	
14/05/2012	 2	 clinical	 118	
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Figure	11:	Consort	diagram	to	show	determination	of	vitamin	D	samples	used	in	the	study	
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5.6.5 Definition	of	vitamin	D	deficiency	
Data	were	explored	using	vitamin	D	as	both	continuous	and	categorical	data.	For	the	latter,	
patients	were	grouped	in	to	those	sufficient	(50	and	over)	and	those	insufficient	(less	than	
50).	The	cut	off	values	used	here	were	chosen	as	they	are	the	most	frequently	used	cut	off	
values	 in	clinical	practice	 (273-276).	Based	on	values	used	 in	other	studies	 (227,	266,	277-
279) and	 to	 ensure	 that	 signals	 were	 not	 being	 missed,	 post-hoc	 analyses	 were	 also
performed	using	alternative	cut-off	values	(Table	6).		
Table	6:	various	cut-off	values	used	for	vitamin	d	deficiency	
	Post	hoc	analyses	were	performed	using	different	cut-off	values	for	vitamin	D	sufficiency	and	insufficiency.	
Original cut-
off values  
Insufficient 
<50 nmol/L 
Relatively 
sufficient 
≥50 nmol/L 
(46) 
Alternative 1 Insufficient 
< 75 nmol/L 
Sufficient 
≥75 nmol/L 
(46) 
Alternative 2 Insufficient 
<50 nmol/L 
Relatively 
sufficient 
50–74 
nmol/L 
Sufficient 
≥75 nmol/L 
(47) 
Alternative 3  Deficient 
<25 nmol/L 
Insufficient 
25–74 nmol/L 
Sufficient 
≥75 nmol/L 
(18;48;
49) 
Alternative 4 Deficient 
<25 nmol/L 
Insufficient 
25–49 
nmol/L 
Relatively 
sufficient 
50–74 
nmol/L 
Sufficient 
≥75 nmol/L 
Combin
ation of 
above 
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5.7 Cytokine	analysis	
5.7.1 Choice	of	assay	
	Cytokine	 analysis	 was	 initially	 planned	 to	 be	 performed	 using	 Luminex	 (Luminex	
corporation,	Texas,	USA)	with	17	cytokines	chosen	to	be	measured;	GRO-α,	G-CSF,	GM-CSF,	
IL-1β,	Il-2,	IL4,	IL5,	IL-6,	Il-7,	IL-8,	IL-10,	IL-12,	IL-13,	IL-17,	IFN-γ,	MCP-1,	MIP1-β	and	TNF-α.	
One	 run	was	 completed	 but	many	 samples	 had	 error	 readings	 as	 insufficient	 beads	were	
read,	 perhaps	due	 to	bead	 clumping	or	 to	difficulties	 encountered	with	 the	 filtration.	 For	
optimal	 results	 >100	 beads	 should	 be	 read	 in	 each	 assay,	 but	 for	 a	 more	 pragmatic	
approach,	 50	 beads	 can	 be	 taken	 as	 acceptable.	 Even	 using	 this	 lower	 bead	 count	 43/80	
(54%)	 were	 insufficient	 meaning	 that	 many	 readings	 obtained	 in	 these	 assays	 were	 too	
inaccurate	to	use.	None	of	the	80	samples	had	>100	beads	read	in	all	17	assays.		
The	 second	 run	 encountered	 instrument	 reader	 equipment	 difficulties	making	 the	 results	
potentially	unreliable,	and	the	earlier	problem	with	insufficient	bead	count	was	see	again	in	
this	run.	25	samples	were	analysed	before	the	machine	stopped	due	to	technical	difficulties;	
of	 these	 25	 samples	 13	 were	 excluded	 for	 insufficient	 bead	 readings.	 The	 technical	
difficulties	with	 the	machine	were	 overcome	 and	 the	 entire	 plate	with	 all	 80	 samples	 on	
measured.	Just	24/80	(30%)	samples	could	be	used	due	to	insufficient	bead	counting.	From	
part	 of	 this	 plate	 being	 read	 twice,	 7	 samples	 had	 sufficient	 quality	 readings	 on	 both	
readings	to	use	and	so	these	7	samples	had	their	17	cytokine	assays	compared				
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Good	agreement	was	seen	in	the	few	samples	with	results	available	from	both	readings	in	
this	second	run	and	further	analysis	was	then	planned	comparing	samples	assayed	in	both	
runs.	29	samples	from	the	1st	run	were	repeated	but	just	3/29	had	valid	results	and	none	of	
these	3	had	valid	results	from	run	1;	comparison	of	the	2	runs	could	therefore	not	be	carried	
out.		
Due	to	problems	encountered	on	both	runs,	culminating	in	little	usable	data,	all	results	were	
discarded	 and	 further	 consideration	 given	 to	 the	 techniques	 available	 for	 cytokine	
measurements.	A	decision	was	made	to	use	meso	scale	discovery	(MSD)	for	measurements	
of	cytokines.		
IL-1β,	 IL-2,	 IL-6,	 IL-8,	 IL-10,	 IL-12,	 IFN-γ,	TNF-α,	GM-CSF	and	 IL-17a	were	measured	using	a	
combination	of	single	and	multiplex	cytokine	assays	(Meso	Scale	Discovery,	Rockville,	USA)	
on	BALF.		
5.7.2 Choice	of	cytokine	
The	pro-inflammatory	cytokines	 IL-8,	 Il-6,	 IL-1β,	TNF-α	are	elevated	 in	 the	CF	airway	 (307)	
and	 there	 are	 reduced	 levels	 of	 what	 has	 traditionally	 thought	 be	 an	 anti-inflammatory	
cytokine,	 IL-10	 (99),	 although	mixed	 functions	 with	 pro-and	 anti-inflammatory	 properties	
have	been	reported	(308,	309).		
IL-8,	 produced	 primarily	 by	 activated	 macrophages,	 is	 a	 potent	 neutrophil	 attractor	
stimulated	by	certain	bacterial	pathogens	and	by	activation	of	the	TLRs	(310).		
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IL-6	 is	 another	 pro-inflammatory	 molecule	 secreted	 by	 monocytes	 and	 macrophages	 in	
response	 to	 infection;	 it	 is	 involved	 in	 the	 B-cell	 response	 signalling	 and	 aids	 the	
differentiation	of	T-helper	cells,	which	in	turn	secrete	IL-17	(311).		
IL-1β	 induces	 production	 of	 adhesion	 molecules	 that	 enable	 leukocytes	 to	 migrate	 into	
inflamed	 tissue	 and	 is	 secreted	 by	 macrophages,	 monocytes,	 dendritic	 cells	 and	 certain	
epithelial	cells	(312).		
TNF-α,	 produced	 by	 activated	 macrophages	 triggers	 a	 wide	 range	 of	 signalling	 pathways	
including	apoptosis,	cytokine	production	and	chemoattraction	(313).	IL-17	was	included	due	
to	 the	 interest	 of	 the	 department	 in	 this	 pro-inflammatory	 cytokine,	 which	 induces	 the	
production	of	many	other	 cytokines	with	pro-inflammatory	effects;	 C-CSF,	GM-CSF,	Gro-α	
TGF-β	and	MCP-1	as	well	as	the	previously	mentioned	pro-inflammatory	cytokines	(113).			
5.7.3 MSD	assay	
In	order	 to	measure	the	cytokines,	an	antibody	 is	coated	onto	a	well,	or	 for	 the	multiplex	
assays,	a	 range	of	antibodies	are	coated	 in	a	specific	pattern	 (Figure	12).	The	samples	are	
prepared	by	 the	addition	of	 a	 solution	 containing	detection	antibodies	 (anti-IL-6,	 anti-IL-8	
etc.)	 each	 of	 which	 is	 labelled	 with	 an	 electrochemiluminescent	 compound.	 During	
incubation	 periods,	 binding	 occurs	 and	 the	 final	 solutions	 are	 used	 for	 the	 readings.	 The	
MSD	 instrument	 measures	 the	 quantity	 of	 emitted	 light,	 which	 provides	 a	 quantitative	
measurement	of	the	desired	compound.			
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1	=	IL-2	
2	=	IL-8	
3	=	IL-12p70	
4	=	IL-1β	
5	=	GM-CSF	
6	=	Blank	
7	=	IFN-γ	
8	=	IL-6	
9	=	IL-10	
10	=	TNF-α	
BALF	samples	were	processed	as	per	the	assay	protocol	with	a	few	minor	changes	(detailed	
here),	as	the	protocol	was	not	written	for	BALF.	12	μl	10%	BSA	solution	was	added	to	each	
of	 the	 samples	 (108μl)	 to	 achieve	 a	 concentration	 of	 1%	 BSA	 within	 each	 sample.	 The	
standards	were	made	up	in	1%	BSA	and	not	the	diluent	as	stated	in	the	protocol	to	allow	for	
increased	 protein	 content	 within	 BALF,	 as	 was	 suggested	 in	 the	 manufactures’	 product	
information	and	by	correspondence	with	others	within	the	lab	experienced	in	working	with	
this	material.		
5.7.4 MSD	detection	ranges	and	standard	curves	
Detection	 limits	 are	 set	 by	 the	MSD	 software	 depending	 on	 results	 of	 the	 standards;	 the	
lower	 limit	 of	 detection	 (LLD)	 is	 2.5	 standard	 deviations	 above	 the	 zero	 calibration	 and	
therefore	 varies	 from	 plate	 to	 plate.	 For	 simplicity,	 the	 highest	 of	 the	 values	 for	 each	
4	
8	
9	
	3	
2	
1	
7	
6	
5	
10	
Figure	12:	Layout	of	luminex	multiassay	plate	
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individual	cytokine	from	the	3	plates	was	used.	The	highest	value	was	used	to	ensure	that	
samples	 below	 the	 level	 of	 detection	 were	 not	 included	 as	 this	 would	 have	 meant	 the	
inclusion	of	unvalidated	results.		
The	upper	limit	of	detection	(ULD)	is	set	at	2500	pg/ml	but	extrapolated	values	are	obtained	
beyond	 this.	 For	 samples	 that	 were	 above	 the	 ULD	 analyses	 were	 performed	 using	 the	
extrapolated	value	and	again	using	just	those	within	the	detection	range	parameters	and	no	
notable	differences	were	seen.	A	decision	was	made	to	use	the	extrapolated	values.	
5.8 HBD-2	ELISA	
5.8.1 HBD-2	measurement	
All	 144	 patients	 included	 in	 the	 vitamin	D	 part	 of	 the	 study	 had	HBD-2	measured	 as	 BAL	
availability	 was	 part	 of	 the	 criteria	 for	 inclusion	 into	 that	 study.	 Some	 results	 were	
above/below	level	of	detection;	therefore	results	are	available	for	128/144	patients.	OF	the	
77	infants	in	the	NBS	cohort,	just	14	had	HBD-2	results	measured	and	within	range.			
HBD-2	was	measured	in	BALF	samples	using	ELISA	(Phoenix	pharmaceuticals,	USA).	This	was	
performed	 as	 per	manufacturers’	 instructions	 the	 lower	 and	 upper	 limits	 of	 detection	 of	
HBD-2	 being	 7.8	 and	 500	 pg/ml	 respectively	 (314).	 Samples	 were	 diluted	 1:1	 with	 assay	
buffer,	 therefore	 after	 correcting	 for	 this	 dilution	 the	 detectable	 range	was	 15.6	 pg/ml	 –	
1000	pg/ml.	A	standard	curve	for	this	can	be	seen	in	Figure	13.	
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Figure	 13:	 HBD-2	 ELISA	 standard	 curve	 showing	 good	 fit	 to	 trendline	 showing	 satisfactory	 experimental	
conditions	for	reliable	interpretation	of	the	measured	assays	(r2	=	0.98)	
5.8.2 Establishing	reproducibility	
Intra	and	inter-run	reproducibility	and	accuracy	were	considered.	
5.8.2.1 Intra-assay	reproducibility	
Firstly,	 intra-run	 reproducibility	 was	 assessed.	 Most	 assays	 could	 not	 be	 performed	 in	
duplicate	due	to	financial	resources,	but	good	agreement	was	observed	in	those	that	were	
done	in	duplicate	in	all	but	one	(Figure	14).	This	sample	was	not	intended	to	be	a	duplicate	
but	 was	 used	 to	 fill	 an	 empty	 well	 left	 at	 the	 end.	 Neat	 sample	 was	 used,	 and	 the	 last	
portion	 of	 the	 aliquot	 used	 up	 and	 this	 sample	 gave	 an	 undetectable	 reading,	 below	 the	
level	of	detection.	Given	the	good	agreement	of	the	rest	of	the	samples,	it	is	likely	that	by	
using	 this	 end	 of	 vial	 sample,	 fibrinous	 material	 was	 obtained;	 therefore	 this	 result	 was	
discarded	as	spurious.	 	Overall,	14	samples	were	measured	 in	duplicate	and	paired	values	
very	similar	(CoV	median	(IQR)	4%	(0.3-10%).	The	remainder	were	run	in	singlicate.	
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5.8.2.2 Inter-run	analysis	
Next,	the	reproducibility	of	samples	between	runs	was	compared.	The	ELISA	was	run	on	4	
separate	 occasions,	 and	 to	 ensure	 comparability	 between	 different	 runs,	 some	 samples	
were	 repeated	 on	 different	 runs.	 Overall,	 20	 samples	 were	 analysed	 on	 2	 different	 runs	
(Figure	15)	with	large	variation	between	runs;	CoV	of	21%	(IQR	9.9	–	52.2).	This	may	be	due	
to	variation	in	technique.	Whilst	there	is	variation	in	the	values,	the	ranking	order	was	not	
significantly	different	 (p	=	0.16).	The	absolute	values	may	 therefore	not	be	 totally	 reliable	
but	as	the	ranking	order	is	not	significantly	different,	this	difference	in	absolute	values	does	
not	affect	the	conclusions.		
Figure	14:	HBD-2	duplicate	measurements	–	intra-assay	reprducibility.	
This	 figure	shows	the	HBD-2	 level	obtained	on	samples	run	 in	duplicate;	all	bar	one	showed	excellent	
agreement	(median	(95%	CI	200	(87	–	331)	vs.	192	(54	–	295)	pg/ml,	p	=	0.49	Wilcoxon	matched	pair	
test).	This	sample	was	not	intended	to	be	a	duplicate	but	was	used	to	fill	an	empty	well	left	at	the	end.	
Neat	 sample	 was	 used,	 and	 the	 last	 portion	 of	 the	 aliquot	 used	 up	 and	 this	 sample	 gave	 an	
undetectable	 reading,	 below	 the	 level	 of	 detection.	 Given	 the	 good	 agreement	 of	 the	 rest	 of	 the	
samples,	it	is	likely	that	by	using	this	end	of	vial	sample,	fibrinous	material	was	obtained;	therefore	this	
result	was	discarded	as	spurious.	
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Figure	15:	HBD-2	levels	(pg/ml)	of	samples	assayed	on	more	than	one	run.		
Whilst	 there	 is	 clearly	 a	 variation	 in	 the	 numerical	 value	 of	 results,	 the	 ranking	 order	 did	 not	 change	
significantly.	No	significant	difference	in	results	between	runs	was	seen.	(p=0.16,	wilcoxon	matched	pair	test).	
5.8.2.3 “Fresh”	vs	“old”	samples	
In	order	to	try	to	explain	the	differences	seen	in	some	samples	between	runs,	the	possibility	
of	 different	 results	 being	 obtained	 from	 samples	 thawed	 for	 the	 first	 time	 (“fresh”)	 and	
samples	previously	thawed	and	refrozen	(“old”)	was	explored.	It	was	hypothesized	that	any	
difference	 seen	 could	 be	 due	 to	 instability	 of	 the	 peptide	 in	 the	 thaw/freeze	 cycle	 and	
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therefore	results	would	be	lower	from	“old”	sample	than	from	“fresh”	samples.	On	the	4th	
run,	paired	“fresh”	and	“old”	samples	were	compared		
Table	7:	Results	obtained	from	“fresh”	and	“old”	samples”.	
There	was	no	statistically	 significant	difference	between	 the	 results	obtained	on	 these	samples	 (p=0.13)	but	
this	may	be	due	to	small	sample	size.	Although	there	are	not	enough	samples	for	accurate	comparisons	to	be	
made	 but	 the	 results	 of	 this	 small	 experiment	 do	 suggest	 that	 the	 protein	 does	 not	 denature	 during	 the	
freezing	process.	
The	difference	between	pairs	was	not	statistically	significant	(p	=	0.13);	this	may	be	due	to	
small	numbers	but	the	results	do	suggest	that	no	degradation	of	the	peptide	has	occurred	
with	the	thawing/refreezing	process.	Values	are	all	therefore	included	in	the	analysis	for	this	
study,	from	fresh	and	from	previously	thawed	samples.			
5.8.2.4 Dilution	experiments		
On	the	1st	run,	some	results	were	above	and	some	were	below	the	level	of	detection.	16%	
of	 the	 serum	 samples	 were	 above	 the	 upper	 level	 of	 detection,	 and	 the	 lowest	 sample	
concentration	was	 137	 pg/ml,	 with	 the	 kit	 being	 able	 to	 detect	 values	 as	 low	 7.5	 pg/ml.	
Therefore	in	the	next	run	the	samples	were	further	diluted	to	1:3	in	order	to	capture	more	
sample	results	within	the	range	of	the	ELISA	kit.		It	was	therefore	very	surprising	that	22%	of	
Study	no.	 HBD-2	(pg/ml)	“fresh”	samples	 HBD-2	(pg/ml)	“old”	samples	 Difference	
150	 38.7	 41.8	 +3.2
150	 71.4	 87.5	 +16.1
600	 <15.6	 <15.6	 0	
620	 <15.6	 31.4	 +15.8
620	 <15.6	 51.6	 +36
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these	 samples	 were	 above	 the	 upper	 level	 of	 detection,	 which	 was	 now	 2000	 pg/ml,	
compared	 to	 1000	 pg/ml	 on	 the	 previous	 run.	 The	 assay	 had	 not	 changed,	 but	 once	 the	
dilution	 factor	was	accounted	 for,	 readings	up	 to	2000	pg/ml	were	now	possible.	 Table	8	
and	Figure	16	show	the	medians	and	ranges	of	samples	assayed	in	the	different	runs.		
No	significant	difference	was	observed	in	the	results	of	the	BALF	samples	processed	in	the	
same	way	from	the	two	runs	and	therefore	it	appeared	to	be	an	issue	with	the	samples	not	
with	the	ELISA	run.		I	hypothesised	that	this	difference	seen	was	due	to	an	effect	of	dilution	
and	to	test	this	hypothesis	dilution	curves	were	planned	for	the	next	run.	
Dilution	 curves	 were	 performed	 on	 two	 BALF	 samples	 and	 two	 serum	 samples,	 but	
unfortunately	the	ELISA	kit	“stop	solution”	leaked	in	transit	meaning	insufficient	volume	was	
available	 for	 all	 ELISA	wells	 and	 so	 results	 were	 only	 obtained	 for	 the	 BALF	 samples.	 No	
dilution	curves	could	be	obtained	for	the	serum	samples.	Limited	resources	prevented	more	
dilution	curves	being	undertaken.	It	was	expected	that	the	read	concentrations	of	different	
dilutions	 of	 the	 same	 sample	 would	 be	 different,	 but	 once	 adjusted	 for	 dilution,	 the	
concentrations	 would	 be	 the	 same,	 allowing	 for	 the	 margin	 of	 error	 within	 the	 assay.	
However,	this	was	not	the	case	and	the	readings	were	not	the	same	but	rather,	increased	in	
a	linear	fashion	as	shown	in	figure	8.	The	same	phenomenon	was	seen	in	both	samples	on	
which	the	dilution	curve	was	performed	(Figure	17).	
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Table	8:	The	results	of	the	serum	samples	assayed	
The	samples	in	run	1	were	diluted	1:1	and	run	2	were	1:3.	The	2nd	run	was	therefore	able	to	capture	a	much	higher	level	of	HBD-2	within	the	sample.	However,	despite	the	
upper	 limit	of	detection	being	2000	pg/ml	 rather	 than	1000	pg/ml,	22%	of	 samples	were	above	 the	upper	 limit	of	detection.	The	median	of	 the	samples	on	run	2	was	
significantly	higher	than	run	1	(p<0.001).	
n	 Min	HβD-2	
(pg/ml)	
Max	HBD-2	
(pg/ml)	
Median	HBD-2	
(pg/ml)	
n	below	detection	
(%)	
n	above	detection		(%)	
Run	1	
(1:1	dilution)	
25	 137.5	 941.6	 800.8	 0	 4	(16%)	
Run2	
(1:3	dilution)	
36	 21.2	 1783.3	 1270	 0	 8	(22%)	
Comparison of run 1&2 serum samples
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Figure	16:	Comparison	of	serum	samples	assayed.		
Samples	diluted	1:3	had	significantly	higher	HBD-2	levels	after	correction	than	samples	diluted	1:1.	This	shows	that	distribution	of	the	molecule	is	not	linear	and	that	assays	
performed	at	different	dilutions	cannot	be	compared.		
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	Figure	 17:	 Dilution	 curves	 of	 2	 samples	 with	 concentrations	 before	 and	 after	 adjustment	 for	 the	
dilution.	
Increased	levels	of	HBD-2	are	detected	in	more	dilute	samples,	this	is	thought	to	be	due	to	an	effect	of	
altering	the	protein	content	within	the	sample	
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The	 results	 were	 reviewed	 along	 with	 the	 method	 used	 in	 the	 ELISA.	 The	 dilution	 was	
performed	 using	 assay	 buffer,	 which	 altered	 the	 protein	 content	 within	 the	 sample.	 The	
likeliest	explanation	for	this	effect	of	increasing	concentration	with	more	dilute	samples	was	
having	proportionally	 less	protein	within	the	sample	affecting	the	ELISA.	This	explains	why	
the	 samples	 as	 a	 group,	 were	 so	 much	 higher	 when	 diluted	 1:3	 rather	 than	 1:1.	 This	
experiment	was	clearly	very	useful	and	showed	that	differing	dilutions	cannot	be	compared.	
As	most	samples	were	assayed	using	a	1:1	dilution,	these	samples	were	used	in	the	analysis	
and	unfortunately,	on	the	basis	of	this	finding,	I	elected	to	exclude	all	other	results.	Samples	
performed	 using	 other	 dilutions	 were	 excluded	 from	 the	 analyses	 and	 re-run	 where	
available.		
5.8.2.5 Outcome	of	HBD2	methodology	experiments	
• Samples	with	1:1	dilution	only	were	used	in	the	analysis
• Both	fresh	and	previously	thawed	samples	were	included.
• For	samples	included	on	more	than	one	run	the	mean	was	used.
5.9 LL-37	ELISA	
5.9.1 LL-37	measurement
All	 144	 patients	 included	 in	 the	 vitamin	 D	 part	 of	 the	 study	 had	 LL-37	measured	 as	 BAL	
availability	 was	 part	 of	 the	 criteria	 for	 inclusion	 into	 that	 study.	 Some	 results	 were	
above/below	level	of	detection;	therefore	results	are	available	for	134/144	patients.	Of	the	
77	infants	in	the	NBS	cohort,	just	14	had	LL-37	results	measured	and	within	range.		
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LL-37	was	measured	in	BALF	using	ELISA	(Hyocult	biotech,	Uden,	The	Netherlands).	Samples
were	undiluted	and	the	ELISA	performed	as	per	manufacturer’s	instructions	(315).	The	assay	
allowed	measurement	over	the	range	0.1	to	100	ng/ml.	
5.9.2 Establishing	reproducibility	
LL-37	results	were	all	performed	on	the	same	run	so	no	inter-assay	analyses	were	required.
The	standard	curve	 (Figure	18)	obtained	 for	 the	ELISA	does	not	show	a	 linear	 relationship	
between	 concentration	 and	 optical	 density	 and	 therefore	 a	 logarithmic	 equation	 to	
extrapolate	unknowns	was	used.		
Due	 to	 cost	 and	 availability	 of	 materials,	 only	 2	 samples	 were	 run	 in	 duplicate.	 Good	
agreement	was	seen	in	these	samples	(Figure	19a).	As	only	2	samples	were	run	as	duplicate,	
Figure	18:	Standard	curves	of	LL-37	assay			
The	curve	shows	a	good	line	fit	between	measured	absorption	and	known	concentrations	
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in	order	to	further	assess	reproducibility	of	the	ELISA,	agreement	between	the	14	standards,	
run	in	duplicate,	was	considered	and	found	to	be	very	good		(Figure	19b)	with	CoV	of	0.89%	
(IQR	0.3	–	3.5%).	
The	assay	was	performed	on	159	different	samples,	and	the	results	ranged	from	less	than	
0.1	 -	 30.0	 ng/ml;	 2	 samples	 fell	 below	 the	 lower	 limit	 of	 detection	 and	 so	 the	minimum	
range	detected,	0.1	ng/ml,	was	used	for	the	analysis	of	these	samples.	
Figure	 19:	 Agreement	 between	 a)	 duplicate	 samples,	 b)	 standards	 and	 c)	 bland-altman	 bias	 plot	 of	
standards	
Good	agreement	is	seen	amonst	duplicate	samples/standards;	CoV	0.89%	(IQR	0.3	–	3.5%);	standards	bias	
0.01,	limits	of	agreement	-0.06	to	0.08.	
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5.10 		Microbiology	of	BALF	samples	
Microbiology	 results	 were	 obtained	 from	 the	 clinical	 laboratory	 which	 follows	 published	
standards	for	the	processing	of	CF	samples	(304).	Patients	were	divided	into	culture	positive	
and	 culture	negative	 groups;	molecular	 techniques	were	not	utilised.	 The	 culture	positive	
group	was	comprised	of	those	with	any	bacterial	or	fungal	growth	in	their	BALF	sample	and	
the	 negative	 group	 had	 sterile	 BALF.	 As	 the	 clinical	 laboratory	 changed	 its	 protocol	 from	
immunofluorescence	to	PCR	during	the	study	period,	data	on	viral	infections	have	not	been	
analysed.		
5.11 	Statistical	analyses	
The	sample	size	is	opportunistic,	as	there	were	no	data	to	inform	a	power	calculation.	Data	
are	 presented	 as	 median	 and	 95%	 confidence	 intervals	 of	 the	 median.	 Non-parametric	
analysis	was	 used:	Mann	Whitney	 for	 2	 groups,	 Kruskal-Wallis	with	Dunn’s	 correction	 for	
multiple	 groups,	 and	 logistic	 regression	 for	 binary	 outcomes.	 In	 view	 of	 the	 multiple	
comparisons	 undertaken,	 the	 null	 hypothesis	 was	 rejected	 at	 p<0.01.	 SPSS	 v21	 (IBM	
Corporation,	New	York)	and	Graphpad	prism	v6	(Graphpad	software,	San	Diego)	were	used.	
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6 Chapter	6:		The	role	of	Vitamin	D	in	infection	and	inflammation	
in	the	airways	of	infants	diagnosed	on	new	born	screening	
6.1 Introduction	
The	purpose	of	this	study	was	to	explore	the	infection	and	inflammation	present	in	a	large	
cohort	of	infants	diagnosed	on	newborn	screening	and	to	examine	the	relationship	between	
these	 findings	 and	 vitamin	 D	 levels,	 to	 try	 to	 determine	 if	 Vitamin	 D	 was	 an	
immunomodulator	in	this	age	group.	As	vitamin	D	is	thought	to	exhibit	immune	modulation	
via	the	innate	immune	pathway,	of	major	importance	in	early	life,	I	hypothesised	that	there	
may	be	a	greater	effect	of	immune	modulation	seen	in	young	infants	than	older	children.	
The	hypothesised	mechanism	of	action	was	a	direct	impact	of	vitamin	D	on	the	antimicrobial	
peptides	 LL-37	 and	 HBD-2	 with	 subsequent	 effect	 on	 infection	 and	 the	 inflammatory	
cascade.	
6.1.1 Early	lung	disease	outcome	measures	
Once	children	are	diagnosed	with	CF,	treatments	are	started	with	the	aim	of	improving	their	
prognosis	and	their	long-term	lung	health.	The	onset	of	lung	disease	is	seen	early	in	CF	(as	
described	 in	 section	 2.4.1)	 and	 if	 not	 treated	 aggressively	 leads	 to	more	 rapid	 decline	 in	
respiratory	function.	In	its	early	stages,	CF	lung	disease	may	be	silent	with	few	or	no	clinical	
symptoms	 meaning	 that	 history	 and	 examination	 are	 not	 sufficient	 for	 accurate	 early	
detection.	 Detection	 of	 early	 lung	 disease	 is	 important	 and	 other	 markers	 are	 therefore	
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needed	but	are	not	without	their	challenges.	The	ideal	scenario	would	be	to	assess	function,	
structure,	 microbiology	 and	 inflammation	 of	 the	 airways,	 but	 procedures	 to	 gain	 this	
information	 involve	more	 co-operation	 than	 is	 often	possible	 in	 such	 young	 children,	 and	
are	invasive	and	many	require	sedation	or	general	anaesthesia;	in	addition	there	is	the	fact	
that	young	children	are	vulnerable	 to	 the	side	effects	of	 radiation	so	 this	exposure	would	
ideally	be	limited.	Due	to	these	challenges,	collecting	data	can	be	difficult	and	confidence	is	
required,	 as	 much	 as	 is	 possible,	 that	 such	 tests	 will	 be	 beneficial	 and	 it	 is	 worthwhile	
subjecting	the	child	to	such	procedures.	Functional	and	structural	changes	are	discussed	in	
more	detail	in	chapter	7.		
6.1.2 Inflammatory	changes	
Detecting	airway	inflammation	usually	requires	direct	airway	sampling,	which	is	invasive	and	
expensive.	Studies	of	infants	with	CF	have	found	airway	inflammatory	changes	in	addition	to	
structural	changes,	and	this	was	associated	with	worse	 lung	function	 (56,	316).	A	study	of	
127	 infants	 with	 CF	 diagnosed	 on	 newborn	 screening	 found	 that	 elevated	 neutrophil	
elastase	at	12	months	of	age	was	associated	with	CT	evidence	of	bronchiectatic	change	at	
12	months	and	at	3	years	of	age	(157).		
A	study	to	evaluate	BALF	directed	therapy	versus	standard	treatment	was	carried	out	and	
no	differences	in	the	outcomes	of	P.	aeruginosa	infection	or	HRCT	chest	score	at	age	5	were	
seen	(317).	Increased	BALF	cell	and	neutrophil	counts	were	seen	in	those	who	had	evidence	
of	bronchiectasis	on	 their	CT	 scan	but	not	 in	 those	with	 just	 airway	wall	 thickening	or	air	
trapping	(316).		
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6.2 Hypotheses	
The	 earlier	 institution	 of	 improved	 and	more	 aggressive	 treatments	 strategies	 possible	 in	
infants	diagnosed	with	CF	by	NBS	leads	to	a	healthy	airway	during	the	first	year	of	life.	
Vitamin	D	has	immunomodulatory	effects	via	antimicrobial	peptide	pathways;	consequently	
vitamin	 D	 deficiency	 will	 lead	 to	 greater	 risk	 of	 bacterial	 infection	 and	 subsequent	
inflammation	and	worse	clinical	outcomes	in	CF	throughout	childhood.	
6.3 Methods	
In	order	to	assess	the	health	of	the	airways	of	infants	diagnosed	on	newborn	screening,	and	
therefore	 diagnosed	 early	 with	 early	 onset	 of	 treatment,	 the	 airways	 were	 examined	 as	
previously	 described	 (section	 5.2).	 Comparisons	 were	 made	 with	 2	 ‘control’	 groups;	 a	
disease	control	group	and	a	healthy	control	group.	The	disease	control	group	consisted	of	
children	 over	 the	 age	 of	 2	 years	with	 an	 established	 diagnosis	 of	 CF	who	had	 undergone	
clinically-indicated	 bronchoscopy	 and	 had	 cellular	 inflammatory	 data	 from	 the	 BALF	
available	 (group	1b).	 The	 age	of	 2	 years	was	 chosen	 so	 that	 there	was	 a	 clear	 distinction	
between	 this	 and	 the	 NBS	 group	 and	 no	 potential	 overlap,	 whilst	 still	 including	 young	
children.	The	healthy	controls	had	no	lower	respiratory	symptoms	and	normal	lower	airways	
on	microscopic	and	macroscopic	examination;	 this	group	 is	 the	same	as	the	control	group	
used	in	other	sections	of	this	thesis	and	are	not	specifically	recruited	to	act	as	a	comparison	
for	new	born	infants	(group	3).		
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Statistical	tests	unless	stated	otherwise	in	this	chapter	are	Mann-Whitney	for	comparison	of	
2	groups	and	Kruskal-Wallis	with	Dunn’s	 correction	 for	multiple	groups.	As	before,	due	 to	
multiple	comparisons	a	priori	p	value	was	set	at		<	0.01.		
6.4 Results	
6.4.1 Subjects	
77	infants	who	were	referred	to	the	RBH	following	positive	NBS	were	confirmed	as	having	
CF	during	this	study	period.	Four	of	these	infants	were	not	included	in	the	study;	1	patient	
moved	away	from	the	area	shortly	after	diagnosis,	1	patient	did	not	have	FOB	performed	by	
parental	choice	and	2	patients	were	excluded	for	significant	co-morbidity	(neurometabolic	
disorder	 and	 mitochondrial	 disorder)	 making	 them	 unrepresentative	 of	 the	 usual	 CF	
population.	Four	additional	patients	were	diagnosed	following	a	positive	NBS	elsewhere	and	
were	 referred	 to	 our	 centre	 within	 the	 first	 few	 weeks	 of	 life	 and	 these	 4	 patients	 are	
included	in	the	study.	There	were	therefore	a	total	of	77	patients	recruited	to	the	study	with	
73	 diagnosed	 at	 RBH	 and	 4	 diagnosed	 elsewhere.	 62/77	 of	 these	 patients	 had	 samples	
suitable	for	inflammatory	cell	analysis.	Data	was	obtained	from	75	paediatric	patients	with	
established	CF	and	6	healthy	controls,	all	of	whom	underwent	FOB.	Demographic	details	of	
all	3	study	groups,	plus	the	NBS	sub-group	with	inflammatory	data	available,	can	be	seen	in	
Table	9.	
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The	median	age	of	infants	undergoing	FOB	was	3.5	months,	with	a	range	of	2	to	9	months	
and	40/77	(52%)	were	male.	As	the	group	being	studied	was	infants	they	were	younger	by	
definition	than	the	disease	control	group.	Unfortunately,	samples	were	not	available	 from	
healthy	infants	so	the	healthy	controls	are	also	older.		
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														Table	9:	Patient	demographics	
NBS	infants	
- all
NBS	infants	–	
inflammatory	analysis	
group	
Established	CF	 Healthy	controls	
N	 77	 68	 75	 6	
Median	age	in	months	
(range)	
3.5	
(2-9)	
3.5	
(2–	7)	
112	
(28–	211)	
149	
(126	185)	
BMI	z-score	
median(95%	CI)	
-0.87
(-1.42	to	-0.57)	
-0.93
(-1.48	to	-0.57)	
-0.28
(-0.56	to	-0.19)	
1.11	
(0.30	to2.74)	
Weight	z-score	
median(95%	CI)	
-0.65
(-1.26	to	-0.20)	
-0.60
(-1.01	to	-0.06)	
-0.44
(-0.63	to	-0.17)	
1.11	
(0.25	to	2.84)	
Height	z-score	
median(95%	CI)	
-0.07
(-1.18	to	0.82)	
-0.05
(-0.99	to	0.89)	
-0.48
(-0.74	to	-0.18)	
0.23	
(-0.08	to	1.86)	
Male	 40	(52%)	 37	(54%)	 27	(36%)	 2	(33%)	
Phe508del*	 56/61	
(92%)	
44/50	
(90%)	
61/75	
(91%)	 Not	done	
• At	least	one	allele
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6.4.2 Nutritional	status	of	NBS	CF	infants	
86%	of	the	infants	were	pancreatic	insufficient	as	shown	by	a	measurement	of	faecal	human	
pancreatic	elastase	of	less	than	15	μg/g	and	were	receiving	pancreatic	enzyme	replacement	
therapy.	 Despite	 these	 infants	 being	 diagnosed	 on	 newborn	 screening	 and	 pancreatic	
supplements	started	 from	a	very	early	age,	nutritional	 state	was	poorer	 than	 that	seen	 in	
the	general	population	with	a	median	z-score	(95%	CI)	BMI	of	-0.87	(-1.42	to	-0.57).	Median	
(95%	CI)	height	was	-0.07	(-1.18	to	0.82)	and	weight	-0.65	(-1.26	to	-0.20)	z-scores.		
6.4.3 Clinical	symptoms	
Data	 regarding	 the	 presence	 or	 absence	 of	 clinical	 respiratory	 symptoms	 at	 the	 time	 of	
bronchoscopy	 are	 not	 available	 for	 all	 patients.	 Of	 the	 38	 infants	 in	 whom	 this	 data	
available,	13	(34%)	reported	clinical	respiratory	symptoms	at	the	time	of	the	bronchoscopy.	
More	patients	with	bacteria	 isolated	 in	 their	airways	had	symptoms	compared	with	 those	
with	 no	 infection	 identified	 although	 this	was	 not	 statistically	 significant	 (p	 =	 0.08),	most	
likely	due	 to	 the	small	numbers.	54%	 (7/13)	culture	positive	patients	 reported	 respiratory	
symptoms	and	24%	(6/25)	culture	negative	patients	reported	symptoms.		
6.4.4 Infection	
23	infants	(30%)	 isolated	26	bacterial	organisms	from	their	BALF	on	routine	culture.	There	
was	no	difference	in	age	between	those	who	had	positive	bacterial	cultures	and	those	who	
did	not.	When	comparing	this	to	the	non-CF	CSLD	control	group	and	those	with	established	
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CF	disease,	slightly	more	of	the	children	with	established	CF,	30/75	(40%)	isolated	bacteria	
on	their	BALF	but	this	was	not	statistically	significant	(Fishers	exact	test	p	=	0.2).	The	specific	
bacteria	that	were	isolated	at	bronchoscopy	can	be	seen	in	Figure	20.	
6.4.5 Inflammation	
The	median	BALF	absolute	cell	count	of	the	NBS	group	was	higher	than	the	healthy	control	
group	 in	 this	 study	 but	 not	 statistically	 significantly	 so	 on	 3-way	 comparison	 (p	 =	 0.18)	
(Figure	21a).	The	children	in	the	established	CF	cohort	had	a	higher	BALF	absolute	cell	count	
than	 either	 of	 the	 other	 groups	 (p	 <	 0.001).	 A	 similar	 picture	 was	 seen	 with	 the	 BALF	
neutrophil	 differential	 (Figure	 21b).	 Neutrophilic	 inflammation	was	 seen	 in	 both	 the	 NBS	
and	 the	 established	 CF	 group	 with	 significantly	more	 inflammation	 in	 the	 established	 CF	
group	 (p<0.0001).	 The	 median	 (95%	 CI)	 neutrophil	 differential	 for	 NBS	 infants	 and	
established	 CF	were	 9.3%	 (6	 -15%)	 and	 38.7%	 (34.6	 -	 49.7%)	 respectively.	 A	much	 lower	
neutrophil	differential	was	seen	in	the	healthy	control	group,	median	1.4%,	(95%	CI	0.3	to	
2.7	 %),	 which	 is	 of	 course	 inevitable	 from	 the	 pre-determined	 patient	 selection	 for	 this	
group.	The	established	CF	group	had	a	statistically	significantly	higher	neutrophil	differential	
than	the	other	2	groups.	Although	there	was	neutrophilic	 inflammation	 in	 the	NBS	cohort	
compared	with	the	healthy	group,	on	3-way	comparison	this	was	not	statistically	significant	
(p	=	0.07).	
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Figure	20:	Pie	chart	of	bacterial	organisms	isolated	on	BALF	in	NBS	CF	infants	
P. aerug	=	Pseudomonas	aeruginosa
S.aureus		=	Staphylococcus	aureus
MRSA	=	Methicillin	resistant	staphylococcus	aureus
S.Malt	=	Stenotrophomonas	maltophilia
S.Pneumo	=	Streptococcus	pneumoniae
M. catt	=	Moraxella	catarrhalis
H.Inf	=	Haemophilus	influenzae
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Figure	21:	BALF	cell	counts	of	the	3	patient	groups.	
a) The	children	in	the	established	CF	cohort	had	a	higher	BALF	absolute	cell	count	(median	(95%	CI)	977	(643	to
1620)	 x103),	 than	 either	 of	 the	 other	 groups	 (p	 <	 0.001).	 There	 was	 no	 statistical	 difference	 between	 the
median	 (95%	CI)	cell	 count	of	 the	 infants	 in	 the	NBS	group	 (355	 (205	 to	568)	x	103)	and	the	healthy	control
group	(143	(70	to	270)	x	103)	(p	=	0.18).
b) Figure	shows	the	neutrophil	differential	of	BALF	of	the	3	patient	groups.	The	median	(95%	CI)	of	neutrophil
differential	for	NBS	infants	and	established	CF	were	9.3%	(6	to	15%)	and	38.7%	(34.6	to	49.7%)	respectively.
There	was	a	much	lower	neutrophil	differential	in	the	healthy	control	group	with	a	median	of	1.4%,	(95%	CI	0.3
to	2.7	%).	Shaded	area	represents	generally	accepted	upper	limit	normal.
a	
b	
NBS CF Established CF Healthy
0
20
40
60
80
100
BA
LF
 n
eu
tro
ph
il d
iff
er
en
tia
l (
%
)
**** ****
130
6.4.6 Relationship	between	infection	and	inflammation	
Comparison	was	then	made	of	infants	with	positive	bacterial	culture	and	those	with	sterile	
BALF.	 Infants	with	 bacteria	 identified	 had	 a	 trend	 towards	 a	 higher	 neutrophil	 count	 (p=	
0.04)	 (Figure	 22)	 and	 more	 symptoms	 (p	 =	 0.08).	 There	 were	 insufficient	 numbers	 of	
children	 isolating	 MRSA,	 Staphylococcal	 aureus	 and	 P.	 aeruginosa	 to	 make	 useful	
comparisons	of	any	different	effects	of	these	micro-	organisms.		
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Figure	22:	Inflammation	according	to	microbiologic	status	
The	different	coloured	dots	represent	the	individuals	with	the	organisms	generally	considered	to	be	the	most	
significant.	The	child	with	MRSA	(red	dot)	had	one	of	the	greatest	levels	of	inflammation	seen	in	this	cohort,	
but	the	3	with	S.	aureus	(blue	dots)	are	divided,	with	2	having	relatively	normal	neutrophil	differential	counts	
whilst	 the	other	had	a	significant	neutrophilia.	One	of	the	patients	with	P.	aeruginosa	 isolated,	 (purple	dot),	
also	had	evidence	of	neutrophilic	inflammation.			
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Table	10:	Comparison	of	infants	with	culture	+ve	and	culture	–ve	BALF	
NBS - all NBS – bacteria +ve NBS – bacteria -ve p-value
N 77 23 54 
Age 
(months) 
3.5 (2-9) 3.4 (2-6) 3.6 (2-9) 0.15 
Height 
(cm) 
61.0 
(58.6 – 62.5) 
59.95 
(56.2 – 61.8) 
61.0 
(57.3 – 63.5) 
0.28 
Weight 
(kg) 
5.76 
(5.3 – 6.08) 
5.38 
(4.46 – 6.16) 
5.8 
(5.48 – 6.3) 
0.11 
Respiratory 
symptoms at 
FOB 
13/38 
(34%) 
7/13 
(54%) 
6/25 
(24%) 
0.08 
Previous 
P. aeruginosa
4/73 
(5%) 
1/23 
(4%) 
3/50 
(6%) 
1.00 
BALF total cell 
count (x 103) 
355 
(205 – 568) 
574 
(178 – 1047) 
343 
(193 – 510) 
0.16 
BALF 
neutrophil 
differential (%) 
9.3 
(6 – 15) 
15 
(6 – 43) 
8.4 
(3 – 13) 
0.04 
Priori	p	value	p	<	0.01	
6.4.7 Antimicrobial	peptides	
Antimicrobial	 peptide	 levels	 were	 only	 available	 for	 13	 (17%)	 of	 this	 cohort;	 5	 of	 these	
infants	 had	bacteria	 isolated	 in	 their	 BALF	 and	7	 did	 not.	 Even	with	 these	 small	 numbers	
there	was	a	trend	towards	more	LL-37	in	infected	BALF	(p	=	0.06)	but	no	difference	in	BALF	
HBD-2	 according	 to	 infection	 state	 (p=0.1).	 No	 correlation	 was	 seen	 between	 the	
antimicrobial	peptides	and	cellular	or	soluble	markers	of	inflammation.	
6.4.8 Vitamin	D	in	relation	to	infection	and	inflammation	within	the	airways	
6.4.8.1 Vitamin	D	levels	
48/77	of	the	NBS	cohort	had	vitamin	D	measured	at	the	time	of	the	bronchoscopy.	Median	
(95%	CI)	vitamin	D	was	77	(72:	84)	nmol/L	and	only	4	babies	were	deficient	(<	50	nmol/L).	
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6.4.8.2 Vitamin	D	and	Antimicrobial	peptides	
Contrary	 to	 my	 hypothesis,	 no	 relationship	 between	 vitamin	 D	 and	 the	 antimicrobial	
peptides	HBD-2	and	LL-37	was	seen	(Table	11).		
Table	11:	Correlation	of	vitamin	D	with	antimicrobial	peptides	
Inflammatory	marker	 Spearman	r	 p-value
BALF	LL-37	ng/ml	 0.03	 0.93	
BALF	HBD-2	(pg/ml)	 0.20	 0.51	
Linear	correlation	statistical	test	
6.4.8.3 Vitamin	D	and	Inflammatory	markers	
No	relationship	was	seen	between	vitamin	D	and	any	of	the	cellular	or	soluble	inflammatory	
markers.		
6.4.8.4 Vitamin	D	and	microbiology	
Vitamin	D	levels	were	similar	 in	 infants	who	isolated	bacteria	 in	their	BALF	and	those	who	
did	not	(p	=	0.85).	Median	(95%	CI)	vitamin	D	was	77	(54:	99)	nmol/l	 in	the	positive	group	
and	78	(72:	85)	nmol/L	in	the	negative	group	(Figure	23).		
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Figure	23:	Vitamin	D	by	BALF	culture	status	
There	was	 no	 difference	 in	 vitamin	 level	 according	 to	 bacterial	 culture	 on	 BALF	 samples	 in	 infants	with	 CF	
diagnosed	on	newborn	screening.		
6.5 Discussion	
6.5.1 Statement	and	interpretation	of	principal	findings	
I	 hypothesised	 that	 earlier,	 improved	 and	 more	 aggressive	 treatments	 made	 possible	
through	NBS	programmes	would	lead	to	better	airway	health	in	the	first	year	of	life	and	also	
that	vitamin	D	has	 immunomodulatory	effects	with	vitamin	D	deficiency	 leading	 to	worse	
airway	health	with	more	infection	and	inflammation	via	the	antimicrobial	peptide	pathway.		
Contrary	 to	 this	 hypothesis,	 no	 relationship	 was	 seen	 between	 vitamin	 D	 and	 cellular	 or	
soluble	 inflammation	 in	 this	 cohort	 of	 NBS	 diagnosed	 infants	 with	 CF.	 Additionally,	 no	
relationship	was	identified	with	vitamin	D	and	the	antimicrobial	peptides	LL-37	and	HBD-2,	
which	were	hypothesised	to	be	the	mechanism	of	action.		
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LL-37	and	HBD-2	have	antimicrobial	activity,	and	given	their	lack	of	relationship	with	vitamin
D	it	was	not	surprising	that	following	on	from	this,	there	was	no	difference	in	vitamin	D	level	
of	 those	 with	 infection	 in	 their	 BALF	 and	 those	 without.	 This	 suggests	 that	 not	 only	 is	
vitamin	D	not	impacting	on	infection	via	antimicrobial	pathway,	but	that	no	other	Vitamin-D	
dependant	pathway	is	involved	instead.		However,	an	alternate	explanation	may	be	that	the	
study	was	underpowered	to	show	this.		
A	 large	 proportion	 of	 the	 NBS	 infants	 in	 this	 study	 had	 evidence	 of	 infection	 and	
inflammation	within	their	airways	despite	being	diagnosed	on	routine	screening	and	having	
treatment	implemented	within	the	first	few	weeks	of	life.	Almost	1/3	had	bacterial	growth	
on	 their	 BALF	 and	 some	 infants	 had	 neutrophilic	 inflammation	with	 levels	 of	 up	 to	 75%.		
Unsurprisingly,	more	inflammation	was	seen	in	those	with	bacterial	growth	but	this	was	not	
statistically	significant	which	may	be	due	to	the	small	number	or	perhaps	due	to	sampling	
errors	 for	 infection.	 Some	 infants	 without	 any	 bacterial	 infection	 detected	 also	 had	
increased	neutrophilic	inflammation.		
Data	 were	 not	 available	 for	 all	 infants	 for	 all	 parameters.	 The	 low	 numbers	 of	 available	
antimicrobial	peptides,	vitamin	D	and	cytokines	mean	that	limited	conclusions	can	be	made	
and	 may	 contribute	 to	 an	 underpowering	 effect	 and	 if	 all	 data	 had	 been	 available	 it	 is	
possible	that	outcomes	would	be	different.		
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6.5.2 Strengths	of	the	study	
A	large	number	of	infants	were	included	in	the	study,	which	is	a	major	strength.	In	addition,	
the	 study	 is	 able	 to	 compare	 clinical	 data	 with	 invasive	 markers	 of	 inflammation.	 By	
collecting	information	from	bronchoscopy	and	BALF,	the	inflammatory	status	of	the	airway	
could	 be	 assessed	 and	 correlated	 with	 other	 invasive	 sampling	 results	 such	 as	 bacterial	
growth,	but	also	viewed	in	relation	to	clinical	symptoms	experienced	by	the	infants.		
6.5.3 Limitations	of	the	study	
Due	 to	 the	 fact	 I	 used	 clinically	 collected	 data	 rather	 than	 proforma	 driven	 data,	 on	
occasions,	 the	 outcome	 of	 interest	 was	 missing.	 This	 was	 the	 case	 regarding	 data	 on	
whether	the	infants	were	symptomatic	or	asymptomatic	at	the	time	of	their	bronchoscopy.	
It	 is	 important	 in	 such	 situations	 to	 be	 aware	 of	 potential	 reporting	 bias.	 I	 suspect	 the	
percentages	reported	here	are	significant	overestimates	of	the	true	figures	due	to	reporting	
bias	as	the	presence	of	symptoms	is	far	more	likely	to	be	documented	than	the	absence	of	
symptoms.	However	information	can	still	be	gained	from	the	data	that	are	available.	At	least	
2/3	of	 the	 infants	were	asymptomatic	at	 the	time	of	 the	procedure.	 	Almost	half	of	 those	
with	bacteria	isolated	in	their	airways	had	no	respiratory	symptoms	at	all	at	the	time	of	the	
bronchoscopy	which	supports	earlier	findings	that	infection	is	seen	at	an	early	age	even	in	
asymptomatic	infants.		
It	 is	 impossible	ethically	to	obtain	samples	from	truly	healthy	 infants.	The	control	group	 is	
significantly	older	 than	 this	group	of	NBS	CF	 infants	 reflecting	 this.	Unfortunately	 samples	
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were	not	available	on	age	matched	healthy	individuals.	This	is	an	issue	in	all	studies	of	this	
nature.	
Neutrophil	elastase	was	not	measured	in	the	present	study	and	with	retrospect	would	have	
made	a	good	addition	to	the	current	findings.		
6.5.4 Findings	in	relation	to	other	studies	
BALF	neutrophil	differential	count	was	higher	 in	 infants	with	CF	than	the	healthy	controls;	
although	a	criterion	for	entry	into	the	control	group	was	neutrophil	differential	less	than	4%	
it	can	still	be	seen	that	even	at	this	early	age	the	airways	of	infants	with	CF	are	abnormally	
inflamed	 compared	 with	 healthy	 individuals.	 When	 evaluating	 airway	 inflammation	 in	
infants,	 it	 is	difficult	to	say	what	is	normal	due	to	limited	data	on	absolute	cell	counts	and	
neutrophil	 differentials	 in	 healthy	 infants.	 Tessier	 et	 al	 (318)	 obtained	 samples	 from	 16	
healthy	children,	of	whom	8	were	aged	under	12	months.	Of	 these	8	 infants,	 the	median	
total	cell	count	was	350	x	103,	(range	180-680	x	103)	and	mean	neutrophil	differential	1.5%,	
(range	0-3%).	Another	group	(319)	found	the	median	cell	count	and	neutrophil	differential	
to	be	much	higher	 in	their	population.	Of	the	9	 infants	within	their	study,	the	median	cell	
count	was	400	x	103(range	200-1300	x	103)	and	the	neutrophil	differential	7%	(range	2-17%).	
The	median	total	cell	count	of	the	CF	NBS	population	 in	my	study	was	higher	than	that	of	
normal	healthy	infants	regardless	of	which	of	these	two	‘normal’	value	cut-offs	are	chosen	
for	comparison.	Even	taking	the	higher	suggested	value	discussed	above,	19/49	(39%)	of	the	
CF	 NBS	 infants	 had	 evidence	 of	 neutrophilic	 inflammation	 with	 values	 above	 the	 95th	
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confidence	 interval	 (11.6%).	 In	 addition,	 there	 is	 a	 strong	 skew	 towards	 greater	 level	 of	
inflammation	 in	 this	 cohort,	 with	 some	 significantly	 raised	 values.	 There	 were	 no	 other	
striking	features	about	these	infants	compared	to	the	others;	they	were	no	older,	they	were	
a	mixture	of	genotypes,	pancreatic	status	and	sex	in	similar	proportion	to	the	entire	groups	
and	one	of	these	infants	had	no	bacteria	isolated	on	BALF.		
Similarly	 to	 previous	 studies,	 there	 was	 an	 increase	 in	 inflammatory	 markers	 within	 this	
population	(103)	and	a	trend	towards	an	increase	in	those	with	bacterial	infection	compared	
to	 those	with	sterile	BALF	 (320).	Brennan	et	al,	as	part	of	 the	Australian	Respiratory	Early	
Surveillance	Team	for	CF	(AREST	CF)	study	evaluated	airway	inflammation	of	24	children	and	
found	a	neutrophil	differential	of	52%	 in	 those	with	 infected	BALF	compared	with	17%	 in	
those	without	 infection.	The	 total	cell	 count	was	also	 increased;	1290	x	103	vs.	340	x	103.	
The	neutrophilic	 inflammation	 seen	 in	 this	 population	was	 greater	 than	 the	 cohort	 in	my	
study,	 which	 likely	 reflects	 the	 older	 age	 of	 these	 patients,	 a	 median	 of	 19	 months	
compared	 with	 3.4	 months	 in	 my	 study	 population.	 Another	 study	 by	 the	 same	 group	
explored	airway	inflammation	shortly	after	diagnosis	(321).	Infants	were	diagnosed	on	NBS	
at	a	median	age	of	28	days	and	had	FOB	and	BAL	carried	out	at	a	median	age	of	3.6	months.	
In	agreement	with	 the	present	 study,	 the	authors	 found	evidence	of	airway	 inflammation	
with	a	BAL	total	cell	count	of	242	x	103,	(355	x	103	in	my	study);	and	neutrophil	differential	
of	 18.7%	 (IQR	 9.4	 to	 35.7%)	 (9.3%	 (IQR	 3.2	 to	 20%)	 in	 my	 study).	 Similarly,	 increased	
neutrophil	differential	count	changes	were	seen	in	the	presence	of	bacterial	infection.		
To	my	knowledge	this	is	the	largest	cohort	of	infants	with	CF	diagnosed	on	NBS	to	have	BALF	
examined	 for	 infection	and	 inflammatory	 changes.	Almost	one	 third	of	 infants	 isolated	at	
least	one	bacterial	organism	and	there	is	evidence	of	airway	inflammation	by	3.5	months	of	
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age.	Levels	of	vitamin	D	did	not	have	any	association	with	the	presence	of	infection	or	any	
of	the	measured	markers	of	inflammation.	The	results	suggest	that	abnormal	lung	function	
at	3	months	as	found	in	other	studies,	may	be	due	to	the	presence	of	airway	inflammation	
suggesting	early	 treatment	 indicated,	even	 in	 the	absence	of	 symptoms.	The	cause	of	 the	
inflammation	 needs	 to	 be	 determined	 in	 order	 for	 this	 to	 be	 treated.	 Patients	 with	
inflammation	and	no	detected	 infection	were	not	 targeted	 for	 treatment	other	 than	 their	
routine	antibiotic	prophylaxis	 (twice	daily	oral	 flucloxacillin	 from	diagnosis)	 and	perhaps	 if	
they	had	been	treated	with	more	infection	cover	less	inflammation	may	have	been	seen.		
6.6 Conclusions	
Disappointingly	 neutrophilic	 airway	 inflammation	 and	 bacterial	 infection	 were	 present	 in	
the	airways	of	infants	diagnosed	on	NBS	despite	early	treatment.	This	may	be	because	the	
airway	 is	 abnormal	 at	 birth	 as	 suggested	 by	 the	 CF	 pig,	 or	may	 be	 due	 to	 early	 bacterial	
exposure.		
The	evidence	here	does	not	support	a	role	of	vitamin	D	in	infection	and	airway	inflammation	
of	 this	 cohort	 of	 young	 infants.	 This	 is	 a	 young	 group	of	 patients,	 possessing	 less	 chronic	
inflammation	 and	 likely	 proteolytic	 activity	 within	 the	 airway	 than	 those	 with	 more	
established	CF	lung	disease	and	therefore	the	chance	that	a	significant	relationship	is	being	
masked	by	degradation	is	likely	reduced.		
139
I	 aimed	 to	 evaluate	 the	 difference	 between	 patients	 who	 were	 vitamin	 D	 sufficient	 and	
those	 with	 vitamin	 D	 deficiency,	 but	 only	 4	 patients	 in	 this	 group	 had	 deficient	 levels.	 I	
therefore	decided	to	explore	this	further	in	older	patients	to	assess	the	relevance	of	vitamin	
D	 over	 a	 wider	 range	 of	 vitamin	 D	 values	 and	 to	 ascertain	 its	 role	 in	 more	 established	
disease	(chapter	8).		
I	also	wanted	to	explore	the	impact	that	vitamin	D	level	may	have	longitudinally,	so	before	
going	on	to	explore	an	expanded	CF	cohort,	addressed	the	question	of	whether	vitamin	D	at	
3	 months	 was	 associated	 with	 longitudinal	 outcome	 measures,	 or	 whether	 it	 could	 be	
viewed	as	a	biomarker	of	disease	severity	predicted	future	outcomes	(chapter	7).	
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7 Chapter	 7:	 Longitudinal	 study	 of	 newborn	 screened	 infants;	
infection,	 inflammation,	 structural	 and	 functional	 change	 and	
serum	vitamin	D	levels	
7.1 Introduction	
As	 has	 already	 been	 discussed	 and	 demonstrated	 in	my	 data	 in	 Chapter	 6,	 infection	 and	
inflammation	are	seen	early	on	in	children	with	CF	and	these	are	associated	with	long-term	
adverse	structural	and	functional	changes.		
This	 chapter	 explores	 the	 impact	 on	 inflammation	 during	 that	 first	 year	 of	 life,	 and	 the	
structural	and	functional	changes	associated	with	this.	It	also	looks	at	the	impact	of	vitamin	
D	to	ascertain	if	there	is	a	clinical	relevance	of	this;	although	the	results	have	shown	that	it	is	
not	of	relevance	to	outcomes	in	the	cross-sectional	study,	this	study	explores	its	predictive	
value.	 If	 vitamin	 D	was	 found	 to	 be	 a	 better	 biomarker	 for	 adverse	 outcomes	 this	 could	
define	 a	 group	 in	 whom	 intensification	 of	 conventional	 therapy,	 or	 early	 introduction	 of	
novel	molecular	therapies,	could	be	justified.	
7.1.1 Early	functional	changes	
The	LCFC	comprises	6	paediatric	CF	centres	within	London;	Royal	Brompton	Hospital,	Great	
Ormond	Street	Hospital	(GOSH),	The	Royal	London	Hospital,	Kings	College	Hospital,	St	Helier	
Hospital	 and	 Lewisham	 University	 Hospital.	 Infants	 from	 each	 of	 these	 6	 centres	 were	
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recruited	to	a	longitudinal	study	to	evaluate	their	lung	health.	Importantly,	this	longitudinal	
study	also	recruited	contemporaneous	healthy	controls.		
The	Collaboration	began	prior	to	newborn	screening	being	implemented	in	the	region	and	
the	 initial	 studies	were	 conducted	on	 children	diagnosed	 clinically.	 They	 reported	 that,	 at	
diagnosis,	 infants	 with	 CF	 (even	 with	 no	 respiratory	 symptoms)	 had	 airflow	 obstruction	
measured	 by	 the	 raised	 lung	 volume	 rapid	 thoracoabdominal	 compression	 technique	
(RVRTC)	compared	with	healthy	controls	(296,	297)	and	that	this	abnormality	persisted	on	
follow-up	testing	at	both	6	months	post-diagnosis	(138)	and	3-5	years	of	age	(139)	despite	
appropriate	treatments.		
Following	 the	 introduction	 of	 NBS	 a	 new	 cohort	 of	 infants	 was	 recruited.	 Despite	 early	
identification	 of	 these	 infants	 and	 early	 initiation	 of	 treatment,	 lung	 function	 was	 also	
abnormal	 when	 tested	 at	 a	 median	 of	 3	 months	 of	 age.	 By	 this	 age,	 hyperinflation,	
diminished	airway	function	(FEV0.5)	and	increased	ventilation	inhomogeneity	(lung	clearance	
index	(LCI))	was	already	present	 in	over	1/3	of	 infants	and	values	were	significantly	worse	
than	healthy	age-matched	controls	(55).	Surprisingly,	by	the	age	of	12	months,	these	infants	
had	stable	or	improved	lung	function	(322).	Improvements	have	been	maintained	out	to	2	
years	 (322,	 323).	 Previous	 work	 at	 my	 centre	 found	 that	 abnormal	 airway	 obstruction	
occurred	within	the	first	year	and	was	independent	of	infection,	inflammation	or	symptoms	
in	clinically	diagnosed	children	(145).	The	AREST	CF	study	is	a	longitudinal	study	evaluating	
inflammatory,	functional	and	structural	change	in	the	airways	of	CF	children	diagnosed	on	
newborn	screening	and	this	study	did	not	find	evidence	of	airflow	limitation	in	their	infants	
with	 CF,	 although	 a	 decline	 was	 seen	 in	 the	 first	 2	 years	 of	 life	 (56).	 Pre-school	 results	
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however,	 do	 suggest	 that	 this	 significant	 deterioration	 in	 lung	 function	 is	 in	 fact	 not	 real	
(324) so	this	deterioration	in	lung	function	in	the	early	years	should	be	viewed	with	caution.
Multiple-breath	washout	(MBW)	tests	have	been	carried	out	in	young	children	with	CF	and	
the	outcome	measure,	LCI,	 found	to	be	a	sensitive	marker	of	early	 lung	disease.	The	LCFC	
evaluated	the	LCI	of	48	children	with	CF,	diagnosed	clinically,	and	45	healthy	controls.	LCI	
was	 abnormal	 in	 almost	 three-quarters	 (73%)	 of	 pre-school	 children	 and	 of	 these	 the	
majority	had	persisting	abnormality	with	elevated	LCI	also	being	present	at	school	age.	The	
results	suggest	that	LCI	may	be	a	good	marker	to	detect	early	lung	disease	(325).	MBW	has	
been	 shown	 to	 be	 a	 more	 sensitive	 measure	 of	 early	 lung	 disease	 than	 spirometry	 or	
plethysmography	 (326)	 and	 superior	 to	 measurement	 of	 cough	 frequency	 and	 nocturnal	
oxygen	saturations	which	 found	no	difference	between	CF	pre-school	 children	 (n=20)	and	
healthy	 age	 matched	 controls	 (n=30)	 (327).	 In	 older	 children	 LCI	 is	 more	 sensitive	 than	
spirometry	 but	 in	 infants	 this	 is	 less	 clear	 and	 there	 appear	 to	 be	 some	 differences	 in	
physiology	of	tests	in	this	age	group;	LCI	and	RVRTC	are	complimentary,	with	each	detecting	
abnormalities	not	detected	by	the	other	(328).	
Where	airway	 function	 is	 decreased,	whether	 this	 is	 due	 to	 inflammation,	 infection	or	 an	
innate	abnormality	remains	unclear.	The	CF	pig	suggest	that	airway	cartilages	are	abnormal	
at	birth,	but	 the	 improvement	seen	 in	 the	LCFC	NBS	 infants	over	 the	 first	year	 suggests	a	
shorter	term	abnormality	that	can	be	improved	with	treatment,	rather	than	an	abnormality	
pre-dating	birth	and	exposure	to	a	non-sterile	world.		
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7.1.2 Early	Structural	changes	
Structural	changes	 found	on	thoracic	HRCT	scans,	 in	 the	 form	dilated	airways,	airway	wall	
thickening,	air	trapping	and	large	and	small	mucous	plugs	have	been	demonstrated	to	occur	
very	early	in	life	(329-331),	including	in	asymptomatic	infants.	This	finding	has	been	said	to	
suggest	 that	 structural	 changes	 as	 seen	 on	 HRCT	 scan	 may	 be	 an	 early	 marker	 of	 lung	
disease.	In	the	AREST-CF	study,	structural	changes	were	seen	in	80%	of	infants	at	the	age	of	
3	months	 following	 diagnosis	 on	 newborn	 screening	 (321).	 This	 study	 concluded	 that	 the	
structural	changes	occur	early,	within	the	first	few	years	of	life,	and	are	related	to	increased	
infection	 and	 increased	 inflammation	 (316).	 Longitudinal	 CT	 scans	 showed	 progression	 of	
lung	disease	in	most	cases,	although	apparent	resolution	of	abnormalities	was	seen	in	26%	
(140) to	40%	(157)	questioning	the	accuracy	of	the	interpretation	of	the	initial	scan	result.
An	alternative	explanation	for	this	is	a	potential	over-interpretation	of	small	changes	on	the	
initial	 scans.	 It	 may	 be	 that	 what	 is	 thought	 to	 be	 irreversible	 lung	 damage	 is	 in	 fact	
reversible	pathology.	Bronchiectasis	is	defined	as	the	bronchial	diameter	being	greater	than	
its	corresponding	artery	but	airway	dilatation	maybe	due	to	mucus	plugging	and	airway	wall	
thickening	due	to	transient	airway	oedema,	both	reversible	with	treatment	rather	than	the	
irreversible	pathological	process	of	bronchiectasis.		
As	part	of	 the	 LCFC	 study,	 thoracic	HRCT	 scans	were	performed	at	12	months	of	age	and	
changes	 were	 very	 mild.	 In	 addition,	 despite	 rigorous	 prior	 training,	 interobserver	
agreement	of	 changes	was	poor	 (mean	 (95%CI)	k	 coefficient	0.34	 (0.20	 to	0.49))	meaning	
that	the	technique	is	of	questionable	value	in	determining	longitudinal	changes	in	the	lung	
health	 of	 infants	 (332).	 In	 the	 AREST	 CF	 study,	 just	 one	 person	 interpreted	 all	 studies	 so	
there	was	no	 interobserver	agreement	assessment.	 Intraobserver	 repeatability	was	 fair	 to	
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good	 for	 diagnosis	 of	 bronchiectasis	 and	 air	 trapping	 (k	 coefficient	 0.64	 and	 0.55	
respectively)	and	poor	for	airway	wall	thickening	(k	coefficient	0.24)(316).		
Whilst	this	evidence	from	the	AREST	CF	study	appears	to	suggest	that	such	structural	 lung	
change	 is	 a	 good	 marker	 of	 early	 disease,	 the	 apparent	 resolution	 of	 bronchiectasis,	
methodological	concerns	regarding	inter-and	intra-	observer	repeatability	and	lack	of	similar	
data	 being	 seen	 in	 all	 populations	 casts	 some	 doubt	 over	 the	 reliability	 of	 thoracic	 HRCT	
scans	as	a	source	of	early	lung	detection	and	longitudinal	data	collection.			
7.2 Hypotheses	
In	 this	 section	of	my	work,	 I	 tested	my	hypothesis	 that	 the	earlier	 institution	of	 improved	
and	more	 aggressive	 treatments	 strategies	 possible	 in	 infants	 diagnosed	 with	 CF	 by	 NBS	
leads	to	a	healthy	airway	during	the	first	year	of	life.	
I	 also	 explored	 vitamin	 D	 as	 an	 immunomodulatory	 agent	 in	 this	 cohort	 testing	 my	
hypothesis	that	vitamin	D	deficiency	will	lead	to	worse	clinical	outcomes	in	CF.	
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7.3 Methods	
7.3.1 Patient	selection	
19	of	the	infants	included	in	my	NBS	CF	cohort	were	invited	to	be	part	of	the	LCFC	study	for	
which	they	underwent		
- A	further	bronchoscopy	at	12	months	of	age
- Lung	function	at	3	and	at	12	months	of	age
- HRCT	thorax	at	12	months	of	age.
19	of	the	77	infants	included	in	my	NBS	cohort	had	data	available	at	12	months	of	age	and	
therefore	 longitudinal	 evaluation	 could	 be	made	 of	 these	 infants	 based	 on	 bronchoscopy	
findings	at	3	months.		
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7.3.2 Longitudinal	evaluation	
Using	available	data	from	the	3	month	bronchoscopy,	I	explored	the	health	of	the	airways	at	
12	months	to	see	if	3	month	data	can	be	used	to	inform	of	the	health	of	the	airways	at	12	
month,	and	evaluated	longitudinal	change	over	the	time	period	where	data	allowed.		
NBS	infant	
cohort	
n	=	77	
No	12-month	
data	available	
	n	=	58	
12-month
data	available	
n	=	19	
Included	
longitudinal	study	
n	=	19	
Excluded	
n	=	58	
Lung	function	
n	=	17		
Bronchoscopy	
	n	=	17	
HRCT	thorax	
n	=	17	
Figure	24:	Consort	diagram	to	show	patients	included	in	NBS	longitudinal	study	
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To	see	if	vitamin	D	levels	could	be	a	biomarker	and	predictive,	even	if	causative,	of	airway	
function	 later	on,	 vitamin	D	 levels	 from	3	months	of	 age	were	 compared	 to	physiological	
airway	results	from	12	months.		
7.3.3 12	month	bronchoscopy	
FOBs	were	carried	out	at	12	months	of	age	as	part	of	the	LCFC	study.	All	children	recruited	
to	 this	 study	 had	 the	 procedure	 carried	 out	 at	 one	 of	 3	 of	 the	 CF	 centres	 and	 all	 infants	
included	in	my	study	had	this	performed	at	Royal	Brompton	Hospital.	Informed	consent	was	
obtained	and	the	procedure	carried	out	as	described	in	section	5.2.	
7.3.4 HRCT	thorax	
All	 thoracic	 HRCT	 scans	 were	 done	 under	 GA	 at	 12	 months	 of	 age,	 under	 the	 same	
anaesthetic	 as	 the	 bronchoscopy.	 CT	 scan	 was	 performed	 using	 a	 standardised	 protocol	
devised	 by	 the	 LCFC	 team	 with	 details	 of	 not	 just	 radiation	 and	 scanning	 but	 inflation	
pressures	 (332)	 to	 ensure	 meticulous	 scan	 methodology	 for	 standardisation;	 a	 team	
member	 was	 present	 at	 all	 scans	 to	 ensure	 good	 protocol	 adherence	 at	 all	 centres.	 All	
infants	 included	 in	my	study	had	this	performed	at	Royal	Brompton	Hospital.	CT	scan	was	
performed	immediately	prior	to	the	FOB.		
Images	 were	 sent	 to	 GOSH	 for	 review	 and	 were	 assessed	 by	 2	 independent	 radiologists	
using	the	Brody	scoring	system	(141,	333).	Despite	one	of	the	assessors	being	Dr	Brody,	and	
the	second	assessor	being	trained	in	the	scoring	system	by	Dr	Brody,	poor	agreement	was	
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seen	(332).	Each	CT	thorax	was	marked	on	set	criteria	and	the	scores	for	each	assessor	were	
kindly	made	available	to	me	for	the	19	patients	included	in	my	study.		
7.3.5 Lung	function	
Infants	attended	GOSH	at	3	months	and	12	months	for	 lung	function	testing	to	be	carried	
out;	airway	function	at	raised	volume	was	measured	using	RVRTC	technique	and	MBW	test	
was	 performed	with	 inhalation	 of	 sulpha-hexafluoride	 during	 tidal	 breathing.	 Testing	was	
performed	at	both	time	points	during	quiet	sleep	using	oral	or	rectal	sedation	and	has	been	
described	in	detail	elsewhere	(322).	
Functional	 resistance	 capacity	 (FRC),	 FVC	 and	 FEV0.5	 measurements	 were	 obtained	 from	
RVRTC	and	LCI	measurements	were	obtained	from	MBW	testing.		
7.3.6 Statistics	
As	 stated	 previously,	 non-parametric	 analysis	 was	 used:	 Mann	 Whitney	 for	 2	 groups,	
Kruskal-Wallis	with	Dunn’s	correction	for	multiple	groups,	Fisher’s	exact	test	for	categorical	
outcomes	 and	 Wilcoxon	 paired	 test	 for	 paired	 samples.	 	 	 In	 view	 of	 the	 multiple	
comparisons	 undertaken,	 the	 null	 hypothesis	 was	 rejected	 at	 p<0.01.	 SPSS	 v21	 (IBM	
Corporation,	New	York)	and	Graphpad	prism	v6	(Graphpad	software,	San	Diego)	were	used	
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7.4 Results	
7.4.1 Subjects	
19	 (25%)	 of	 the	 77	 NBS	 infant	 cohort	 also	 had	 a	 routine	 bronchoscopy	 performed	 at	 12	
months	of	age	as	part	of	the	LCFC	study.	This	subgroup	did	not	differ	from	the	main	cohort	
in	terms	of	age,	weight	at	3	months	or	sex.		
BALF	absolute	cell	count	from	the	time	of	the	12	month	bronchoscopy	was	available	in	just	
5/17	and	cytokine	data	in	just	6/17	so	these	parameters	were	not	explored.		
Vitamin	D	was	available	from	blood	taken	at	the	3-month	FOB	in	12/17	infants	and	this	was	
compared	to	 later	 results	 to	establish	 if	vitamin	D	 levels	has	a	 role	 to	play	 in	determining	
future	lung	health.	Median	(95%	CI	of	the	median)	vitamin	D	level	was	79.5	(66	-	87)	nmol/L,	
similar	to	that	of	the	entire	NBS	cohort	(77	(72	-	84)	nmol/L).		
7.4.2 Lung	function	
Mean	(95%	CI)	FEV0.5	z-score	was	-0.76	(-1.38	-		-0.13)	at	3	months	which	improved	slightly	
throughout	the	first	year	of	life	to	-0.48	(-1.16	-		0.2)	at	12	months	of	age,	although	this	did	
not	reach	statistical	significance	(p=0.08,	Wilcoxon	matched	paired	test).		
150
7.4.3 Infection	at	3	months	does	not	predict	infection	and	inflammation	at	12	months		
The	 infants	 who	 underwent	 FOB	 at	 3	months	 were	 divided	 into	 those	 with	 and	 without	
positive	 bacterial	 isolates	 in	 their	 BALF	 and	 comparison	 of	 the	 airway	 infection	 and	
inflammation	at	12	months	of	these	2	groups	made.	5/17	(29%)	infants	had	culture	positive	
BALF	 and	 12/17	 (71%)	were	 culture	 negative	 from	 the	 bronchoscopy	 at	 3	months.	 Those	
with	culture	negative	BALF	at	3	months	had	median	neutrophil	differential	of	9.3%	(95%	CI	
1.7	to	24%)	at	12	months	which	was	similar	to	those	with	culture	positive	BALF	who	had	a	
median	neutrophil	differential	of	8%	(95%	CI	3.7	-	10.7%)	(p	=	0.72)(Figure	25).		
There	 was	 no	 relationship	 seen	 between	 identification	 of	 bacteria	 at	 3	 months	 and	
identification	of	bacteria	at	12	months.	4/12	(33%)	of	those	with	culture	negative	BALF	at	3	
months	and	2/5	(40%)	culture	positive	infants	went	on	to	have	positive	culture	at	12	months	
of	age	(Fisher’s	exact	test	p	=	0.1)	(Figure	26).		
Figure	25:	BALF	neutrophil	differential	at	12months	according	to	culture	status	on	3	month	bronchoscopy	
There	is	no	difference	seen	in	the	BALF	neutrophil	differential	of	the	BALF	at	12	months	of	age	between	those	
were	culture	negative	at	3	months	and	those	who	were	culture	positive.	Median	neutrophil	differential	was	
9.3%	(95%	CI	1.7	-	24%)	vs.	8%	(95%	CI	3.7	-	10.7%)	respectively				(p	=	0.72),	Mann-Whitney	U	test).	
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Figure	26:	Infection	at	12months	according	to	infection	status	on	3	month	bronchoscopy	
There	was	no	relationship	between	culture	status	at	3	months	and	culture	status	at	12	months	in	this	cohort	of	
NBS	CF	infants	(Fisher’s	exact	test	p	=	0.1)	
7.4.4 Inflammation	at	3	months	is	persistent	at	12	months	
Of	 the	 19	 patients	 included	 in	 this	 part	 of	 the	 study	 10	 patients	 had	 data	 available	 on	
inflammation	within	their	airways	at	3	months	of	age.	5/10	(50%)	of	infants	had	no	evidence	
of	 inflammation	 (BALF	 neutrophil	 differential	 ≤4%)	 and	 5/10	 (50%)	 had	 neutrophilic	
inflammation	(BALF	neutrophil	differential	>4%).	 I	compared	these	2	groups	to	establish	 if	
differences	 could	 be	 seen	 in	 the	 data	 from	 the	 12-month	 bronchoscopies.	 4/5	 infants	
without	inflammation	had	corresponding	data	available	at	12	months	and	3/5	infants	with	
inflammation.	Of	 those	 infants	without	 inflammation	 at	 3	months,	 75%	 (3/4)	 also	had	no	
evidence	 of	 inflammation	 at	 12	 months	 and	 of	 those	 with	 inflammation,	 all	 (3/3)	 had	
evidence	of	 inflammation	at	 12	months	 (Figure	27).	 There	was	no	 statistical	 difference	 in	
these	groups	(Fishers	exact	test	p	=	0.14)	but	the	numbers	are	very	small.	
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Figure	27:	Inflammation	at	12months	according	to	inflammation	status	on	3	month	bronchoscopy	
25%	of	infants	without	inflammation	(neutrophil	differential	>4%)	at	3	months	had	inflammation	at	12	months	
compared	with	100%	of	those	with	evidence	of	airway	inflammation	at	3	months.	There	was	no	statistical	
difference	between	these	2	groups,	which	may	be	a	type	2	error	due	to	the	small	sample	size.	Hatched	area	
indicates	normal	neutrophil	differential	
7.4.5 Neutrophilic	 airway	 inflammation	 at	 3	months	 is	 not	 associated	 with	 functional	
change	at	3	or	12	months	
No	 correlation	 was	 seen	 between	 BALF	 neutrophil	 differential	 on	 the	 3-month	
bronchoscopy	and	any	lung	function	parameter	at	3	or	12	months.		
7.4.6 Infection	at	3	months	correlates	with	functional	change	at	3	and	12	months		
Infants	 with	 infection	 at	 3	 months	 had	 a	 worse	 outcome	 in	 terms	 of	 lung	 function	 at	 3	
months	and	these	changes	persisted	at	12	months.		
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At	3	months	of	age,	at	a	similar	time	to	the	infection	being	identified,	infants	with	infection	
had	a	statistically	significant	worse	FRC	z	score(p	=	0.018)	and	FVC	z	score	(p	=	0.029).	No	
difference	was	seen	in	FEV0.5	z	score	(	Figure	28).		
It	might	be	expected	that	infants	with	evidence	of	bacterial	infection	would	have	worse	air	
trapping	 (demonstrated	by	higher	 FVC)	 than	 those	without	 infection	but	 this	was	not	 the	
case	 in	 this	study.	A	possible	explanation	 is	 that	 infants	with	bacteria	had	mucus	plugging	
causing	them	to	lose	volume	hence	having	lower	FVC	and	FRC	than	their	non-infected	peers.	
Alternatively,	early	 infection	may	slow	lung	growth	hence	 lower	 lung	volumes;	conversely,	
small	 lungs	may	predispose	to	more	infection?	In	order	to	try	to	address	this	I	 looked	at	a	
sub-group	of	those	without	infection	at	3	months	(n	=	12)	and	compared	the	lung	function	
at	this	time	according	to	their	microbiological	state	at	12	months.	
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Figure	28:	Lung	function	at	3	months	of	age	
Infants	with	bacteria	isolated	form	their	BALF	had	worse	FRC	and	FVC	than	infants	without	infection	identified	(Mann-Whitney	U	test).	
Priori	p-value	<0.01.	
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If	it	is	the	case	that	some	infants	have	small	lungs	and	that	this	group	are	predestined	to	get	
more	 infection,	 then	a	difference	 in	 lung	volume	would	already	be	expected	at	3	months.	
Four	 of	 these	 infants	 had	 bacteria	 identified	 in	 their	 BALF	 at	 12	months;	 there	 were	 no	
differences	in	lung	volume	or	lung	function	between	these	4	infants	and	the	8	infants	with	
no	evidence	of	infection,	which	does	not	support	this.	Decreased	volume	due	to	plugging	is	
therefore	more	likely.		
At	 12	months,	 there	 was	 a	 greater	 difference	 in	 lung	 function	 seen	 between	 those	 with	
infection	at	3	months	and	those	without,	with	worse	lung	function	in	those	with	infection,	
see	Figure	29.		
FVC	z-score	(p	<=	0.006),	FRC	z-score	(p	<	0.008)	and	LCI	score	and	z-score	(p	<	0.03	and	p	<	
0.02)	were	statistically	significantly	worse	in	those	with	infection;	there	was	a	trend	towards	
worse	FRC	z-score	(0	=	0.06).	By	1	year	of	age	there	was	no	difference	in	the	FEV0.5.	
The	longitudinal	change	in	lung	function	in	each	infant	did	not	differ	according	to	infection	
isolation	at	3	months	(Table	12).		
Table	12:	Longitudinal	change	in	lung	function	by	infection	state	on	BALF.	
Values	are	median	(95%	CI	of	median)	change	in	lung	function	between	3	and	12	months.	Lung	function	was	
worse	at	3	months	in	those	with	infection	but	this	was	not	predictive	of	change	at	12	months	(Mann-Whitney	
U	test).		
Micro	+ve	 Micro	-ve	 P	value	
FRC	(mbw)	
z-score
-0.96
(-1.18;	-0.09)	
-0.77
(-1.15;	-0.09)	
ns	
FEV0.5	
z-score
0.73	
(-0.6;	1.23)	
0.42	
(-0.6;	0.91)	
ns	
FVC	
z-score
0.26	
(-1.54;	0.83)	
0.09	
(-0.5;	0.69)	
ns	
LCI	 0.21	
(-1.6;	1.36)	
-0.79
(-1.29;	0.21)	
ns	
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Figure	29:	Difference	in	lung	function	at	12months	of	age	between	infants	culture	positive	and	culture	negative	at	3	months		
Worse	functional	outcomes	at	12	months	of	age,	as	measured	by	FVC,	FRC	(as	measured	by	plethysmography)	and	LCI,	were	seen	in	infants	with	bacteria	isolated	in	their	
BAL	at	3	months	of	age.	(Mann-whitney	U	test;	priori	p-value	p<0.01)
Bacteria +ve Bacteria -ve
-4
-2
0
2
4
3 month BALF culture
FV
C
 z
-s
co
re
p < 0.007
12 months
Bacteria +ve Bacteria -ve
-4
-3
-2
-1
0
1
3 month BALF culture
FR
C
 z
-s
co
re
p < 0.008
12 months
Bacteria +ve Bacteria -ve
-2
0
2
4
6
3 month BALF culture
LC
I  
z-
sc
or
e
12 months
p < 0.02
Bacteria +ve Bacteria -ve
0
5
10
15
3 month BALF culture
LC
I
12 months
p < 0.03
157
7.4.7 CT	scores	
CT	 scores	 of	 infants	 with	 bacterial	 infection	 in	 their	 BALF	 were	 compared	 with	 children	
without	infection	and	no	difference	was	seen.	Due	to	the	discrepancies	in	observer	scores,	
each	score	was	analysed	separately	rather	than	meaning	the	results.		
7.4.8 Vitamin	D	
Comparison	 of	 3-month	 vitamin	D	with	 3	 and	 12-month	 lung	 function	 results	 showed	no	
relationship.	
I	 also	 assessed	 the	 change	 over	 time	 of	 airways	 function	 and	 in	 height	 and	 weight	
parameters	 over	 the	 first	 year	 of	 life	 as	 a	 function	 of	 vitamin	 D	 at	 3	months	 of	 age.	 No	
relationship	 was	 seen	 with	 vitamin	 D	 and	 the	 change	 in	 any	 of	 these	 clinical	 markers	
between	3	and	12	months	of	age	(Figure	30).		
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Figure	30:	Vitamin	D	and	change	in	lung	function.	No	relationship	was	found	with	vitamin	D	measured	in	serum	at	3	months	and	functional	airway	change	or	growth	over	
the	first	year	of	life.	(Spearman	correlation;	priori	p-value	<	0.01).
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7.5 Discussion	
7.5.1 Statement	and	interpretation	of	principal	findings	
I	hypothesised	that	vitamin	D	deficiency	would	lead	to	worse	clinical	outcomes	in	CF.	
Vitamin	D	 levels	did	not	appear	 relevant	 to	 the	evolution	of	 functional	 change	over	 time;	
small	 numbers	 may	 account	 for	 this,	 but	 given	 previous	 findings	 with	 vitamin	 D	 and	 an	
absence	in	association	with	clinical	findings	the	results	support	a	lack	of	relevance	of	vitamin	
D	in	early	years.	However	the	study	does	lack	deficient	infants,	so	it	is	not	possible	to	say	if	
really	low	levels	might	have	been	relevant.	
From	 the	 small	 numbers	 available,	 inflammation	 persists	 once	 it	 has	 occurred:	 all	 (n	 =	 3)	
infants	with	inflammation	seen	at	3	months	also	had	evidence	of	inflammation	at	12	months	
whilst	those	with	no	inflammation	at	3	months	(n	=	4)	generally	had	no	inflammation	at	12	
months;	these	figures	are	in	keeping	with	findings	by	another	group	(321).		
Infection	at	the	3-month	bronchoscopy	did	not	predict	inflammation	seen	at	a	year,	which	
may	be	due	 to	 the	 fact	 that	culture	 techniques	only	were	used	and	work	using	molecular	
diagnostic	testing	to	identify	bacteria	might	have	given	a	different	conclusion.		
Another	possibility	 is	 that	because	the	 infection	was	detected,	treatment	was	given	which	
may	 have	 altered	 the	 disease	 course,	 whereas	 treatment	 decisions	 were	 not	 made	 on	
inflammatory	counts	so	 inflammation	outside	of	detected	infection	was	not	treated.	 If	the	
infection	was	missed	at	bronchoscopy	then	this	could	be	a	reason	why	neutrophilia	carries	a	
bad	prognosis.		
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Infection	 in	 infancy	 was	 associated	 with	 worse	 outcome	 in	 lung	 function	 at	 3	 and	 12	
months.	 Bacterial	 infection	 at	 3	 months	 of	 age	 was	 associated	 with	 worse	 functional	
outcome	measures	both	at	the	time	of	infection	and	12	months	later	suggesting	that	early	
infection	may	set	the	course	of	CF	lung	disease.	Interestingly,	these	changes	were	not	seen	
with	 inflammation.	 It	 is	 possible	 that	 the	 infection	 was	 driving	 alternate	 inflammatory	
pathways	 not	 evaluated	 in	 this	 part	 of	 the	 study	 but	 this	 seems	 unlikely	 given	 the	 wide	
range	and	the	choice	of	inflammatory	markers	evaluated.	It	is	more	likely	that	the	study	was	
underpowered	to	see	these	changes.		
In	older	children	LCI	is	more	sensitive	than	spirometry	but	in	infants	the	differences	are	not	
clear;	some	infants	with	normal	LCI	can	have	abnormal	spirometry	 (RVRTC)	and	vice	versa	
showing	 that	 the	 tests	 in	 infants	 differ	 to	 older	 children	 and	 appear	 to	 be	 picking	 up	
different	disease.	Further	work	is	needed	to	explore	this.		
When	looking	at	individual	longitudinal	change	no	pattern	could	be	seen	which	is	likely	to	be	
due	to	the	small	numbers	but	by	evaluating	functional	changes	grouped	by	microbiological	
state	some	patterns	can	be	discerned.		
7.5.2 Strengths	of	the	study	
The	main	strength	of	this	study	is	the	ability	to	follow	up	both	inflammatory	and	functional	
data	of	the	airways	over	the	first	year	of	life.	These	data	are	able	to	give	an	indication	of	the	
progression	of	early	lung	disease.	Another	strength	is	being	able	to	evaluate	vitamin	D	levels	
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at	an	early	age	and	relate	them	to	progressive	change	in	function	over	that	first	year,	of	life,	
and	to	structure	age	one	year.		
A	huge	strength	of	the	LCFC	study	is	the	ability	to	compare	these	results	to	those	of	healthy	
contemporaneous	controls	recruited	as	part	of	the	same	study.	
7.5.3 Limitations	of	the	study	
Only	 18	 infants	 were	 able	 to	 be	 included	 in	 this	 study	 due	 to	 the	 data	 being	 needed	 at	
different	time	points	and	this	was	not	available	for	most	of	the	NBS	infants.	Optimally,	more	
infants	would	have	been	included	and	further	work	could	expand	this	cohort,	and	it	would	
be	important	to	do	this	specifically	to	address	the	question	of	the	relationship	of	future	lung	
function	with	early	infection.	Due	to	funding	constraints,	the	LCFC	stopped	recruiting	to	the	
study	and	so	this	limited	the	numbers	available.	
All	of	the	infants	in	the	longitudinal	study	were	vitamin	D	sufficient	according	to	previously	
defined	 classifications.	 Therefore	 although	 no	 relationship	 was	 seen	 with	 vitamin	 D	 and	
longitudinal	 change	 in	 lung	 function,	 it	 was	 not	 possible	 to	 examine	 the	 effect	 on	 lung	
function	over	a	wide	range	of	vitamin	D	levels.	Vitamin	D	levels	of	the	infants	included	in	the	
longitudinal	cohort	were	similar	to	those	in	the	entire	NBS	cohort	and	reflect	the	fact	that	
levels	in	younger	children	are	higher	than	older	children.	As	these	infants	did	have	adequate	
vitamin	 D	 levels	 it	 does	 suggest	 that	 improving	 vitamin	 D	 levels	 will	 not	 help.	 	 I	 have	
however	been	unable	to	evaluate	immunomodulatory	effects	at	very	high	levels	and	so	am	
unable	to	comment	if	supra-high	levels	would	be	of	benefit.		
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Our	 understanding	 of	 “normal”	 level	 of	 neutrophils	 within	 the	 airway	 of	 infants	 is	
incomplete	 and	 levels	 are	 thought	 to	 be	 increased	 compared	 with	 adults.	 A	 grey	 area	
between	 4-10%	 exists	 and	 it	 is	 therefore	 difficult	 to	 say	 exactly	 what	 constitutes	
inflammation	which	makes	accurate	interpretation	of	these	data	difficult.	It	was	reassuring	
to	see	that	all	those	with	neutrophilia	of	less	than	4%	were	still	less	than	4%	at	12	months	of	
age.	Interestingly	both	those	in	the	borderline	range	of	4-10%	at	3	months	rose	to	over	10%	
by	 12	 months	 of	 age.	 This	 suggests	 that	 those	 in	 the	 borderline	 range	 do	 have	 more	
abnormal	 inflammatory	 processes	 occurring	 and	 therefore	 could	 be	 classed	 at	 having	
inflammation	giving	confidence	 in	using	this	definition	of	 inflammation	for	analyses	 in	this	
study.	However,	the	small	numbers	mandate	confirmatory	studies.			
7.5.4 Findings	of	the	study	in	relation	to	other	studies	
Similarly	to	another	study	by	Ranganathan	et	al,	CF	 infant	airway	function	was	diminished	
from	 a	 very	 early	 age	 (138)	 compared	 to	 reference	 values	 of	 non-CF	 infants,	 but	 unlike	
Ranganathan	 et	 al’s	 study	 where	 a	 reduction	 in	 FEV0.5	 of	 20%	 over	 6	 months	 was	 seen,	
airway	 function	 improved	 in	 the	LCFC	patients	 recruited	 into	my	study.	The	 findings	were	
similar	 to	 that	 of	 the	 whole	 LCFC	 cohort	 (332)	 showing	 that	 this	 sub-cohort	 were	
representative	of	the	entire	cohort.		
In	my	study	the	time	difference	in	between	the	2	measurements	was	9	months	rather	than	
6	months,	and	my	cohort	were	diagnosed	on	NBS	rather	than	clinically.	These	factors	may	
account	for	this	difference	and	support	screening	in	that	lung	function	improved	rather	than	
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decreased	over	the	first	year.	My	results	were	similar	to	that	of	the	entire	LCFC	cohort	(322),	
which	also	found	a	reduction	in	lung	function	parameters	with	an	improvement	in	FEV0.5	by	
12	months	of	age.		
I	 found	 a	 relationship	 between	 lung	 function	 and	 infection	 as	was	 seen	 by	 Belessis	 et	 al	
(334);	but	unlike	their	study,	I	did	not	find	an	association	with	inflammatory	markers	which	
may	be	due	to	the	low	numbers	available	in	this	part	of	the	study.		
There	 is	 little	 in	 the	 literature	about	changes	 in	 inflammation	over	 the	 first	year	of	 life	 so	
comparison	 to	 other	 studies	 cannot	 be	 made.	 Likewise	 with	 vitamin	 D,	 data	 regarding	
vitamin	D	and	its	relationship	to	infection	and	inflammation	in	the	first	year	is	not	available.		
Whilst	 it	 is	 supposed	 that	 inflammation	 leads	 to	 functional	 and	 to	 structural	 change	 it	 is	
possible	that	these	are	unrelated	as	suggested	by	the	authors	in	one	study	(167),	and	there	
may	be	reasons	other	than	inflammation	that	cause	lung	function	to	deteriorate.		
7.6 Conclusions	
Although	only	small	numbers	were	available	for	the	longitudinal	study,	this	data	is	useful	in	
obtaining	 information	 regarding	 airway	 inflammation	 over	 a	 longer	 time	 period	 and	with	
which	 I	 demonstrated	 that	 inflammation	 persists	 and	 early	 infection	 is	 related	 to	 later	
functional	deficit	of	the	airways.	These	findings	are	very	important	highlighting	the	need	for	
early	 interventions.	 The	 findings,	 similar	 to	 the	 previous	 chapters,	 suggest	 that	 vitamin	D	
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does	not	a	role	to	play	in	immunomodulation	in	this	group	and	nor	does	it	have	a	role	as	a	
biomarker	of	airway	health.		
.	
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8 Chapter	 8:	 The	 role	 of	 vitamin	 D	 in	 airway	 infection	 and	
inflammation 
8.1 Introduction	
In	order	to	fully	explore	the	relevance	of	vitamin	D	in	the	innate	immunity	in	CF	the	cohort	
was	expanded	to	include	children	with	a	variety	of	ages,	of	disease	severities	and	a	greater	
spread	of	vitamin	D	levels.	
8.2 Hypotheses	
In	 this	 section,	 I	address	my	hypothesis	 that	vitamin	D	has	 immunomodulatory	effects	via	
antimicrobial	peptide	pathways;	consequently	vitamin	D	deficiency	will	 lead	to	greater	risk	
of	 bacterial	 infection	 and	 subsequent	 inflammation	 and	 worse	 clinical	 outcomes	 in	 CF	
throughout	childhood,	in	a	larger	more	diverse	group	of	children	with	CF.			
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8.3 Methods	
8.3.1 Subjects	
Patients	 included	 in	 the	 study	met	 the	criteria	 for	one	of	 the	3	 following	groups.	Patients	
included	in	each	of	these	groups	are	discussed	in	chapter	4.			
• CF	patients	(groups	1a	and	1	b)
o n=	113	(a	=	31	;	b	=	82)
• Non-CF	CSLD	patients	(group	2a)
o n	=	23
• Following	initial	results,	the	non-CF	CSLD	group	was	expanded	by	including	patients
without	 BALF	 data,	 but	 with	 vitamin	 D	 and	 lung	 function	 results	 available
(subsequently	termed	group	2b;	n	=	26).
• Healthy	controls		(group	3)
o n	=	6
There	were	no	differences	in	demographic	information	between	the	233	patients	eligible	for	
inclusion,	and	the	143	finally	included	(section	5.5.1,Table	13).		
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CF	 Non-CF	CSLD	 Healthy	controls	
Entire	
eligible	
group	
Included	
pts	only	
Entire	
eligible	
group	
Included	
pts	only	
Entire	
eligible	
group	
Included	
pts	only	
N	 176	 113	 45	 23	 12	 6	
%	of	group	included	 64	 51	 50	
Age	years		
Median	(range)	
6.97	
(0.21	 –	
17.6)	
7.8	
(0.1-17.6)	
9.52	
(2.78	 –	
16.26)	
7.8	
(2.8-15.5)	
12.21	
(0.53	 –	
16.4)	
12.4	
	(10.5-15.4)	
Sex	
n	(%)	male	
81	(46)	 47	(42)	 24	(53)	 12	(52)	 5	(42)	 2			(33)	
FEV1	%	predicted
Median	(range)	
66.5	
(28	–	108)	
66	
(30	–	101)	
74.5	
(31	–	95)	
69	
(25	–	95)	
93	
(80	–	131)	
106	
(80	–	131)	
Table	 13:	 Patient	 demographics	 to	 compare	 the	 included	 patients	 with	 entire	 potentially	 included	
population	
8.3.2 Clinical	data	collection	
For	 the	 CF	 cohort,	 in	 addition	 to	 looking	 at	 clinical	 results	 from	 the	 time	 of	 the	
bronchoscopy,	data	from	annual	assessments	(AA)	were	also	evaluated.	Values	were	taken	
from	the	AA	closest	to	the	time	of	the	bronchoscopy	(“AA	FOB”),	the	AA	the	previous	year	
(“AA	pre”)	and	the	following	year	(“AA	post”).	The	data	recorded	were:	spirometric	values	
(FEV1	and	 FVC),	 the	 presence	 or	 absence	 of	 CF	 related	 diabetes,	 the	 number	 of	 days	 on	
intravenous	 antibiotics	 (IVAB)	 and	 body	 mass	 index	 (BMI)	 centile;	 values	 were	 collected	
from	 documentation	 on	 Port	 CF.	 These	 data	 were	 reviewed	 independently	 to	 assess	
respiratory	 health	 prior	 to,	 at	 the	 time	 of,	 and	 after	 vitamin	 D	 measurement;	 and	 were	
reviewed	 combined	 to	 assess	 respiratory	 health	 over	 a	 3	 year	 period	 to	 fully	 explore	 the	
relevance	of	vitamin	D	to	airway	health.	
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The	clinical	data	recorded	for	each	of	these	time	points	were	recorded	as	follows:	
• The	 annual	 assessment	 (AA)	 closest	 to	 the	 time	 of	 the	 bronchoscopy	 (“AA
FOB”)
• The	AA	12	months	prior	to	the	“FOB	AA”	bronchoscopy	(“AA	pre”)
• The	AA	12	months	following	the	“FOB	AA”	bronchoscopy	(“AA	post”).
Microbiological	data	were	collected	 for	a	period	of	3	years,	12	months	before	the	date	of	
the	FOB,	2	years	after	the	date	of	the	FOB.	These	time	periods	are	defined	as	follows:		
• The	12	months	prior	to	the	date	of	the	bronchoscopy	(“pre”)
• The	12	months	commencing	on	the	day	of	the	bronchoscopy	(“year	of	FOB”)
• The	12	months	following	this	(“post”)
For	data	assessing	 inflammation	 in	CF	patients	under	12	months	of	age	who	therefore	did	
not	have	12	months	data	prior	to	the	bronchoscopy,	‘pre”	data	were	collected	from	date	of	
diagnosis	until	the	time	of	the	bronchoscopy.		
8.3.3 Statistical	analysis	
Statistical	 analysis	 was	 carried	 out	 as	 discussed	 in	 generic	 methods	 chapter	 4.	 Non-
parametric	 analysis	 was	 used:	 Mann	 Whitney	 for	 2	 groups,	 Kruskal-Wallis	 with	 Dunn’s	
correction	for	multiple	groups,	and	 logistic	regression	for	binary	outcomes.	Multiple	 linear	
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regressions	were	performed	 to	determine	significant	 relationships	of	any	 to	 the	BALF	and	
serum	components	measured.	The	factors	tested	in	all	cases	were	age,	gender,	total	vitamin	
D	 level,	 genotype	 (phe508del/phe508del	 versus	 the	 rest)	 and	 winter	 (October	 to	 March	
inclusive)	 versus	 summer	 (April	 to	 September	 inclusive).	 Forward	 conditional	 logistic	
regression	with	S.	aureus	or	P.	aeruginosa	bacterial	 isolation	or	not	as	the	binary	outcome	
was	performed	using	age	and	total	vitamin	D	level	as	factors.	Correlations	were	performed	
and	reported	using	Spearman’s	ranking	correlation	coefficient.		
Bacterial	isolation	was	first	defined	as	isolation	on	BALF,	and	performed	again	with	bacterial	
isolation	being	defined	as	any	positive	culture	of	 these	organisms	within	 the	3-year	 study	
period.	In	view	of	the	multiple	comparisons	undertaken,	the	null	hypothesis	was	rejected	at	
p<0.01.	 Unless	 otherwise	 stated,	 results	 are	 presented	 as	 medians	 with	 95%	 confidence	
intervals	of	the	median.		
8.4 Results	
8.4.1 Subjects	
142	patients	 (113	CF,	 23	non-CF	CSLD	and	6	healthy	 controls)	were	 included	 in	 the	 study		
(Table	14).	
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Table	14:	Patient	demographics	
Patient	demographics	of	 the	3	groups	 included	 in	 the	study.	There	were	no	differences	between	the	groups	
except	that	 the	proportion	of	children	under	the	age	of	1	year	was	higher	 in	 the	CF	group	(p<0.01).	Despite	
clear	numerical	differences	in	FEV1	between	the	CF	group	and	the	healthy	controls	this	did	not	reach	statistical	
significance,	presumably	due	to	the	small	numbers	in	the	control	group.		
* ≥	1	F508del	gene
†					3	patients	missing	data
‡				1	patient	data	missing
8.4.2 Vitamin	D	levels	
Serum	vitamin	D	levels	differed	across	the	three	disease	groups	(p	=	0.0024).	Despite	91%	of	
CF	subjects	being	prescribed	fat-soluble	vitamin	supplements,	41/113	(36%)	were	vitamin	D	
deficient	 (<	 50	 nmol/L).	However,	median	 (95%CI)	 values	 in	 the	CF	 group	were	 similar	 to	
those	of	the	healthy	controls;	57	(52–	66)	and	57	(24	–	74)	nmol/L	respectively,	(Figure	31	
and	Table	15).		
In	 contrast,	 the	 patients	 with	 non-CF	 bronchiectasis,	 in	 whom	 vitamin	 D	 is	 not	 routinely	
measured	or	 supplemented	 (and	unlike	CF,	 do	not	 have	malabsorption)	 had	 lower	 serum	
levels	(42	(26	-	51)	nmol/L	p<0.01	vs.	CF);	70%	of	them	were	deficient	(chi	squared	p	value	
0.003	vs.	CF).	There	was	no	relationship	with	current	microbiological	state	(Figure	31).	
CF	 Non-CF	CSLD	 Healthy	 p	value	
N	 113	 23	 6	 -	
Age	years	
Median	(range)	
7.8	
(0.1-17.6)	
7.8	
(2.8-15.5)	
12.4	
	(10.5-15.4)	
0.014	
Sex	
n	(%)	male	
47	(42)	 12	(52)	 2			(33)	 0.57	
F508del	*	 102	
(93%)			†	
n/a	 n/a	 -	
Pancreatic	
insufficiency	
99	
(88%)	
n/a	 n/a	 	-	
Vitamin	
supplements	
102	
(91%)	‡	
Not	available	 Not	available	 	-	
FEV1	%	
predicted
Median	(range)	
66	
(30	–	101)	
69	
(25	–	95)	
106	
(80	–	131)	
0.14	
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Figure	31:	Vitamin	D	levels	of	the	3	patient	groups	
The	median	(95%	CI)	serum	25(OH)D2	levels	were	57	(52	–	66),	42	(26	–	51)	and	57	(24	–	74)	nmol/L	in	the	CF,	non-CF	CSLD	and	the	healthy	control	groups	respectively.	The	
non-CF	CSLD	group	had	a	significantly	lower	vitamin	D	level	than	the	CF	group	(Kruskal–Wallis	p<0.01).	There	was	no	relationship	with	current	microbiological	state.		
Priori	p-value	<	0.01.	
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Table	15:	inflammatory	markers	and	antimicrobial	peptide	levels	of	the	3	groups	
Vitamin	D	levels,	cellular	inflammatory	markers	and	antimicrobial	peptide	levels	for	the	3	patient	groups.	Results	shown	are	median	(95%	CI	of	the	median).	Patients	with	
non-CF	CSLD	had	 lower	 levels	of	vitamin	D	than	the	CF	patients	and	the	healthy	controls.	The	CF	group	had	higher	BALF	absolute	cell	counts	than	either	of	the	other	2	
groups;	and	the	CF	and	non-CF	CSLD	groups	had	higher	neutrophil	differentials	 than	the	healthy	controls.	There	was	no	difference	 in	serum	neutrophils	between	the	3	
different	groups.	
* CF	>	healthy	on	Dunn’s	multiple	comparison	test
$	 	CF	>	non-CF	CSLD	and	healthy	
¥ CF	and	non-CF	CSLD	>	healthy
Δ	 	CF	>	healthy	
CF	 Non-CF	CSLD	 Healthy	 p-value
Serum	25(OH)D2	
nmol/L	
57	
(52-66)	
42	
(26	–	51)	
57	
(24	–	74)	
P<0.01	
*	
BALF	absolute	cell	count	
(x	103)	
620	
(500	-	850)	
364	
(115	-	540)	
143	
(70	–	270)	
P<0.001	
	$	
BALF	neutrophil	differential	(%)	 31	
(19.0	–	41.7)	
14.5	
(2.0	–	46.3)	
1.4	
(0.3		-	2.7)	
P	=	0.001	
¥	
BALF	neutrophil	count	
	(	x	103)	
166	
(45.6	–	306.9)	
16.5	
(4.2	–	346.5)	
2.8	
(0.2	–	5.1)	
P	=	0.0001	
Δ	
Serum	neutrophils	
(	x	109/L)	
4.3	
(3.7	-		4.9)	
4.6	
(3.6	–	5.7)	
3.9	
(2.6	–	4.6)	
ns	
BALF	LL-37	
(ng/ml)	
0.5	
(0.3	–	0.75)	
0.4	
(0.3	–	0.8)	
0.3	
(0.3	–	0.6)	
ns	
BALF	HBD-2	
(pg/ml)	
149	
(115.8	–	202.6)	
51		
(<15.6	–	170.5)	
120	
(	<15.6	-	250)	
ns	
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8.4.3 	Age	
The	proportion	of	children	under	the	age	of	1	year	was	higher	 in	the	CF	group	than	the	2	
other	groups	(p<0.01).	One	reason	for	this	is	that	infants	with	CF	routinely	undergo	FOB,	but	
this	 is	 not	 the	 case	 in	 non-CF	 CSLD	 and	 the	 6	 healthy	 controls	 were	 also	 older.	 For	 the	
patients	with	CF,	vitamin	D	correlated	 inversely	with	age	 (r	=	 -0.35,	p	=	0.001)	 (Figure	32)	
and	therefore	multiple	regression	has	been	done	where	relevant.		
No	 relationship	 was	 seen	 between	 vitamin	 D	 and	 age	 in	 patients	 with	 non-CF	 CSLD	 (r	 =	
0.008,	p	=	0.96).	
There	was	no	association	between	FEV1	or	FVC	with	age	in	either	patient	group.	As	it	would	
be	expected	that	lung	function	would	decrease	with	age	in	CF	children,	it	may	be	that	bias	
exists	 in	that	patients	requiring	bronchoscopy	at	a	younger	age	have	more	severe	disease,	
or	that	some	younger	children	may	have	had	poor	technique.		
For	 CF	 patients,	 as	 expected,	 age	 was	 also	 positively	 correlated	 with	 absolute	 BALF	 cell	
count	(r	=	0.3,	p	=	0.002),	neutrophil	differential	(r	=	0.3,	p	=	0.002)	and	blood	neutrophils	(r	
=	0.4,	p	=	0.001).	The	antimicrobial	peptide	LL-37	was	also	strongly	correlated	with	age	(r	=	
0.38,	p	<	0.0001).	This	relationship	was	not	seen	with	HBD-2.	These	relationships	were	not	
found	in	the	group	with	non-CF	CSLD.		
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	Figure	32:	Vitamin	D	level	by	age		
For	CF	patients,	as	age	increases	vitamin	D	level	decreases.	This	was	not	seen	for	non-CF	CSLD	patients.	Priori	
p-value	<	0.01.
In	order	to	account	for	the	children	with	routine	bronchoscopies	which	were	done	at	3	and	
at	 12months	 of	 age	 for	 some	 infants,	 post-hoc	 analyses	 were	 performed	 excluding	 all	
children	 under	 2	 years	 of	 age	with	 no	 alteration	 to	 outcomes.	 Two	 years	was	 chosen	 as	
some	bronchoscopies	were	performed	late	and	to	ensure	all	 routine	bronchoscopies	were	
excluded.		
8.4.4 Season	
For	the	purposes	of	ascertaining	if	a	seasonal	variation	occurred,	the	year	was	divided	into	2	
six-month	 seasons;	 “summer”	 months	 are	 defined	 as	 April	 to	 September	 and	 “winter”	
months	as	October	to	March.	74	procedures	were	carried	out	in	the	winter	months	and	62	
in	the	summer	months.	
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The	effect	of	season	on	vitamin	D	level,	spirometry,	nutrition,	infection,	cellular	and	soluble	
inflammatory	 markets	 and	 antimicrobial	 peptides	 were	 examined	 and	 there	 were	 no	
significant	differences	 in	any	parameters	 (Mann-Whitney	U	 test).	No	significant	difference	
was	observed	between	vitamin	D	level	measured	in	winter	months	(median	(CI)	=	55	(44	:	
63) nmol/L)	and	in	summer	months	(63	(53	:	71	)nmol/L)(p	=	0.09)	.
8.4.5 Pancreatic	status	
99/113	 (88%)	 of	 the	 CF	 patients	were	 pancreatic	 insufficient.	 Interestingly,	 there	was	 no	
difference	 in	 nutritional	 status	 between	 pancreatic	 sufficient	 and	 insufficient	 patients.	
Median	 vitamin	 D	 levels	 were	 similar	 for	 both	 groups	 (Figure	 33)	 and	 no	 difference	was	
observed	in	cell	counts	or	FEV1	between	the	2	groups.	
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Figure	33:	Vitamin	D	levels	in	pancreatic	sufficient	and	insufficient	children	
Vitamin	D	 levels	were	 similar	 irrespective	of	 pancreatic	 status.	Median	 (95%	CI)	 vitamin	D	was	 58	 (53	 :	 66)	
nmol/L	in	pancreatic	insufficient		patients	vs.	51	(25	:	79)	nmol	in	pancreatic	sufficient	patients,		p	=	0.2.	
8.4.6 Growth	
In	 the	 CF	 cohort,	 height,	 weight	 and	 BMI	 median	 z	 scores	 were	 all	 below	 zero	 showing	
below	average	nutritional	status.	Median	(95%	CI)	z-scores	for	height,	weight	and	BMI	were	
-0.2	(-0.6:	0.2),	-0.3	(-0.6:	-0.1)	and	-0.5	(-0.7:	-0.1)	respectively.	Both	weight	and	BMI	were
lower	in	the	CF	cohort	than	either	of	the	other	2	groups	but	no	difference	was	observed	in	
height.	
No	 relationship	 was	 seen	 between	 vitamin	 D	 and	 height,	 weight	 or	 BMI	 z-scores	 with	
vitamin	D	as	either	a	categorical	or	continuous	variable.	This	was	true	when	considering	the	
year	of	the	FOB	(Table	16)	and	the	periods	before	and	afterwards.		
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Table	16:	Nutritional	health	of	the	cf	cohort	by	vitamin	d	status	
BMI,	height	and	weight	z-scores	of	CF	cohort.	Values	shown	are	median	(95%	CI).	
Vitamin	D	
<	50	nmol/L	
Vitamin	D	
	≥	50	nmol/L	
P	value	 Correlation	
Height	 -0.5	(-1.1:	0.4) -0.1	(-0.6:	0.3) 0.3	 r	=	-0.10,	
p	=	0.3	
Weight	 -0.3	(-0.8:	0.4) -0.5	(-0.7:	-0.1) 0.3	 r	=	-0.07,	
p	=	0.5	
BMI	 -0.3	(-0.7:	0.4) -0.6	(-1.1:	-0.3) 0.07	 r	=	-0.19,	
p	=	0.06	
8.4.7 Spirometry	
Spirometry	 results	 were	 available	 for	 60/113	 (53%)	 CF	 patients	 and	 16/23	 (70%)	 non-CF	
CSLD	group	but	not	for	the	others	either	because	they	were	too	young	(CF	=	50,	CSLD	=	2)	or	
because	spirometry	was	not	performed	close	to	the	time	of	the	bronchoscopy	(CF	=	3,	CSLD	
=	4).	Spirometry	was	performed	 in	 just	2	of	 the	healthy	controls	and	therefore	analysis	of	
this	group	was	not	performed.		Median	(95%	CI)	FEV1	was	66	(62	:	73)%	in	the	CF	group	and	
69	 (62	 :	 85)%	 in	 non-CF	 CSLD.	 The	 difference	 between	 the	 groups	 was	 not	 of	 statistical	
significance	(p	=	0.1).		
There	was	no	difference	in	spirometric	values	between	those	who	were	vitamin	D	sufficient	
and	 those	vitamin	D	 insufficient	 in	either	 the	CF	nor	 the	non-CF	CSLD	group.	 	 In	addition,	
there	was	no	correlation	between	vitamin	D	and	FEV1	or	FVC	in	CF	or	non-CF	CSLD	groups	
(Figure	34	and	Table	17).	The	CF	and	non-CF	CSLD	groups	were	then	combined	and	again,	no	
relationship	was	found	(FEV1	r	=	-	0.06,	p	=	0.6.	FVC	r	=	-	0.01,	p	=	0.9).	
The	 lack	of	 relationship	as	seen	from	data	 from	the	time	of	 the	bronchoscopy	persisted	 if	
the	spirometric	values	from	the	AA	pre,	AA	FOB	and	AA	post	were	analysed,	or	if	all	3	were	
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meaned.	The	change	 in	FEV1	over	 the	 time	period	was	also	evaluated	and	no	relationship	
with	vitamin	D	seen.		
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Figure	34:	Vitamin	D	and	lung	function	
Figure	a	and	b	show	the	correlation	(spearman’s	correlation	coefficient)	between	serum	vitamin	D	and	FEV1	for	CF	
(a) and	CSLD	(b)	patients.	Figures	c	and	d	show	the	FEV1	for	vitamin	D	deficient	vs.	vitamin	D	sufficient	patients.
(Mann-Whitney	test).	There	was	no	correlation	between	vitamin	D	and	FEV1	(a	and	b)	for	either	group	(CF:	r	=	0.03,
ns;	non-CF	CSLD:	r	=	0.3,	ns)	and	when	comparing	vitamin	D	sufficiency	and	deficiency	(c	and	d),	no	difference	was	
seen	(median	(CI)	vitamin	D	in	CF:	66	(58-71)%	vs.	71.5(61–76)%,	ns;	non-CF	CSLD:69(36-88)%	vs.	70(62–95)%,	ns).
dc
ba
V ita m in  D  (n m o l/L )
F
E
V
1
(%
 p
re
d
ic
te
d
)
< 5
0
³
5 0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
ns
C F
V ita m in  D  (n m o l/L )
F
E
V
1
(%
 p
re
d
ic
te
d
)
0 2 0 4 0 6 0 8 0 1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
r  =  0 .0 3
n s
C F
<  
5 0
³
5 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
V ita m in  D  (n m o l/L )
F
E
V
1
(%
 p
re
d
ic
te
d
)
n s
N o n -C F  C S L D
0 2 0 4 0 6 0 8 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
V ita m in  D  (n m o l/L )
F
E
V
1
(%
 p
re
d
ic
te
d
)
r = 0 .3
n s
N o n -C F  C S L D
180
Table	17:	Clinical	parameters	by	vitamin	D	status	
The	table	shows	Vitamin	D	levels	and	clinical	parameters	for	CF	and	non-CF	CSLD	patients.	Median	(95%	CI	of	
median)	FEV1,	number	of	days	per	year	spent	on	IVAB	and	BMI	centile	are	shown.	There	was	no	relationship	
demonstrated	between	serum	vitamin	D	level	and	FEV1,	FVC	(figures	not	shown),	the	number	of	days	on	IVAB	
or	BMI	centile.	
8.4.8 Intravenous	antibiotics	
These	data	were	collected	from	the	CF	AA	reports	and	are	therefore	only	available	for	the	
CF	cohort.	The	number	of	days	spent	on	 IVAB	 in	the	previous	year	was	collected	from	AA	
pre,	AA	 FOB	 (Table	17)	 and	AA	post	 reports.	 The	data	were	 analysed	 separately	 and	also	
meaned.	There	were	no	relationships	with	vitamin	D	levels.		
8.4.9 Infection	
Vitamin	 D	 levels	 of	 each	 of	 the	 3	 groups	 were	 related	 to	 microbiological	 status.	 64/113	
(57%)	of	the	CF	patients	and	10/23	(43%)	of	the	non-CF	CSLD	patients	had	a	positive	isolate	
Vitamin	 D	 <	
50	nmol/L	
Vitamin	D	 >	 50	
nmol/L	
Difference	 between	 2	
groups	(p	value)	
Correlation	 with	
serum	vitamin	D	
CF	patients	
FEV1	 %	 predicted	
median	(95%	CI)	
66.0	
(58	-	71)	
71.5	
(61	-	76)	
ns	 r=		0.03	
ns	
FVC	%	predicted	
Median	(95%	CI)	
83.5	
(69-	93)	
82	
(72	–	89)	
ns	 r	=	-	0.08	
ns	
Days	on	IVAB	
Median	(range)	
14	
(0-56)	
12	
(0-18)	
ns	 r	=	-0.05	
ns	
BMI	z-score	
Median	(range)	
- 0.3
(-3.0	–	2.1)
- 0.6
(-4.0	–	2.6	)
ns	 r	=	-0.19	
ns	
Non-CF	CSLD	
FEV1	 %	 predicted	
median	(range)	
69.0	
(36-88)	
70.0	
(62-95)	
ns	 r	=	0.34	
ns	
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on	 their	 BALF	 culture.	 There	 was	 no	 apparent	 relationship	 with	 current	 microbiological	
status	in	either	group	(Figure	31	and	Figure	35).	For	CF	patients,	median	(95%	CI)	vitamin	D	
was	 63	 (52-68)	 nmol/L	 in	 those	with	 sterile	 BALF,	 compared	with	 56	 (47	 –	 63)	 nmol/L	 in	
those	who	cultured	any	bacteria	or	fungi	on	their	BALF.	The	non-CF	CSLD,	median	vitamin	D	
was	43	(27	–	59)	nmol/L	for	those	who	were	culture	negative	and	33	(21	–	60)	nmol/L	in	the	
group	with	positive	isolates	on	their	BALF.	By	definition,	the	healthy	control	group	were	all	
culture	negative.		
182
C F  c u ltu r e  -v e C F  c u ltu r e  + v e
0
5 0
1 0 0
1 5 0
V
it
a
m
in
 D
 (
n
m
o
l/
L
)
ns
B A L F
C F
C S L D  c u ltu r e  -v e C S L D  c u ltu r e  + v e
0
2 0
4 0
6 0
8 0
V
it
a
m
in
 D
 (
n
m
o
l/
L
)
n s
B A L F
N o n -C F  C S L D
Figure	35:	Vitamin	D	level	of	culture	positive	and	culture	negative	patients	
	Vitamin	D	levels	of	CF	patients	who	isolated	any	organisms	in	their	BALF	were	compared	with	CF	patients	with	sterile	BALF.	No	difference	was	seen	between	the	culture	
negative	and	culture	positive	groups	(median	(CI);	63	(52-68)	vs.	56	(47	–	63)	nmol/L,	ns).	This	was	also	true	for	the	non-CF	CSLD	group	(median	(CI);	43	(27	–	59)	vs.	33	(21	
– 60)	nmol/L,	ns).
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As	well	 as	 evaluating	 vitamin	 D	 status	 of	 those	who	 isolated	 any	 bacteria	 on	 their	 BALF,	
comparison	was	done	for	those	whose	samples	grew	P.	aeruginosa	against	those	who	did	
not	(Figure	36),	and	those	who	isolated	S.	aureus	against	those	who	did	not	(Figure	37).	In	
addition	 to	 looking	 at	 bacterial	 organisms	 isolated	 on	 BALF,	 results	 of	 all	 microbiological	
swabs	 taken	 during	 the	 study	 period	 were	 examined.	 	 14	 (12%)	 of	 patients	 isolated	 P.	
aeruginosa	 on	 their	 BALF.	 There	was	 a	 trend	 towards	 a	 lower	median	 vitamin	 D	 level	 in	
these	patients	compared	to	those	without	P.	aeruginosa	isolation	(median	(95%	CI)	vitamin	
D	level	39	(31	:	57)	vs.	62	(53	:	68)	but	this	did	not	reach	the	pre-defined	significance	level	of	
<0.01	 (	p	=	0.014).	This	 trend	was	not	 seen	 in	 the	1	year	or	3	year	 surveillance	 follow	up	
periods.		
When	evaluating	the	vitamin	D	level	by	pseudomonal	status	in	more	depth,	it	was	seen	that	
the	 group	 with	 P.	 aeruginosa	 infection	 were	 older	 than	 those	 without	 although	 not	
statistically	 significantly	 so.	 Median	 age	 was	 10.9	 (3.1:	 14.4)	 years	 in	 the	 P.	 aeruginosa	
positive	group	compared	with	6.9	(3.4:	8.7)	years	in	those	without	P.	aeruginosa	infection	(p	
=	0.16);	adjustment	for	age	was	done	with	no	alteration	to	results.		
In	addition	to	comparing	 individuals	with	P.	aeruginosa	 infection	with	those	P.	aeruginosa	
negative,	I	also	compared	them	with	individuals	who	had	no	organisms	at	all	isolated.	These	
comparisons	were	done	at	each	time	point	with	similar	 results.	There	was	no	relationship	
with	vitamin	D	and	isolation	of	P.	aeruginosa	in	any	of	the	3	ways	of	exploring	this;	isolation	
from	BALF,	from	surveillance	swabs	over	a	one	year	follow	up	period,	or	the	3	year	follow	
up	period.	
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Figure	36:	Vitamin	D	level	of	Pseudomonas	aeruginosa	positive	and	negative	patients	
There	was	no	statistically	significant	difference	between	the	CF	patients	who	isolated	p.	aeruginosa	and	those	who	did	not	in	any	of	the	3	ways	used	to	explore	the	data.	
Mean	vitamin	D	at	FOB	was	39	(31	:	57)	vs.	62	(53	:	68)	and	53	(38	:	66)	nmol/L	vs.	59	(53	:	68)	nmol/L	(p	=	0.2,	Mann-Whitney)	and	55	(45	:	61)	nmol/L	vs.	63	(53	:	69)	
nmol/L	(p	=	0.14)	in	the	1	and	3	year	follow	up	periods	respectively.	Priori	p-value	set	at	p	<	0.01.	(Kruskal	Wallis	with	Dunn’s	comparison).	
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Figure	37:	Vitamin	D	level	of	staphylococcus	aureus	positive	and	negative	patients	
Mean	vitamin	D	 levels	of	patients	with	and	without	Staphylococcal	aureus	 infection	at	each	of	 the	3	ways	of	exploring	 this.	Patients	with	S.	aureus	 in	 their	BALF	had	a	
median	(95%	CI)	vitamin	D	of	54	(27	:	58)	nmol/L	which	was	similar	to	the	level,	62	(53	:	68)	nmol/L,	for	those	without	this	infection	(p	=	0.06	Mann-Whitney).	For	the	1	
year	follow-up	period	patients	with	S.	aureus	did	have	a	lower	vitamin	D	(49	(33	:	57)	nmol/L	vs.	63	(53	:	68)	nmol/L,	p	=	0.006)	but	in	the	3	year	period	the	difference	did	
not	reach	statistical	significance	(mean	vitamin	D	52	(40	:	58)	nmol/L	vs.	63	(53	:	73)	nmol/L,	p	=	0.04).	However,	the	apparent	relationship	disappeared	when	accounting	
for	age.	Priori	p-value	set	at	p	<	0.01.	(Kruskal	Wallis	with	Dunn’s	comparison).	
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For	S.	aureus,	there	was	an	initial	apparent	relationship	in	the	1-year	follow-up	period	but	
not	in	the	other	2	analyses;	this	apparent	relationship	disappeared	when	age	was	assessed	
as	an	independent	variable.	
The	S.	aureus	group	was	also	compared	to	those	with	no	organisms	isolated	on	culture	and	
a	similar	picture	seen	to	the	comparison	to	those	S.	aureus	negative.		
8.4.10 Cellular	and	soluble	markers	of	inflammation		
BALF	total	inflammatory	cell	counts	were	higher	in	CF	patients	than	in	either	of	the	other	2	
groups	(p	<	0.001)	and	neutrophil	differential	was	higher	in	both	CF	and	non-CF	CSLD	than	
healthy	controls	(Figure	38).	BALF	IL-6	and	IL-8	were	higher	in	CF	patients	although	this	did	
not	reach	our	pre-defined	statistical	cut-off	of	 (p	<	0.01).	No	other	differences	 in	cytokine	
levels	were	seen.		
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Figure	38:	BALF	cellular	inflammation	seen	in	the	3	groups	
BALF	total	cell	count	was	higher	in	the	CF	group	than	both	the	control	groups	(CF	620	(500:	850),	non-CF	CSLD	364	(115:	540)	and	healthy	143	(70	:	270)	x103,	p	<	0.001).	
BALF	neutrophil	differential	was	higher	in	CF	than	healthy	controls	(CF	31	(19	:	42),	non-CF	CSLD	15	(2.0	:	46),	healthy	1.4	(0.3	:	2.7)%,	p	=	0.001).	CF	patients	had	a	higher	
BALF	neutrophil	count	than	healthy	controls	(166	(46	:	307)	vs.	2.8	(0.2	:	5.1)	x	103,	p	=	0.0001).	(Kruskal	Wallis	with	Dunn’s	comparison).		
* =	p	<	0.05
**	=	p	<	0.01
***	=	p	<	0.001
Priori	p-value	set	at	p	<	0.01	
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The	cellular	and	soluble	markers	of	 inflammation	correlated	with	infection	status;	patients	
with	 bacteria	 positive	 BALF	 had	 higher	 cell	 counts	 and	 pro-inflammatory	 cytokine	 levels	
than	patients	with	no	bacteria	identified	on	BALF	in	CF	patients	(Table	18).	A	similar	pattern	
was	seen	in	the	non-CF	CSLD	group.	
Table	18:	Cellular	and	soluble	markers	of	inflammation	of	the	CF cohort	by	bacterial	culture	status	
	CF	patients	with	bacteria	isolated	in	their	BALF	had	higher	BALF	total	cell	count,	neutrophil	count,	neutrophil	
differential,	blood	neutrophils,	and	higher	BALF	LL-37,	 IL-10,	 IL-1B,	 IL-8	and	TNF-a.	Values	shown	are	median	
(95%	CI	of	the	median).	
BALF	
culture	+ve	
BALF	
culture	-ve	
p-value
BALF	absolute	count	(x	103/L)	 1,035	(730	:	1880)	 368	(273	:	525)	 <	0.0001	
BALF	neutrophil	differential	(%)	 58	(42	:	71)	 14	(8	:	23)	 <	0.0001	
BALF	neutrophil	count	(	x	103/L)	 521	(209	:	1142)	 39	(23	:	82)	 <	0.0001	
Serum	neutrophils		(	x	109/L)	 5.3	(4.3	:	6.3)	 3.5	(2.7	:	4.3)	 <	0.0001	
BALF	LL-37	ng/ml	 0.82	(0.49	:	1.13)	 0.35	(0.30	:	0.43)	 <	0.0001	
BALF	HBD-2	(pg/ml)	 166	(123	:	231)	 119	(66	:	204)	 0.16	
TNF-α	(pg/ml)	 3.36	(1.53	:	9.11)	 0.5	(0.15:	0.80)	 <	0.0001	
GM-CSF	(pg/ml)	 0.72	(0.26	:	1.90)	 0.18	(0.13	:	0.81)	 0.02	
INF-γ	(pg/ml)	 0.14	(0.00	:	1.63)	 0.13	(0.13	:	0.13)	 0.02	
IL-10	(pg/ml)	 1.20	(0.43	:	2.17)	 0.20	(0.17	:	0.42)	 <	0.0001	
IL-1β	(pg/ml)	 43.0	(15.3	:	77.4)	 4.22	(1.06	:	8.68)	 <	0.0001	
IL-6	(pg/ml)	 21.4	(9.30	:	31.3)	 6.4	2	(4.21	:	14.2)	 0.04	
IL-8	(pg/ml)	 2,347	(1307	:	4163)	 442	(234	:	995)	 0.0004	
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Relationships	between	these	cellular	and	soluble	inflammatory	markers	and	vitamin	D	were	
explored	and	no	relationship	was	seen	(Table	19).		
Table	19:	Cellular	and	soluble	markers	of	inflammation	of	the	CF	cohort	by	vitamin	d	status	
Vitamin	 D	 and	 cellular	 makers	 of	 inflammation,	 median	 (95%	 CI	 of	 median).	 There	 was	 no	 relationship	
between	vitamin	D	level	and	any	of	the	cellular	markers	of	inflammation	for	either	CF	or	non-CF	CSLD	patients.	
n	 Vitamin	D	<	50	nmol/L	 Vitamin	D	>	50	nmol/L	 P	value	
CF	patients	
BALF	total	cell	count	
(X	103)	
101	 652	(500-1,220)	 528	(390	-	850)	 ns	
BALF	neutrophil	differential	
(%)	
84	 36	(20-56)	 25	(15	-	50)	 ns	
BALF	neutrophil	count	
	(X	103)	
76	 207	(40	–	521)	 102	(43	–346)	 ns	
Serum	neutrophil	count	
(	x	109/L)	
102	 4.9	(3.8	-	6.5)	 4.2	(3.4	–	4.9)	 ns	
Non-CF	CSLD	
BALF	total	cell	count	
(X	103)	
16	 364	(200	–	500)	 460	(60	–	1240)	 ns	
BALF	neutrophil	differential	
(%)	
18	 13.4(2.0	–	79)	 29.3	(0.0	–	72)	 ns	
BALF	neutrophil	count	
	(X	103)	
13	 8.6(3.3	–	347)	 299	(16.4	–	582)	 ns	
Serum	neutrophil	count	
(	x	109/L)	
18	 5.1	(3.6	–	5.7)	 2.7	(2.2	–	11.8)	 ns	
8.4.11 Analyses	with	alternative	vitamin	D	categories	
Post-hoc	 analyses	were	 carried	out	 using	different	 vitamin	D	 categorical	 groups	 to	define	
vitamin	D	deficiency	as	described	in	section	5.6.5.	The	conclusion	was	the	same,	regardless	
of	the	cut-off	value	chosen.	
8.4.12 Antimicrobial	peptides	
BALF	levels	of	LL-37	and	HBD-2	were	similar	in	the	3	patient	groups	(Table	15).	
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8.4.12.1 Antimicrobial	peptides	and	vitamin	D	
Counter to the initial hypothesis, no relationship was seen between BALF levels of 
either of the antimicrobial peptides and serum vitamin D (Figure 39 and Figure 40).
8.4.12.2 Antimicrobial	peptides	and	airway	infection	and	inflammation	
BALF	LL-37	was	higher	in	patients	with	infected	BALF	(Figure	41)	and	for	CF	patients	levels	
correlated	positively	with	other	markers	of	 inflammation,	 including	cell	count	 (r	=	0.7;	p	<	
0.0001,	 neutrophil	 differential	 (r	 =	 0.5;	 p	 <	 0.0001)	 and	 several	 of	 the	 BALF	 pro-
inflammatory	 cytokines	 (Figure	 42).	 This	 was	 true	 when	 vitamin	 D	 was	 considered	 as	 a	
continuous	 and	 a	 categorical	 variable.	 For	 non-CF	 patients,	 a	 similar	 but	 non-statistically	
significant	trend	was	seen.	In	neither	patient	group	was	there	a	similar	relationship	between	
HBD-2	and	vitamin	D.		
8.4.12.3 Antimicrobial	peptides	and	lung	function	
No	correlation	was	seen	between	either	LL-37	or	HBD-2	and	FEV1	or	FVC	in	CF	(Figure	43)	or	
non-CF	CSLD	patients.	
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Figure	39:	Vitamin	D	and	HBD-2.	
No	correlation	(Spearman’s	correlation	coefficient)	was	seen	between	serum	vitamin	D	and	BALF	HBD-2	in	either	CF	(r	=	-0.02,	ns)	or	non-
CF	CSLD	 (r	=	 -0.4,	ns)	patients	 (a,b).	 In	addition,	no	difference	was	observed	 in	either	group	between	vitamin	D	deficient	and	vitamin	D	
sufficient	patients	 (Mann-Whitney).	 (Median	 (95%	CI):	CF	patients;	149	 (115	–	235)	pg/ml,	ns.	Non-CF	CSLD	patients;	139	 (15.6	–	1002)	
pg/ml	vs.	15.6	(15.6	–	83)pg/ml	ns	(c,d).	Priori	p-value	set	at	p	<	0.01.		
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Figure	40:	Vitamin	D	and	LL-37.	No	correlation	(Spearman’s	correlation	coefficient)	was	seen	between	serum	25(OH)D2	and	BALF	LL-37	in	either	CF	(r	=	-	0.06,	ns)	or	non-
CF	 CSLD	 (r	 =	 -	 0.02,	 ns)	 patients	 (a,b).	 In	 addition,	 no	 difference	 was	 observed	 in	 either	 group	 between	 vitamin	 D	 deficient	 and	 vitamin	 D	 sufficient	 patients	 (Mann	
Whitney).	(Median	(CI):	CF	patients;	0.49	(0.37	–	0.86)	ng/ml	vs.	0.44	(0.37	–	0.94)	ng/ml,	ns.	Non-CF	CSLD	patients;	0.37	(0.31	–	1.62)	ng/ml	vs.	0.40	(0.27	–	1.	49	ng/ml,	ns)	
(c,d).	Priori	p-value	set	at	p	<	0.01.	
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Figure	41:	LL37	level	in	culture	positive	and	culture	negative	CF	patients	
CF	patients	who	isolated	bacterial	or	fungal	organisms	from	their	BALF	had	higher	levels	of	LL37	than	those	with	sterile	BALF.	Median	(range)	0.82	(0.3	–	21.2)	vs.	0.35	(0.1	
–	6.7	ng/ml.	(Mann-whitney	test,	priori	p-value	p	<	0.01).	
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(figure	continued)		
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Figure	42:	LL37	and	inflammatory	markers	
A	 positive	 correlation	was	 seen	with	 LL-37	 and	 BALF	 absolute	 cell	 count,	 BALF	 neutrophil	 count	 and	 differential	 and	 inflammatory	 cytokines.	 (Spearman’s	 correlation	
coefficient).			
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Figure	43:	LL37	and	HBD-2	and	FEV1	in	CF	patients	
No	relationship	was	observed	between	HBD-2	or	LL37	and	FEV1	in	CF	patients.	There	was	no	correlation	(Spearman’s	correlation	coefficient)	with	LL37	and	FEV1	(r	=	-0.14,	
p	=	0.3)	nor	LL37	and	FVC	(r	=	-0.15,	p	=	0.3).	This	lack	of	relationship	was	also	seen	for	HBD-2	and	FEV1	(r	=	0.01,	p	=	0.9)	and	HBD-2	and	FVC	(r	=	-0.07,	p	=	0.6).	
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	8.5 Discussion	
8.5.1 Statement	and	interpretation	of	principle	findings	
8.5.1.1 Overall	findings	
Contrary	 to	 my	 hypothesis,	 I	 have	 demonstrated	 that	 there	 are	 no	 detectable	 adverse	
outcomes	in	a	range	of	clinically	relevant	pulmonary	parameters	in	association	with	Vitamin	
D	deficiency.	
8.5.1.2 Vitamin	D	level	
Over	 half	 of	 our	 CF	 population	 did	 not	 achieve	 optimal	 vitamin	 D	 levels	 (≥	 75	 nmol/L),	
despite	 most	 (91%)	 being	 prescribed	 supplements.	 This	 may	 reflect	 the	 decreased	
absorption	seen	in	this	group	of	patients,	meaning	inadequate	levels	achieved	with	routine	
supplementation	 and	 that	 higher	 supplemental	 doses	 are	 required.	 12%	of	 the	 CF	 cohort	
were	pancreatic	sufficient	but	it	is	known	that	pancreatic	sufficient	patients	still	have	some	
impairment	to	pancreatic	 function	and	this	group	also	had	suboptimal	vitamin	D	 levels.	 In	
fact	 vitamin	 D	 levels	 were	 similar	 in	 the	 pancreatic	 sufficient	 and	 insufficient	 groups.	
Another	reason	for	the	low	levels	despite	prescribed	supplementation	may	be	a	reflection	of	
decreased	adherence.	 Studies	have	 found	 that	 vitamins	are	 some	of	 the	 least	 adhered	 to	
medications	prescribed	to	patients	with	CF	(335).	This	group	of	patients	are	also	frequently	
prescribed	antibiotics	with	photosensitivity	as	a	side	effect	meaning	that	sun-protection	 is	
essential	 to	prevent	burning,	but	also	decreases	vitamin	D	exposure.	Finally,	patients	with	
CF	have	been	shown	to	have	lower	levels	of	vitamin	D	binding	protein	(270),	which	are	not	
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	related	 to	 levels	 of	 vitamin	 D.	 Vitamin	 D	 binding	 protein	 is	 required	 for	 Vitamin	 D		
transportation	and	low	levels	may	lead	to	less	tissue	vitamin	D.		
When	comparing	CF	patients	with	the	2	control	groups,	it	was	interesting,	and	unexpected,	
to	observe	that	CF	children	and	healthy	controls	have	a	significantly	higher	vitamin	D	level	
than	non-CF	CSLD	(p	<	0.01).	34%	of	CF	patients	and	33%	of	healthy	controls	were	vitamin	D	
insufficient	 (<	50	nmol/L)	compared	with	67%	of	non-CF	CSLD,	an	admittedly	small	group,	
but	an	effect	not	accounted	for	by	ethnicity	or	age.	This	group	of	patients	have	no	known	
gastrointestinal	 problems	 or	 reasons	 for	 malabsorption.	 Further	 work	 is	 needed	 to	
understand	this	finding,	which	is	outwith	the	scope	of	the	thesis.	
	
Seasonal	effect	
As	vitamin	D	is	largely	obtained	by	a	pathway	involving	sunlight,	it	would	be	expected	that	
vitamin	D	levels	would	be	higher	in	the	summer	months	when	there	is	more	direct	exposure	
of	 skin	 to	 sunlight,	 but	 this	 was	 not	 seen,	 for	 reasons	 that	 are	 not	 clear.	 A	 possible	
explanation	 is	 that	 since	most	 CF	 patients	 are	 taking	 oral	 vitamin	 supplements,	 this	may	
obscure	 the	 seasonal	 variation	 related	 to	 endogenous	 synthesis.	 However,	 in	 healthy	
individuals	over	80%	of	 vitamin	D	 is	 from	 sunlight	 requiring	direct	 skin	exposure,	without	
sunscreen.	This	of	course,	necessitates	time	spent	outdoors	with	bare	skin	exposed	in	order	
to	 allow	 sunlight	 rays	 to	 penetrate	 the	 skin.	 There	 do	 not	 appear	 to	 be	 any	 studies	
addressing	the	sunlight	exposure	of	CF	children	versus	sunlight	exposure	of	non-CF	children.	
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	Age	effect	
I	 also	 examined	 the	 effect	 of	 age	 on	 vitamin	 D	 level	 and	 found	 a	 weak,	 but	 statistically	
significant,	 inverse	 relationship	 between	 in	 the	 CF	 group.	 There	 are	 a	 number	 of	 reasons	
why	 younger	 children	 may	 have	 higher	 levels	 of	 vitamin	 D	 than	 older	 children.	 Several	
foods,	including	formula	milks,	are	fortified	with	vitamin	D	and	children	in	the	younger	age	
range	may	be	more	 likely	 to	have	 such	 foods	as	part	of	 their	diet.	Also,	 younger	 children	
may	be	more	compliant	with	their	medications,	as	these	are	administered	by	parents	(336).	
It	is	also	possible	that	older	children	may	have	a	higher	treatment	burden	preventing	them	
from	spending	as	much	time	outside	as	the	younger	children.		
Unlike	 the	 CF	 cohort,	 vitamin	 D	 was	 not	 related	 to	 age	 in	 the	 non-CF	 CSLD	 group.	 This	
population	 are	 not	 routinely	 prescribed	 supplements,	 which	 might	 lend	 support	 to	
adherence	 being	 the	 main	 influence	 of	 the	 age	 relationship	 in	 CF.	 Alternatively,	 their	
treatment	 burden	 may	 be	 less,	 in	 particular	 treatment	 with	 antibiotics	 requiring	 sun	
protection	(particularly	ciprofloxacin	due	to	less	Pseudomonal	infection	in	this	group).		
The	 apparent	 relationship	 of	 more	 Pseudomonal	 infection	 in	 vitamin	 D	 deficiency	 with	
infection	did	not	persist	 through	different	 time	points	 as	would	be	expected	 if	 they	were	
real.	These	apparent	trends	and	relationships	could	be	entirely	accounted	for	by	age.		
8.5.1.3 Antimicrobial	peptides	
There	is	no	relation	between	Vitamin	D	deficiency	and	BALF	LL-37	and	HBD-2	levels,	nor	any	
relationship	between	these	peptides	and	outcomes	despite	biological	plausibility,	given	the	
genes	contain	VDREs.	
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	The	antimicrobial	peptides	HBD-2	and	LL-37	have	previously	been	shown	to	be	induced	by	
vitamin	D,	but	 there	was	no	 relationship	between	 these	peptides,	measured	 in	BALF,	and	
serum	vitamin	D.	
The	majority	of	the	work	finding	induction	of	cathelicidin	by	vitamin	D	has	been	conducted	
in-vitro	rather	than	in-vivo,	and	clearly	not	all	results	translate.	In-vivo	other	environmental	
factors	 can	 alter	 relationships.	 Induction	 of	 cathelicidin	 could	 occur	 but	 increased	
proteolysis	 could	 mean	 that	 the	 protein	 gets	 broken	 down	 immediately	 and	 therefore	
increases	in	protein	levels	are	not	seen.	In	addition,	most	in-vitro	experiments	measure	the	
CAMP	gene	expression,	not	 LL-37	protein	 levels.	An	 increase	 in	 gene	expression	does	not	
necessarily	 translate	 to	 increase	 in	 protein	 level;	 the	 production	 of	 the	 LL-37	 protein	
requires	 proteinase	 3	 to	 cleave	 it	 from	 its	 propeptide	 and	 the	 presence	 of	 this	 enzyme,	
present	in	neutrophils,	is	therefore	also	required	for	an	increase	in	LL-37.	In	addition,	most	
authors	describe	a	2-fold	increase	in	CAMP,	which	may	not	equate	to	significantly	increased	
protein	 production	 in-vivo	 (245).	 However,	 Yim	 et	 al	 (1)	 did	 demonstrate	 an	 increase	 in	
protein	levels	and	a	10-fold	increase	in	gene	expression	so	this	does	not	seem	to	be	the	only	
explanation	 for	 the	 lack	 of	 effect	 seen	 in	 my	 study.	 In	 the	 work	 by	 Yim	 et	 al,	 the	
concentration	 of	 vitamin	 D	 far	 exceeded	 the	 concentration	 that	 would	 be	 seen	 in-vivo	
providing	an	explanation	as	to	why	effects	may	not	translate.		
Other	 explanations	 for	 a	 lack	 of	 effect	 seen	 in-vivo	 is	 the	 possibility	 that	 there	 are	 other	
influences	on	gene	expression	present	in	the	airways	that	over-ride	the	potential	increased	
expression	by	vitamin	D	in	a	competitive	manner.		
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	There	is	a	lack	of	data	on	induction	of	LL-37	by	vitamin	D	in-vivo;	a	study	evaluating	the	level	
of	LL-37	before	and	after	administration	of	high	dose	vitamin	D	found	an	 increase	 in	gene	
expression	but	similarly	to	my	study,	no	increase	in	protein	levels	(225).	Grossman	et	al	also	
found	no	effect	on	LL-37	levels	with	a	large	dose	of	vitamin	D	in	a	double	–blind	randomised	
control	trial	(292).			
LL-37	was	found	to	be	related	to	age	in	the	CF	group.	LL-37	is	released	by	neutrophils	and	
macrophages	 as	 well	 as	 epithelial	 cells	 and	 older	 children	 have	 more	 inflammatory	 cells	
present.	Therefore,	the	increase	in	LL-37	may	be	a	consequence	of	an	increased	number	of	
cells	 rather	 than	a	direct	age	effect.	This	 study	did	not	allow	 these	 two	possibilities	 to	be	
distinguished.	
Whilst	 no	 relationship	 was	 found	 with	 LL-37	 and	 vitamin	 D,	 I	 did	 find	 that	 LL-37	 levels	
correlated	with	other	markers	of	inflammation.	BALF	total	cell	count,	neutrophil	count	and	
neutrophil	 differential,	 serum	neutrophils	 and	BALF	 cytokines	 all	 demonstrated	 a	 positive	
correlation	with	LL-37.	No	relationship	was	seen	with	LL-37	and	lung	function	(FEV1	and	FVC)	
As	LL-37	 is	stored	 in	neutrophils,	this	relationship	might	have	been	anticipated.	Therefore,	
rather	 than	being	 a	marker	 of	 benefit	 to	 lung	 health,	 perhaps	 LL-37	 should	 be	 viewed	 as	
another	 biological	marker	 of	 airway	 inflammation.	 The	 positive	 findings	 seen	 here,	 again,	
add	further	weight	to	the	negative	results	with	LL-37	and	vitamin	D.	They	demonstrate	that	
assays	were	performed	correctly,	samples	stored	and	processed	correctly	and	the	negative	
results	 seen	were	 not	 due	 to	 a	 defect	 in	 the	methodology,	 but	 due	 to	 a	 true	 absence	 of	
relationship	because	vitamin	D	is	irrelevant,	or	not	relevant	at	these	levels.	.		
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	8.5.2 Strengths	of	the	study	
One	 strength	 of	 this	 study	 is	 that	 the	mechanistic	 differences	were	 confirmed	 by	 clinical	
findings.	We	 found	 no	mechanistic	 difference	 between	 vitamin	 D	 sufficient	 and	 deficient	
groups,	and	no	associations	between	vitamin	D	and	clinical	parameters.		
In	order	to	ensure	a	signal	was	not	missed,	and	as	the	optimal	vitamin	D	level	for	respiratory	
health	is	unknown,	different	cut-off	values	were	used	to	define	cohorts,	but	with	no	change	
in	 outcome.	 Some	 groups	 have	 used	 a	 higher	 cut-off	 of	 75nmol/L	 to	 distinguish	 deficient	
from	 insufficient	patients	 (44,	227,	253,	275,	278).	The	 insufficient	group	have	sometimes	
been	sub-divided	but	again,	different	cut-off	values	have	been	used;	some	groups	have	used	
<25nmol/L	and	25-<75nmol/L	(278)	and	others	of	<50nmol/L	and	50-<75nmol/L	(227,	253,	
275).	 	 This	 discrepancy	 in	 values	 used	 shows	 the	 lack	 of	 consensus	 as	 to	 an	 appropriate	
vitamin	D	level	that	should	be	accepted.	The	performance	of	post-hoc	analyses	with	several	
cut-off	values	increases	the	likelihood	that	negative	findings	were	not	due	to	differences	in	
definitions	of	vitamin	D	deficiency.		
To	maximise	 the	 reliability	 of	 the	 conclusions,	 large	 numbers	 (113)	 of	 CF	 patients	 with	 a	
wide	range	of	disease	severity	were	studied.	However,	the	numbers	in	the	non-CF	CSLD	and	
healthy	control	group	were	smaller	due	to	the	relatively	less	frequent	performance	of	FOB	
in	these	patients.	
Finally,	many	different	parameters	were	explored,	including	clinical	and	biological	aspects.	A	
thorough	 exploration	 of	 immunological	 and	 clinical	 benefits	 was	 therefore	 performed.	
Although	many	other	potential	pathways	could	have	been	examined,	the	total	absence	of	a	
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	signal	of	 low	vitamin	D	 levels	with	any	clinically	 significant	downstream	measurement	 led	
my	to	conclude	that	such	a	search	was	unlikely	to	be	fruitful.	
	
8.5.3 Weaknesses	of	the	study	
Whilst	a	large	number	of	CF	patients	were	recruited	to	the	study,	due	to	the	opportunistic	
nature	of	the	study,	a	smaller	number	of	control	patients	were	recruited.		
A	limitation	worthy	of	discussion	is	that	few	CF	patients	beyond	the	first	year	of	life	undergo	
FOB	 at	 a	 time	 of	 clinical	 stability.	 Patients	 are	 recruited	 opportunistically,	 when	 having	
clinically	 indicated	 bronchoscopy,	 biasing	 towards	 the	 exacerbating	 state.	 It	 is	 possible	
therefore	that	these	data	cannot	be	directly	extrapolated	to	the	stable	CF	lung.	However,	as	
CF	 is	 a	 condition	 with	 frequent	 exacerbations,	 which	 impact	 directly	 chronic	 respiratory	
health,	these	findings	are	of	likely	relevance.		
Additionally,	 the	BALF	data	are	cross-sectional,	 reflecting	a	single	time	point;	 there	are	no	
data	 on	 the	 longitudinal	 changes	 of	 many	 of	 the	 markers	 measured	 in	 this	 study.	
Microbiological	 culture	 status	at	 the	 time	of	bronchoscopy	may	be	affected	by	 the	use	of	
antibiotics	 and	 sampling	 errors;	 future	 studies	 should	 use	 molecular	 techniques	 if	 the	
relationship	of	Vitamin	D	on	the	whole	microbiome	is	to	be	studied,	although	 it	has	to	be	
said	 that	 the	 relevance	 of	 molecular	 studies	 to	 clinical	 management	 has	 yet	 to	 be	
determined.		
Microbiological	 results	may	 also	 be	 affected	 by	 sampling	 errors	 as	 the	BAL	 samples	were	
routinely	 obtained	 from	 the	 right	 middle	 lobe	 and	 lingula,	 whilst	 some	 studies	 have	
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	reported	 that	 whereas	 inflammation	 and	 inflammatory	 changes	 are	 homogenous	
throughout	the	 lung,	there	 is	considerable	geographical	variability	amongst	airway	regions	
with	regards	to	bacterial	culture	(110).		
BALF	 proteases	 were	 not	 measured	 and	 with	 hindsight,	 neutrophil	 elastase	 would	 be	 a	
useful	addition	to	my	study	and	would	have	allowed	fuller	consideration	of	whether	vitamin	
D	is	only	relevant	at	certain	stages	of	the	disease	process.	VDBP	levels	are	not	available	so	
the	 amount	 of	 free	 vitamin	 D	 available	 for	 action	 cannot	 be	 calculated.	 VDBP	 can	 be	
measured	 in	 serum	 using	 commercially	 available	 ELISA	 kits	 but	 due	 to	 the	 lack	 of	
relationship	 seen	with	 vitamin	 D	 and	 the	 innate	 immune	markers	 with	 clinically	 relevant	
outcomes,	 in	 this	 study	 a	 decision	 was	 taken	 not	 to	 investigate	 this	 vitamin	 D	 related	
marker.		
It	 may	 be	 that	 whilst	 serum	 levels	 of	 vitamin	 D	 are	 not	 relevant,	 BALF	 levels	 are;	 and	
another	weakness	to	this	study	is	that	BALF	vitamin	D	levels	were	not	measured.	Previous	
investigators	within	the	department	had	unsuccessfully	attempted	to	perform	this	assay	and	
so	no	 further	attempts	were	of	made	as	part	of	 this	 study.	 It	 is	 therefore	not	possible	 to	
comment	on	whether	local	levels	would	have	had	an	impact	but	if	they	are	important,	it	is	
not	via	LL-37	and	HBD-2.	
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	8.5.4 Findings	in	relation	to	other	studies	
8.5.4.1 Vitamin	D	levels	
Similarly	to	our	study,	many	other	investigators	have	reported	low	levels	of	vitamin	D	in	CF	
and	the	comparability	of	my	results	to	these	is	a	further	validation	of	the	results	I	obtained.	
A	review	of	29	studies	of	CF	patients	over	the	past	20	years	documented	that	just	one	study	
found	the	median	vitamin	D	to	be	in	the	optimal	range	(≥	75	nmol/L)	(267).	The	vitamin	D	
levels	 of	 our	 patients	 were	 higher	 than	 that	 of	many	 other	 studies,	 with	 18	 of	 these	 29	
studies	 reporting	a	 lower	median	vitamin	D	than	that	seen	 in	our	population	 (57	nmol/L).	
However,	the	6	studies	included	in	this	review	with	younger	patients	(median	age	<12	years)	
all	had	similar	or	higher	median	vitamin	D	levels	(55	–	87.75	nmol/L).		A	recent	study	(290)	
looking	 at	 175	 CF	 children	 found	 that	 39%	 were	 vitamin	 D	 sufficient	 (≥	 75	 nmol/L),	
compared	to	25%	in	our	study,	and	18%	were	deficient	(<50nmol/L)	compared	to	34%	in	our	
study.	 These	 differences	were	 statistically	 significant	 (Fishers	 exact	 test	 <0.01);	 the	 study	
was	 conducted	 in	a	 sunnier	 climate,	which	may	at	 least	partially	explain	 the	higher	 levels	
seen.		
Several	 groups	 have	 found	 that	 satisfactory	 levels	 can	 be	 achieved	 with	 adequate	
supplementation.	 A	 trial	 done	 in	 Liverpool,	 UK,	 found	 that	 a	 weekly	 dose	 of	 50,000	
international	units	of	vitamin	D3	increased	the	median	serum	vitamin	D	from	17.6	to	78.6	
nmol/L	 (337)	 and	 an	observational	 study	of	 	 26	CF	 children	 found	 that	 vitamin	D	 level	 of	
over	75	nmol/L	were	seen	in	half	of	the	pancreatic	insufficient	children	(338).	Interestingly,	
this	was	only	achieved	in	40%	of	the	pancreatic	sufficient	children	which	may	reflect	the	fact	
that	 pancreatic	 sufficient	 CF	 children	 are	 not	 always	 routinely	 supplemented	with	 the	 fat	
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	soluble	vitamins.	This	was	also	seen	in	a	study	of	148	Boston	children	with	60%	of	pancreatic	
insufficient	patients	achieving	vitamin	D	 levels	over	75	nmol/L	but	only	50%	of	pancreatic	
sufficient	 children	 (339).	 In	my	 study,	median	 vitamin	 D	 levels	were	 similar	 in	 pancreatic	
sufficient	 and	 insufficient	 groups;	 25%	 of	 pancreatic	 sufficient	 and	 21%	 of	 pancreatic	
insufficient	patients	achieved	vitamin	D	level	over	75	nmol/L	patients	reflecting	the	need	for	
supplementation	 in	 both	 groups.	 Vitamin	 D	 deficiency	 is	 commonly	 seen	 in	 the	 healthy	
population	and	so	the	pancreatic	sufficient	do	not	differ	from	this	population	in	this	regard,	
although	may	have	subclinical	 insufficiency	predisposing	them	to	deficiency.	 It	 is	therefore	
believable	 that	 if	 healthy	 population	 are	 deficient	 then	 so	 too	 might	 the	 pancreatic	
sufficient	cohort.		
Seasonal	variation	in	vitamin	D	levels	has	been	reported	(266,	340)	but	not	universally	(339);	
it	may	be	that	ingested	supplements	make	sunlight	and	therefore	season	less	important.		
Other	 investigators	have	 found	 increased	 levels	 in	BALF	 in	patients	with	 severe	asthma,	a	
correlation	 with	 inflammatory	 markers	 and	 a	 deactivation	 of	 vitamin	 D	 in-vitro	with	 the	
addition	 of	 VDBP	 (341).	 The	 results	 may	 imply	 that	 increased	 VDBP	 impairs	 vitamin	 D	
activity	 by	 reducing	bio-availability,	 or	 it	may	 exert	 its	 chemotactic	 effects	 on	neutrophils	
and	macrophages	increasing	the	inflammatory	state	of	the	airways	thereby	and	contributing	
the	severity	of	disease	in	asthma	(342);	or	it	could	be	a	marker	of	inflammation	rather	than	
a	 causative	 agent	 as	 VDBP	 protein	 expression	 is	 known	 to	 be	 increased	 by	 inflammatory	
cytokines	(343).		
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	8.5.4.2 Clinical	and	immunological	effects	
There	was	no	relationship	between	spirometry	and	vitamin	D	unlike	the	findings	of	a	large	
study	 in	Scandinavia	 (286).	This	study	 found	a	positive	correlation	between	vitamin	D	and	
FEV1	(r2	=	0.308,	p	=	0.025)	and	an	inverse	relationship	with	vitamin	D	and	IgG	(r2	=	0.376,	
p<0.001).	However,	the	correlation	coefficient	was	small	and	the	study	involved	around	800	
patients.	 By	 exploring	 the	 spirometry	 of	 patients,	 not	 just	 at	 the	 time	 of	 the	 vitamin	 D	
measurement,	 but	 over	 a	 3	 year	 period	 we	 are	 confident	 that	 our	 conclusion	 of	 no	
relationship	 being	 present	 is	 correct	 for	 our	 population.	 In	 addition,	 other	 clinical	
parameters	such	as	BMI	and	days	on	IVAB,	showed	no	relationship	to	vitamin	D.	We	cannot	
account	 for	 the	 reasons	 in	 the	 difference	 between	 the	 Scandinavian	 cohort	 and	 our	
population.	 However,	 in	 our	 study,	 we	 looked	 at	 possible	 mechanistic	 as	 well	 as	 clinical	
effects	and	found	no	difference	in	either.		
In	 a	 pilot	 double-blind	 RCT	 of	 30	 adults	 with	 CF,	 subjects	 experiencing	 a	 pulmonary	
exacerbation	received	vitamin	D	or	placebo	(344)	and	there	was	a	trend	towards	improved	
clinical	outcomes	with	patients	supplemented	with	vitamin	D	compared	with	placebo.	Our	
patient	group	did	not	have	 levels	comparable	to	this	and	there	 is	a	possibility	 that	clinical	
benefit	 could	 have	 been	 observed	 at	 much	 higher	 serum	 levels.	 As	 most	 patients	 never	
achieve	such	a	high	level,	whether	in	clinical	practice	or	research	studies,	it	is	not	known	if	
this	 finding	 would	 be	 reproducible	 across	 other	 settings	 and	 it	 is	 possible	 that	
immunomodulation	for	CF	patients	requires	much	higher	levels	than	the	level	required	for	
bone	health.	The	fact	that	only	a	trend	towards	positive	effects	was	seen	even	at	such	high	
levels	makes	it	 less	certain	that	any	true	relationship	exists,	and	more	likely	that,	as	in	our	
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	study,	there	is	not	a	significant	benefit	of	higher	vitamin	D	levels	in	respiratory	health	in	CF.	
It	may	be	that	vitamin	D	levels	required	for	bone	health	and	immune	health	are	different.		
Similarly	to	other	studies	(290,	339,	345)	we	did	not	find	any	association	between	vitamin	D	
and	clinical	parameters	or	inflammatory	markers.	One	of	these	studies	(290)	examined	the	
vitamin	D	levels	of	130	children	and,	comparable	to	the	findings	of	my	study,	they	found	no	
association	with	vitamin	D	and	 lung	 function	 (FEV1,	FVC	and	FEV1/FVC).	They	did	 find	that	
more	 pulmonary	 exacerbations	were	 seen	 in	 adolescents	with	 vitamin	D	 deficiency	 (<	 75	
nmol/L)	than	those	not	deficient	(≥	75	nmol/L).	However,	this	finding	was	not	seen	in	other	
age	groups	and	was	not	associated	with	a	difference	in	lung	function	so	the	significance	of	
this	 finding	 remains	 unclear.	 Another	 possibility	 is	 that	 low	 level	 of	 vitamin	 D	may	 be	 a	
marker	 of	 poor	 treatment	 adherence	 and	 it	 is	 the	 poor	 adherence	 that	 leads	 to	
exacerbations,	not	the	low	vitamin	D.	
Hall	 et	 al.	 compared	 sputum	 inflammatory	markers	with	 vitamin	D	 in	 adult	 patients	with	
non-CF	bronchiectasis	(227)	and	found	that	levels	of	the	pro-inflammatory	cytokines	IL-8,	IL-
1β	 and	 TNF-α	 were	 higher	 in	 vitamin	 D	 deficient	 patients	 compared	 to	 those	 vitamin	 D	
sufficient	(≥75	nmol/L)	whilst	we	found	no	such	relationship.	Although	this	study	examined	
sputum	whereas	we	examined	BAL,	one	would	expect	similar	findings	in	both	and	so	would	
not	 expect	 this	 to	 account	 for	 the	 differences	 in	 findings.	 However,	 more	 proteolysis	 is	
expected	 in	 CF	 than	 in	 non-CF	 bronchiectasis,	 which	may	 account	 for	 the	 lack	 of	 effects	
seen.	We	used	different	vitamin	D	cut-off	values	to	those	used	in	this	study	but	on	post-hoc	
analysis	 using	 the	 cut-off	 values	 used	 in	 this	 study	 we	 found	 no	 difference	 in	 vitamin	 D	
deficient	 and	 sufficient	 groups.	 Our	 study	 examined	 children	 with	 CF	 and	 this	 study	
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	examined	 adults	 with	 non-CF	 bronchiectasis;	 therefore	 the	 study	 populations	 were	
different.	 The	 different	 results	 seen	 in	 these	 2	 studies	 are	 likely	 due	 to	 the	 different	
population	 groups	 studied.	 If	 this	 relationship	 is	 indeed	 true,	 the	 relationship	 between	
vitamin	D	 and	 inflammatory	markers	 is	 therefore	 either	 not	 applicable	 in	 children	 or	 not	
applicable	to	CF	patients.		One	explanation	for	a	lack	of	relationship	being	seen	in	children	
as	compared	to	adults	is	that	this	group	may	have	relatively	healthy	airways.		It	may	be	that	
more	severe	inflammation	is	needed	for	vitamin	D	to	demonstrate	an	effect;	that	at	lesser	
levels	of	 inflammation	other	factors	have	more	of	an	impact	and	so	no	additional	effect	 is	
observed	with	vitamin	D.	Alternatively,	it	may	be	that	the	underlying	CF	pathology	and	the	
presence	 of	 abnormal	 CFTR	 with	 its	 consequences	 have	 an	 impact	 with	 other	 disease	
specific	factors	within	the	airway	negating	any	benefit	that	would	otherwise	be	seen.		
8.5.4.3 Bacteriology	
Unlike	 my	 cohort	 of	 CF	 and	 non-CF	 CSLD	 paediatric	 patients,	 vitamin	 D	 deficiency	 was	
associated	with	 increased	bacterial	 infection	 in	adults	with	non-CF	bronchiectasis	 (227).	A	
possible	explanation	 for	 the	difference	 in	 findings	could	be	due	 to	CF	airways	being	more	
complex	with	multiple	 defects	 contributing	 to	 disease	 processes,	 or	 adult	 patients	 having	
altered	 immune	function.	 	The	 findings	 in	my	non-CF	cohort	may	be	due	to	 lack	of	power	
but	the	absence	of	a	trend	in	any	parameter	supports	a	true	lack	of	relationship.		
One	factor	to	consider	in	comparing	my	results	with	published	data	is	that	publication	bias	
means	that	positive	 findings	are	more	 likely	 to	appear	 in	 the	 literature;	 it	 is	 therefore	not	
known	whether	other	 groups	have	 found	 similar	 results	 to	mine	but	 the	negative	 studies	
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	have	 just	 not	 been	 published.	 This	 is	 a	 common	 factor	within	medical	 literature	 and	 not	
unique	to	this	study.			
A	study	conducted	in	infants	and	pre-school	children	with	CF	(345)	found	that	low	vitamin	D	
was	associated	with	increased	risk	of	lower	respiratory	infection	with	S.	aureus.	A	separate	
study	 found	 that	 patients	 with	 P.	 aeruginosa	 had	 a	 lower	median	 serum	 vitamin	 D	 than	
those	without	(339).	This	study	was	conducted	 in	Boston,	USA	and	examined	148	children	
(339).	The	median	vitamin	D	of	patients	 in	 this	 study	was	higher	 than	 in	our	 study	with	a	
median	vitamin	D	of	81	nmol/L,	compared	with	57	nmol/L	in	our	study.	Just	43%	of	subjects	
had	a	level	less	than	75	nmol/L;	75%	of	the	subjects	in	my	study	had	levels	below	this.	This	
study	found	that	patients	who	had	ever	 isolated	P.	aeruginosa	had	a	 lower	median	serum	
vitamin	 D	 than	 those	 without	 P.	 aeruginosa	 (69.3	 nmol/L	 vs.	 82.3	 nmol/L,	 p	 =	 0.02).	
However,	 significant	 overlap	was	 seen	 between	 the	 two	 groups,	 the	 p-value	was	 greater	
than	the	value	considered	significant	in	my	study	and	the	effect	was	not	seen	for	S.	aureus.	
More	meaningfully,	 in	neither	of	these	were	any	downstream	inflammation	consequences	
of	 this	 apparent	 increased	 bacterial	 infection	 demonstrated,	 and	 therefore	 it	 may	 be	
questioned	as	to	whether	these	findings	were	real.	The	authors	of	one	of	these	studies	(339)	
comment	themselves	that	whilst	the	difference	was	statistically	significant	it	may	have	been	
of	 doubtful	 clinical	 significance	 as	median	 values	 in	 the	 groups	 were	 so	 close.	 They	 also	
commented	that	even	if	an	association	did	exist,	it	does	not	imply	causation	and	suggest	it	
could	be	a	reflection	of	medication	adherence.		
Although	we	did	find	lower	vitamin	D	with	S.	aureus	and	P.	aeruginosa	at	some	time	points	
within	 the	 study,	 in	 logistical	 regression	models	 these	 relationships	disappeared	once	age	
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	had	 been	 accounted	 for,	 and	we	 found	 no	 relationship	 between	 vitamin	 D	 level	 and	 the	
presence	of	any	bacterial	or	fungal	organisms.	The	lack	of	this	relationship	being	seen	in	all	
settings	and	its	relationship	to	age	make	us	confident	that	at	least	in	our	cohort,	there	is	no	
true	relationship	between	vitamin	D	and	bacterial	isolation.		
Unfortunately,	due	to	a	change	in	methodology	of	viral	detection	during	the	study	period,	
we	were	not	able	to	accurately	explore	this.	
8.5.4.4 Antimicrobial	peptides	
The	authors	of	another	study	(124)	also	found	that	LL-37	level	increased	with	BALF	total	cell	
count	and	BALF	neutrophil	count	and	similarly	to	our	study	they	found	no	association	with	
LL-37	and	HBD-2.		
I	did	not	find	a	relationship	between	LL-37	and	FEV1	and	this	was	similar	to	the	finding	in	the	
study	previously	described	(124)	although	they	did	find	a	negative	association	with	MEF25%	
(r	=	-0.33,	p=0.016)	implying	increasing	small	airways	disease	with	increasing	levels	of	LL-37	.	
These	data	were	not	collected	in	this	study	as	it	is	a	measure	with	far	greater	variability	than	
FEV1.	Future	work	should	use	LCI	to	examine	the	effect	on	small	airways.		
These	results	suggest	that	rather	than	increased	levels	of	LL-37	meaning	more	antimicrobial	
activity	and	subsequent	better	 lung	health,	LL-37	is	 increased	in	diseased	states.	 It	 is	 likely	
that	LL-37	is	not	a	causative	factor	of	poorer	lung	health,	but	a	marker	of	disease.	As	LL-37	
has	 immunomodulatory	 actions	 as	 well	 as	 antibacterial,	 it	 could	 add	 to	 the	 increased	
inflammatory	state	within	the	airway	thereby	having	adverse	effects.	However,	longitudinal	
or	intervention	studies	are	required	to	differentiate	causation	from	association.	
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	The	presence	of	 a	 vitamin	D	 response	element	 in	 the	promoters	 of	 camp	and	defB2	 (the	
genes	encoding	LL-37	and	HBD-2)	suggests	that	vitamin	D	is	relevant	to	LL-37/HBD-2	and	in-
vitro	 data	 has	 shown	 increased	 expression	 of	 LL-37	 and	 to	 a	 lesser	 extent	 HBD-2	 with	
vitamin	D	 in	CF	cells	 (213).	LL-37	and	HBD-2	gene	expression	can	be	measured	using	real-
time	 quantitative	 PCR	 from	 extracted	 DNA.	 Some	 of	 the	 study	 subjects	 had	 BALF	 cells	
suspended	in	RNAlater®	and	stored	at	-80	degrees	available	and	may	have	been	possible	to	
perform	this	technique	from	these	cells;	measurement	of	gene	expression	rather	than	just	
protein	 levels	 would	 have	 been	 an	 interesting	 addition	 to	 the	 study	 to	 examine	 if	 gene	
expression	 correlates	 with	 vitamin	 D	 level.	 It	 is	 possible	 that	 vitamin	 D	 promotes	 gene	
expression	 of	 the	 antimicrobial	 peptides	 but	 these	 molecules	 are	 degraded	 quickly	 and	
subsequently	 a	 relationship	 with	 the	 protein	 cannot	 be	 seen.	 However,	 even	 is	 such	 a	
relationship	does	exist,	this	does	not	translate	to	a	clinical	effect	and	is	thereby	somewhat	
irrelevant.			
One	 small	 RCT	 involving	 30	 CF	 patients	 treated	 with	 either	 intramuscular	 vitamin	 D	 or	
placebo	at	the	time	of	a	pulmonary	exacerbation	found	no	difference	in	plasma	LL-37	levels	
between	 the	 groups,	 although	 they	 did	 report	 a	 treatment-associated	 reduction	 in	 TNF-α	
(292).	Similarly	to	this	study	we	found	no	effect	of	vitamin	D	on	LL-37	level,	contrasting	with	
in-vitro	 data	 of	 vitamin	 D	 induced	 expression	 of	 LL-37	 in	 CF	 cells.	 	 This	 finding	 is	 also	 in	
agreement	with	previous	work	which	found	no	relationship	between	serum	LL-37	(225)	and	
serum	vitamin	D.	It	is	possible	that	the	expression	of	LL-37	and	HBD-2	is	induced	by	vitamin	
D,	but	that	these	peptides	are	degraded	in	the	proteolytic	environment	of	the	CF	airway	and	
therefore	 no	 relationship	 is	 found	 with	 peptide	 levels.	 Against	 this,	 LL-37	 correlated	
positively	with	other	markers	of	inflammation	including	neutrophil	numbers.	Depending	on	
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	survival	 time	 on	 the	 airway	 surface	 one	might	 also	 expect	 to	 see	 a	 relationship	 between	
vitamin	 D	 and	 infection,	 which	was	 clearly	 lacking	 in	 our	 group.	 Another	 study	 found	 an	
association	with	BAL	LL-37	and	BAL	vitamin	D	in	allergic	patients	but	this	was	only	seen	after	
allergen	 challenge	 (346)	 and	 only	 with	 BAL	 vitamin	 D,	 not	 serum	 vitamin	 D.	 LL-37	 levels	
significantly	 increased	 after	 allergen	 exposure,	 which	 may	 be	 due	 to	 the	 influx	 of	
inflammatory	 cells	 that	 occurs	 as	 a	 result	 of	 the	 allergic	 response.	 Although	 LL-37	 is	
predominantly	stored	in	neutrophilic	granules,	other	inflammatory	cells	including	mast	cells	
express	this	peptide.	It	was	interesting	that	this	association	was	only	seen	with	BAL	vitamin	
D	and	suggests	that	local	action	and	local	levels	are	more	important	than	circulating	levels.		
It	is	worth	noting,	that	whilst	in-vitro	studies	have	shown	LL-37	to	be	induced	by	vitamin	D,	
experimental	conditions	have	been	based	on	exposures	of	a	much	higher	concentration	of	
vitamin	D	 than	 that	 seen	 in	 in	human	physiological	 conditions.	Also,	 such	 studies	use	 the	
active	 form	 of	 vitamin	 D	 (1,25(OH)D2,	 and	 are	 therefore	 not	 relying	 on	 the	 enzymatic	
conversion	of	the	inactive	form	(25(OH)D2).	One	study	used	a	concentration	of	1,25(OH)D2	
of	10-100	nM	compared	with	the	50-100	pM	seen	 in-vivo,	a	1000-fold	 increase	 (221).	 It	 is	
therefore	difficult	to	make	a	direct	comparison.				
It	is	possible	that	the	expression	of	LL-37	and	HBD-2	is	induced	by	vitamin	D,	but	that	these	
peptides	 are	 degraded	 in	 the	 proteolytic	 environment	 of	 the	 CF	 airway	 and	 therefore	 no	
relationship	 is	 subsequently	 apparent	 with	 peptide	 levels.	 Against	 this,	 LL-37	 correlated	
positively	with	other	markers	of	inflammation	including	neutrophil	numbers,	although	they	
could	have	initially	been	much	higher.		
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	We	 chose	 two	 innate	 defence	 peptides	 based	 on	 in-vitro	 evidence	 that	 their	 promoters	
contain	VDRE	 and	 increased	 expression	 in	 response	 to	 vitamin	D	 (213).	 It	 is	 possible	 that	
vitamin	D	affects	other	defence	proteins	that	have	not	been	explored	here,	although	in	the	
absence	 of	 detectable	 down-stream	 consequences,	 any	 such	 mechanisms	 may	 be	 of	
questionable	 clinical	 relevance.	 If	 there	 is	 a	biological	 effect	of	 vitamin	D	on	any	of	 these	
pathways,	the	benefit	is	not	translated	to	a	clinical	one.	
	
8.5.5 Conclusions	
In	conclusion,	I	hypothesised	that	levels	of	antimicrobial	peptides	in	BALF	would	be	related	
to	vitamin	D	status	in	children	with	CF,	which	would	provide	an	explanation	for	the	reported	
improvements	in	lung	function	via	improved	airway	defence	to	bacterial	infections.	I	aimed	
to	explore	the	relationships	between	serum	vitamin	D	levels	and	a)	 levels	of	 inflammatory	
mediators,	 antimicrobial	 peptides	 and	 bacterial	 infection	 in	 the	 airway	 and	 b)	 clinical	
parameters	 including	 lung	 function,	 requirement	 for	 intravenous	 antibiotics	 and	BMI.	 The	
data	demonstrate	that	there	is	no	relationship	between	serum	levels	of	vitamin	D	and	BALF	
levels	 of	 either	 HBD-2	 or	 LL37	 and	 no	 effect	 on	 airway	 inflammation	 and	 no	 detectable	
clinical	or	physiological	effects	of	vitamin	D	deficiency.		
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	9 Chapter	9:	Final	discussion,	conclusions	and	future	work	
9.1 Principal	findings	
I	 hypothesised	 that	 the	 earlier	 institution	 of	 improved	 and	 more	 aggressive	 treatments	
strategies	possible	because	of	NBS	would	lead	to	improved	airway	health	and	that	vitamin	D	
has	 immunomodulatory	 effects	 via	 antimicrobial	 peptide	 pathways	 with	 vitamin	 D	
deficiency	leading	to	worse	clinical	outcomes.	I	set	out	to	describe	the	spectrum	of	airway	
disease	 in	 a	 large	 cohort	 of	 young	 infants	 diagnosed	 on	 NBS	 and	 was	 able	 to	 recruit	 77	
infants	 and	 well	 described	 the	 infection	 and	 inflammation	 seen	 in	 their	 airways	 cross-
sectionally,	 and	 described	 longitudinal	 changes	 with	 relation	 to	 structural	 and	 functional	
change	 in	 19	 of	 them.	 I	 also	 set	 out	 to	 describe	 vitamin	D	 levels	 in	 children	with	 CF	 and	
compare	them	to	2	control	groups	and	was	able	to	recruit	113	children	with	CF,	23	patients	
with	 non-CF	 CSLD	 and	 6	 healthy	 controls.	 I	 collected	 BALF	 samples	 and	 blood	 samples	 in	
order	to	measure	vitamin	D,	inflammatory	markers	and	antimicrobial	peptides.		
There	was	no	association	between	serum	vitamin	D	and	airway	levels	of	LL-37	and	HBD-2,	or	
any	marker	of	airway	 inflammation	and	 infection,	 in	 children	with	CF,	nor	any	correlation	
with	 clinical	 outcomes.	 This	 discrepancy	 between	my	hypothesis	 and	my	 results	 could	 be	
because	(a)	Vitamin	D	is	irrelevant;	(b)	it	is	only	relevant	at	certain	stages	of	the	disease,	for	
example	early	on	when	fewer	proteases	are	seen	in	the	BALF	and	in	the	initial	response	to	
infection;	(c)	only	tiny	amounts	of	Vitamin	D	are	needed	for	optimal	immune	health,	and	all	
patients	were	 on	 the	 top	 flat	 part	 of	 the	 dose-response	 curve;	 (d)	much	 higher	 levels	 of	
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	Vitamin	D	are	needed	 to	 show	an	effect,	 all	 patients	being	at	 the	bottom	 flat	part	of	 the	
curve;	(e)	Local	levels	of	Vitamin	D	are	relevant,	and	unrelated	to	systemic	levels.	
The	optimal	 level	of	vitamin	D	for	 immunological	functioning	 is	not	known	and	it	could	be	
that	all	recruited	children	were	either	all	above,	or	all	below	this,	which	is	why	no	difference	
was	 seen.	As	 the	 children	 spanned	a	wide	 range	of	 vitamin	D	 it	would	be	difficult	 to	 find	
children	with	supra-high	or	supra-low	levels	to	use	as	a	comparison	as	the	vitamin	D	ranges	
in	this	study	are	comparable	with	the	literature.	Biologically,	given	the	known	toxic	effects	
of	 high	 dose	 vitamin	 D,	 it	 seems	 unlikely	 that	 much	 higher	 doses	 than	 conventionally	
attained	would	be	necessary	for	immunological	health,	so	(d)	above,	although	theoretically	
an	explanation,	seems	least	likely	to	be	true.		
Numerous	polymorphisms	exist	in	the	VDR,	which	binds	to	vitamin	D	allowing	it	to	enter	the	
cell	 to	 exhibit	 its	 effects.	 Some	 polymorphisms	 may	 be	 more	 effective	 than	 others	 at	
carrying	out	these	conversions	and	it	may	be	this	activation	that	is	relevant	rather	than	the	
availability	of	free,	inactive,	vitamin	D.	
As	 vitamin	 D	 is	 actually	 LOWER	 in	 non-CF	 bronchiectasis,	 a	 condition	 in	 which	 better	
outcomes	are	expected;	this	supports	(a)	and	the	idea	that	Vitamin	D	is	irrelevant	to	airway	
health	 in	 chronic	 suppurative	 lung	 disease,	 at	 least	 in	 the	 range	 studied.	 The	 lack	 of	
correlations	 with	 vitamin	 D	 and	 clinical	 outcomes	 (FEV1,	 FVC,	 BMI,	 days	 on	 antibiotics;	
infection	state)	further	support	the	likely	lack	of	any	clinical	significance	of	Vitamin	D	levels	
in	CF.		
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	I	addressed	the	possibility	of	vitamin	D	only	being	relevant	at	certain	stages	of	disease	by	
splitting	 into	 early	 and	 later	 disease	 and	 found	 no	 effects	 of	 Vitamin	 D.	 The	 results	
presented	in	this	thesis	include	children	of	all	ages.	Post-hoc	analyses	confirmed	there	was	
no	change	 in	the	conclusions	when	children	under	the	age	of	2	years	were	excluded	from	
the	group	 in	order	to	 look	at	the	relationship	of	vitamin	D	 in	those	with	more	established	
disease.	 Perhaps	 more	 importantly,	 post-hoc	 analyses	 of	 CF	 patients	 <2-years-old	 were	
performed.	Innate	host	defence	mechanisms	are	thought	to	be	of	particular	importance	in	
the	early	years,	before	the	body	has	had	time	to	develop	acquired	antibody	 immunity	but	
even	 in	 this	 age	 group,	 vitamin	 D	 level	 did	 not	 correlate	 with	 markers	 of	 inflammation.	
Results	of	these	2	post-hoc	analyses	demonstrated	no	alteration	to	findings.		
Two	innate	defence	peptides	were	chosen	based	on	 in-vitro	evidence	that	their	promoters	
contain	VDRE	and	there	was	increased	expression	in	response	to	vitamin	D	(213).	However,	
it	is	possible	that	there	are	effects	in	other	defence	proteins	which	have	not	been	explored	
here,	 although	 in	 the	 absence	 of	 detectable	 down-stream	 consequences,	 any	 such	
mechanisms	may	be	of	questionable	clinical	relevance.	
	
	
9.2 Strengths	of	the	study	
	A	 strength	 of	 this	 piece	 of	 work	 is	 the	 large	 number	 of	 children	 and	 different	 disease	
severities	studied	with	the	same	conclusion	being	drawn	from	each	sub-study.	Some	of	the	
data	that	I	was	able	to	collect	was	longitudinal	adding	further	to	the	strength	of	the	results.		
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	Inflammatory	cells,	both	cellular	and	soluble	correlated	with	clinical	features.	For	example,	
those	 with	 infection	 in	 their	 BALF	 had	 higher	 pro-inflammatory	 cytokines,	 more	 airway	
neutrophilia,	a	greater	number	of	 total	 inflammatory	cells	 in	 their	BALF	and	higher	serum	
neutrophils	than	those	BALF	culture	negative.	Also,	total	cell	count	in	BALF	correlates	with	
numerous	 BALF	 cytokines.	 The	 fact	 that	 this	 expected	 result	 was	 demonstrated	 (an	
important	 positive	 control)	 gives	 confidence	 to	 the	 result	 obtained	 demonstrating	 an	
absence	of	 relationship	between	 inflammation	and	vitamin	D,	and	also	demonstrates	 that	
the	study	was	adequately	powered	to	show	relationships.	
	
	
9.3 Weaknesses	of	the	study	
The	opportunistic	nature	of	the	study	limited	selection	over	patient	recruitment,	particularly	
in	the	controls.	Limitations	due	to	financial	and	sample	availability	meant	it	was	not	possible	
to	repeat	assays	if	no	reading	was	obtained	meaning	that	full	results	were	not	available	for	
every	recruited	child.	
Although	 I	 had	 some	 longitudinal	 data	 a	 number	 of	 the	 studies	 were	 unavoidably	 cross-
sectional.	 I	 also	did	not	 recruit	any	adults	 to	 the	study,	 it	 is	 conceivable	 that	 in	end-stage	
disease	the	pattern	may	be	different,	but	I	have	no	data	to	comment	on	this.		
Another	limitation	is	the	variability	seen	with	the	HBD-2	assay	and	in	future	work	I	would	try	
to	perform	all	assays	at	the	same	time	point	rather	than	on	different	runs	to	try	to	limit	the	
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inter-run	 variability.	 However,	 given	 the	 rest	 of	 the	 laboratory	 data	 and	 the	 fact	 that	my	
conclusions	 rest	 on	 clinical	 endpoints,	 I	 do	 not	 believe	 that	 the	 problems	with	 this	 assay	
affect	my	core	conclusions.		
9.4 Future	work	
9.4.1 Vitamin	D	
Vitamin	D	measured	in	serum	does	not	correlate	with	clinical	outcomes,	but	local	levels	may	
not	relate	to	systemic	(341).	If	levels	of	1,25(OH)D	in	BALF	were	found	to	be	relevant	then	
perhaps	a	future	direction	would	be	to	explore	vitamin	D	analogues	as	therapeutic	agents.	
1,25(OH)D	analogue	use	rather	than	vitamin	D	itself	may	avoid	potential	limitations	in	dose	
due	to	toxicity	and	also	have	the	benefit	that	it	would	not	be	reliant	on	conversion	enzymes	
and	negate	the	effects	of	 the	polymorphisms	seen	 in	the	VDBP.	 In	order	to	achieve	this	 it	
would	be	necessary	to	reliably	be	able	to	measure	vitamin	D	and	VDBP	in	BALF	and	future	
work	could	develop	these	assays.		
It	would	also	be	interesting	to	ascertain	if	polymorphisms	in	the	VDBP	gene	are	CF	disease	
modifiers	because	to	my	knowledge	this	has	never	been	looked	for.	
It	would	be	interesting	to	observe	if	an	increase	in	LL-37	is	seen	after	inflammatory	response	
due	to	infection	as	well	as	to	allergen	exposure	as	was	previously	demonstrated;	both	would	
result	 in	 influx	 of	 inflammatory	 cells	 and	 so	 one	 would	 expect	 similar	 findings.	 By	
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experimenting	with	CF	and	non-CF	cells,	 it	would	be	possible	to	detect	 if	a	difference	was	
due	 to	 underlying	 pathology	 such	 as	 increased	 proteolysis	 or	 the	 pro-inflammatory	 state	
seen	in	the	CF	airway.	Clearly	such	an	experiment	would	not	be	possible	in	humans	and	so	
such	 experiments	 would	 need	 to	 be	 conducted	 in	 animals	 or	 cell	 studies	 although	 both	
methods	pose	difficulties	in	translating	findings	to	human	subjects.	Even	if	a	difference	was	
seen	 it	 is	 difficult	 to	 see	 how	 this	 translates	 to	 clinical	 relevance	 given	 the	 absence	 of	
findings	 in	 this	 work.	 If	 a	 direct	 in-vitro	 effect	 is	 seen,	 it	 may	 be	 worthwhile	 looking	 at	
possibility	of	administering	very	high	doses	of	vitamin	D	or	vitamin	D	analogues.		
9.4.2 Early	inflammation	
More	work	on	infants,	early	lung	function	and	inflammation	with	longitudinal	monitoring	is	
needed	to	further	understand	the	airway	and	understand	how	early	new	treatments	need	
to	be	given.	Delay	in	such	treatments	may	be	advantageous	due	to	unknown	side	effects	on	
the	 developing	 organs,	 but	 if	 significant	 inflammation	 is	 consistently	 seen	 that	 sets	 the	
course	 for	 life	 then	 it	may	 be	 that	waiting	 is	 not	 possible.	 Further	 evaluation	will	 enable	
decisions	to	be	made	when	such	treatments	become	available	by	providing	information	as	
to	whether	some	infants	are	predestined	to	a	more	complicated	course,	or	if	early	exposure	
to	bacteria	sets	the	course	of	more	severe	disease.	Early	and	longitudinal	measurement	of	
inflammatory	markers	alongside	 lung	 function	 is	 required	but	poses	difficulties	due	to	 the	
invasive	nature	of	obtaining	airway	samples.	This	study	has	shown	BALF	LL-37	to	correlate	
with	other	clinical	parameters	and	I	would	like	to	go	on	and	compare	the	levels	in	BALF	to	
serum	to	address	the	question;	how	can	we	find	a	non-invasive	biomarker	for	those	who	will	
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do	badly	 in	order	 to	enable	early	aggressive	and	prompt	 treatments	 to	alter	 their	
disease	progression?		
9.5 Conclusions	
If	 vitamin	 D	 was	 exerting	 a	 biologically	 important	 effect	 on	 the	 innate	 immune	 system,	
regardless	of	the	mechanism	of	action,	we	would	expect	to	see	downstream	consequences	
with	 decreased	 cellular	 markers	 of	 inflammation	 and	 decreased	 pro-inflammatory	
cytokines.	 This	 was	 not	 the	 case	 in	 this	 study	 and	 no	 relationship	 was	 demonstrated	
between	vitamin	D	and	the	BALF	innate	markers.	If	vitamin	D	is	involved	in	the	induction	of	
such	 defence	 peptides	 in-vivo,	 the	 impact	 of	 this	 on	 protein	 levels	may	 be	 limited	 in	 the	
degradative	environment	of	the	inflamed	airway.		The	fact	that	we	also	had	an	absence	of	
relationship	with	vitamin	D	and	 inflammation/infection	 in	our	non-CF	population	makes	 it	
less	likely	to	be	a	disease	specific	effect	and	more	likely	that	vitamin	D	bears	no	significant	
benefit	on	respiratory	health	in	children	with	chronic	suppurative	lung	diseases.		
In	conclusion,	having	set	out	to	test	the	hypotheses	that	vitamin	D	deficiency	leads	to	worse	
clinical	outcome	I	found	that,	contrary	to	my	hypotheses	no	such	signal	was	seen.	Although	
for	 reasons	 of	 bone	 health	 optimising	 vitamin	 D	 levels	 in	 CF	 is	 important,	 there	 is	
no	 relevance	 of	 serum	 Vitamin	 D	 levels	 to	 immunological	 or	 inflammatory	 airway	
health,	 at	least	in	children.	
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